CONFIDENTIAL ACTIV-6 Protocol [v11.0] 
1 ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed 
Medications 
IND Number: 155481 
Principal Investigator: Adrian Hernandez, MD, MHS 
Duke Clinical Research Institute 200 Morris St. Durham, NC 27701 
Phone: 919-668-7515 
Email: adrian.hernandez@duke.edu 
Co-Principal 
Investigator/IND Sponsor: Susanna Naggie, MD, MHS 
Duke Clinical Research Institute 200 Morris St. Durham, NC 27701 Phone: 919-684-2584 Email: susanna.naggie@duke.edu 
Data Coordinating 
Center Investigator Chris Lindsell, PhD 
Duke Clinical Research Institute 200 Morris St. Durham, NC 27701 Phone: 919-668-8700 Email: chris.lindsell@duke.edu 
Lead 
Funding Agency: National Center for Advancing Translational Sciences  
Version: 11.0 
Date: 26DEC2023 1&7
200 Morris St.
Durham , NC 27701,
Phone: 919-668-7515 
200 Morris St.
Durham , NC 27701,
Phone: 919-684-2584 
200 Morris St.
Durham , NC 27701,
Phone: 919-668-8700 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 2 Statement of Compliance 
 
This trial will be conducted in compliance with the International Council for Harmonisation 
(ICH) E6 (R2) guideline for Good Clinical Pract ice (GCP), and the a pplicable regulatory 
requirements from the United States (US) Code of Federal Regulations (CFR), including 45 CFR 
46 (Human Subjects Protection); 21 CFR 312 (Inve stigational New Drug); 21 CFR 50 (Informed 
Consent), and 21 CFR 56 (Institutional Review Board). 
All individuals who are re sponsible for the conduct, management , or oversight of this study have 
completed Human Subjects Prot ection and ICH GCP Training. 
 
 
  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 3 Site Principal Investigator Statement 
 
I have read the protocol, includ ing all appendices, and the packag e insert(s)/product label(s), and 
I agree that the protocol contains all necessary details for my staff and me to conduct this study 
as described. I will personally oversee the conduct of this study as outlined herein and will make 
a reasonable effort to comple te the study within the time de signated. I agree to make all 
reasonable efforts to adhere to the attached protocol. I will provide all study personnel under my supervis ion with copies of the protocol and access to 
all information provided by the sponsor or the sponsorâ€™s representative. I will discuss this 
material with study personnel to ensure that they are fully informed about the efficacy and safety 
parameters and the conduct of the study in general. I am aware that, before beginning this study, 
the IRB, or equivalent oversite entity must approve this protocol in the clinical facility where it 
will be conducted. 
I agree to obtain informed consent from partic ipants, as required by the IRB of record and 
according to government regulations and ICH guidelin es. I further agree to report to the sponsor 
or its representative any adverse events in accordance with the terms of this protocol and the US 
CFR, Title 21, part 312.64, ICH GCP 4.11. I further agree to ensure the study is conducted in 
accordance with the provisions as stated and will comply with the prevailing local laws and 
customs. 
 
 
   
Site Principal Investigator Name (Print)  
   
   
Site Principal Investigator Signature  Date 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 4 Table of Contents 
1.Â  Protocol Summary ........................................................................................................13 Â 
1.1.Â  Synopsis ...................................................................................................................... ....13Â 
1.2.Â  Schema ........................................................................................................................ ....20Â 
2.Â  Introduction ...................................................................................................................22 Â 
2.1.Â  Study Rationale ...............................................................................................................22 Â 
2.2.Â  Background .................................................................................................................... .22Â 
2.3.Â  Benefit/Risk Assessment ................................................................................................23 Â 
2.3.1.Â Risk Assessment .............................................................................................................23 Â 
2.3.2.Â Benefit Assessment .........................................................................................................23 Â 
3.Â  Objectives and Endpoints ............................................................................................24 Â 
4.Â  Study Design ..................................................................................................................26 Â 
4.1.Â  Overall Design ................................................................................................................26 Â 
4.2.Â  End of Study Definition ..................................................................................................27 Â 
5.Â  Study Population ...........................................................................................................28 Â 
5.1.Â  Inclusion Criteria ............................................................................................................28 Â 
5.2.Â  Exclusion Criteria ...........................................................................................................28 Â 
5.3.Â  Recruitment and Engagement .........................................................................................28 Â 
5.3.1.Â Participant Recruitment ..................................................................................................28 Â 
5.3.2.Â Participant Engagement ..................................................................................................28 Â 
5.3.3.Â Participant Randomization Process .................................................................................29 Â 
5.4.Â  Screen Failures ................................................................................................................29 Â 
5.5.Â  Enrollment .................................................................................................................... ..30Â 
6.Â  Study Drug(s) ................................................................................................................31 Â 
6.1.Â  Repurposed Medication Treatments ...............................................................................31 Â 
6.2.Â  Placebo ....................................................................................................................... .....31Â 
6.3.Â  Study Drug Accountability .............................................................................................31 Â 
6.4.Â  Concomitant Therapy .....................................................................................................31 Â 
6.5.Â  Intervention After the End of the Study ..........................................................................31 Â 
7.Â  Participant Withdrawal/Termination and Study Termination ................................32 Â 
7.1.Â  Participant Withdrawal/Termination ..............................................................................32 Â 
7.2.Â  Premature Termination or Suspension of the Study .......................................................32 Â 
7.3.Â  Lost to Follow-up............................................................................................................32 Â 
8.Â  Study Assessments and Procedures.............................................................................34 Â 
8.1.Â  Schedule of Events..........................................................................................................35 Â 
8.1.1.Â Screening.........................................................................................................................36 Â 
8.1.2.Â Intervention Period ..........................................................................................................36 Â 
8.1.3.Â Follow-up Period ............................................................................................................37 Â 
8.1.4.Â Final Visit........................................................................................................................38 Â 
8.2.Â  Clinical Assessments ......................................................................................................38 Â 
8.3.Â  Quality of Life Questionnaires .......................................................................................40 Â 
9.Â  Safety Assessments ........................................................................................................41 Â 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 5 9.1.Â  Adverse Events and Serious Adverse Events .................................................................41 Â 
9.1.1.Â Adverse Device Effect (ADE) and Unanticipated Adverse 
Device Effect (UADE) ....................................................................................................41 Â 
9.1.2.Â Collection Period for AE and SAE Information .............................................................42 Â 
9.1.3.Â Assessing Causality of a Serious Adverse Event ............................................................43 Â 
9.1.4.Â Reporting and Monitoring of SAEs ................................................................................43 Â 
9.1.5.Â Events of Special Interest................................................................................................44 Â 
9.2.Â  Unanticipated Problem (UP) and Terminations..............................................................45 Â 
9.2.1.Â Definition of Unanticipated Problem ..............................................................................45 Â 
9.2.2.Â Reporting of an Unanticipated Problem .........................................................................45 Â 
10.Â  Statistical Considerations .............................................................................................46 Â 
10.1.Â Statistical Hypotheses .....................................................................................................46 Â 
10.1.1.Â Primary Hypothesis .........................................................................................................46 Â 
10.2.Â Sample Size Determination ............................................................................................46 Â 
10.3.Â Randomization ................................................................................................................4 7Â 
10.4.Â Blinding ...................................................................................................................... ....47Â 
10.5.Â Populations for Analyses ................................................................................................47 Â 
10.6.Â Statistical Analyses .........................................................................................................4 7Â 
10.6.1.Â General Considerations ...................................................................................................48 Â 
10.6.2.Â Statistical modeling .........................................................................................................48 Â 
10.6.3.Â Assessing Effectiveness (Primary Objective) .................................................................48 Â 
10.6.4.Â Interim Analyses (IA), Early Stopping, and Type-I Error Control .................................49 Â 
10.6.5.Â Sensitivity and Supplementary Analyses ........................................................................51 Â 
10.6.6.Â Differential Treatment Eff ects and Subgroup Analyses .................................................51 Â 
10.6.7.Â Secondary Clinical Endpoint ..........................................................................................52 Â 
10.6.8.Â Exploratory Analysis ......................................................................................................52 Â 
10.6.9.Â Adherence and Retention Analysis .................................................................................52 Â 
10.7.Â Interim Reporting ............................................................................................................52 Â 
10.8.Â Independent Data Monitoring Committee (IDMC) ........................................................53 Â 
10.9.Â Adjudication Committee .................................................................................................53 Â 
11.Â  Ethical Standards ..........................................................................................................54 Â 
11.1.Â Institutional Review Board (IRB) ...................................................................................54 Â 
11.2.Â Informed Consent Process ..............................................................................................54 Â 
11.3.Â Participant and Data Confidentiality...............................................................................54 Â 
11.4.Â Site Management and Quality Assurance .......................................................................55 Â 
11.5.Â Site Monitoring ...............................................................................................................55 Â 
12.Â  Data Handling and Record Keeping ...........................................................................57 Â 
12.1.Â Data Collection and Management Responsibilities ........................................................57 Â 
12.2.Â Study Records Retention ................................................................................................57 Â 
12.3.Â Protocol Deviations.........................................................................................................57 Â 
12.4.Â Publication and Data Sharing Policy ..............................................................................57 Â 
13.Â  Study Leadership ..........................................................................................................59 Â 
14.Â  Summary of Changes....................................................................................................60 Â 
15.Â  References .................................................................................................................... ..66Â 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 6 16.Â  Appendix A (Enrollment Clos ed 04FEB2022) â€“ Ivermectin 
400 ..................................................................................................................................73 Â 
16.1.Â Risk Assessment .............................................................................................................73 Â 
16.2.Â Additional Appendix-Level Exclusion Criteria ..............................................................74 Â 
16.2.1.Â Precautions ................................................................................................................... ...74Â 
16.3.Â Ivermectin Information ...................................................................................................75 Â 
16.3.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................75 Â 
16.3.2.Â Drug Dispensing, Storage, and Stability .........................................................................75 Â 
16.3.3.Â Dosing and Administration .............................................................................................75 Â 
16.3.4.Â Rationale for Selection of Dose ......................................................................................75 Â 
16.4.Â Placebo Information ........................................................................................................77 Â 
16.4.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................77 Â 
16.4.2.Â Drug Dispensing, Storage, and Stability .........................................................................77 Â 
16.4.3.Â Dosing and Administration .............................................................................................77 Â 
16.5.Â Events of Special Interest ...............................................................................................77 Â 
17.Â  Appendix B (Enrollment Closed 27MAY2022) â€“ 
Fluvoxamine Maleate ...................................................................................................78 Â 
17.1.Â Risk Assessment .............................................................................................................78 Â 
17.2.Â Additional Appendix-Level Exclusion Criteria ..............................................................79 Â 
17.2.1.Â Precautions ................................................................................................................... ...80Â 
17.3.Â Fluvoxamine Information ...............................................................................................80 Â 
17.3.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................80 Â 
17.3.2.Â Drug Dispensing, Storage, and Stability .........................................................................81 Â 
17.3.3.Â Dosing and Administration .............................................................................................81 Â 
17.3.4.Â Rationale for Selection of Dose ......................................................................................81 Â 
17.4.Â Placebo Information ........................................................................................................84 Â 
17.4.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................84 Â 
17.4.2.Â Drug Dispensing, Storage, and Stability .........................................................................84 Â 
17.4.3.Â Dosing and Administration .............................................................................................84 Â 
17.5.Â Events of Special Interest ...............................................................................................84 Â 
18.Â  Appendix C (Enrollment Clos ed 08FEB2022) â€“ Fluticasone 
Furoate ....................................................................................................................... ....85Â 
18.1.Â Risk Assessment .............................................................................................................85 Â 
18.2.Â Additional Appendix-Level Exclusion Criteria ..............................................................86 Â 
18.2.1.Â Precautions ................................................................................................................... ...86Â 
18.3.Â Fluticasone Furoate Information .....................................................................................86 Â 
18.3.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................87 Â 
18.3.2.Â Drug Dispensing, Storage, and Stability .........................................................................87 Â 
18.3.3.Â Dosing and Administration .............................................................................................87 Â 
18.3.4.Â Rationale for Selection of Dose ......................................................................................87 Â 
18.4.Â Placebo Information ........................................................................................................88 Â 
18.4.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................88 Â 
18.4.2.Â Drug Dispensing, Storage, and Stability .........................................................................88 Â 
18.4.3.Â Dosing and Administration .............................................................................................89 Â 
18.5.Â Events of Special Interest ...............................................................................................89 Â 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 7 18.6.Â Safety Reporting for Fluticasone Furoate .......................................................................89 Â 
19.Â  Appendix D (Enrollment Clos ed 22JUL2022) â€“ Ivermectin 
600 ..................................................................................................................................90 Â 
19.1.Â Risk Assessment .............................................................................................................90 Â 
19.2.Â Additional Appendix-Level Exclusion Criteria ..............................................................90 Â 
19.2.1.Â Precautions ................................................................................................................... ...90Â 
19.3.Â Ivermectin Information ...................................................................................................90 Â 
19.3.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................90 Â 
19.3.2.Â Drug Dispensing, Storage, and Stability .........................................................................90 Â 
19.3.3.Â Dosing and Administration .............................................................................................90 Â 
19.3.4.Â Rationale for Selection of Dose ......................................................................................91 Â 
19.4.Â Placebo Information ........................................................................................................91 Â 
19.4.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................91 Â 
19.4.2.Â Drug Dispensing, Storage, and Stability .........................................................................91 Â 
19.4.3.Â Dosing and Administration .............................................................................................91 Â 
19.5.Â Events of Special Interest ...............................................................................................91 Â 
20.Â  Appendix E (Enrollment Closed 20JAN2023) â€“ Fluvoxamine 
Maleate 100 ....................................................................................................................92 Â 
20.1.Â Risk Assessment .............................................................................................................92 Â 
20.2.Â Additional Appendix-Level Exclusion Criteria ..............................................................92 Â 
20.2.1.Â Precautions ................................................................................................................... ...92Â 
20.3.Â Fluvoxamine Information ...............................................................................................92 Â 
20.3.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................92 Â 
20.3.2.Â Drug Dispensing, Storage, and Stability .........................................................................92 Â 
20.3.3.Â Dosing and Administration .............................................................................................92 Â 
20.3.4.Â Rationale for Selection of Dose ......................................................................................92 Â 
20.4.Â Placebo Information ........................................................................................................93 Â 
20.4.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................93 Â 
20.4.2.Â Drug Dispensing, Storage, and Stability .........................................................................93 Â 
20.4.3.Â Dosing and Administration .............................................................................................93 Â 
20.5.Â Events of Special Interest ...............................................................................................94 Â 
21.Â  Appendix F (Enrollment Closed 23JUN2023) â€“ Montelukast ..................................95 Â 
21.1.Â Risk Assessment .............................................................................................................95 Â 
21.2.Â Additional Appendix-Level Exclusion Criteria ..............................................................96 Â 
21.2.1.Â Precautions ................................................................................................................... ...96Â 
21.3.Â Study Drug Information ..................................................................................................96 Â 
21.3.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................96 Â 
21.3.2.Â Drug Dispensing, Storage, and Stability .........................................................................96 Â 
21.3.3.Â Dosing and Administration .............................................................................................96 Â 
21.3.4.Â Rationale for Selection of Dose ......................................................................................96 Â 
21.4.Â Placebo Information ........................................................................................................99 Â 
21.4.1.Â Formulation, Appearance, Packaging, and Labeling ......................................................99 Â 
21.4.2.Â Drug Dispensing, Storage, and Stability .........................................................................99 Â 
21.4.3.Â Dosing and Administration .............................................................................................99 Â 
21.5.Â Events of Special Interest ...............................................................................................99 Â 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 8 22.Â  Appendix G â€“ Metformin Hydroc hloride Immediate-Release ...............................100 Â 
22.1.Â Risk Assessment ...........................................................................................................100 Â 
22.2.Â Additional Appendix-Level Exclusion Criteria ............................................................100 Â 
22.2.1.Â Precautions ................................................................................................................... .100Â 
22.3.Â Study Drug Information ................................................................................................101 Â 
22.3.1.Â Formulation, Appearance, Packaging, and Labeling ....................................................101 Â 
22.3.2.Â Drug Dispensing, Storage, and Stability .......................................................................101 Â 
22.3.3.Â Dosing and Administration ...........................................................................................101 Â 
22.3.4.Â Rationale for Selection of Dose ....................................................................................101 Â 
22.4.Â Placebo Information ......................................................................................................104 Â 
22.4.1.Â Formulation, Appearance, Packaging, and Labeling ....................................................104 Â 
22.4.2.Â Drug Dispensing, Storage, and Stability .......................................................................104 Â 
22.4.3.Â Dosing and Administration ...........................................................................................104 Â 
22.5.Â Events of Special Interest .............................................................................................105 Â 
22.6.Â Statistical Considerations ..............................................................................................105 Â 
22.6.1.Â Sample Size Considerations ..........................................................................................105 Â 
 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 9 Abbreviations 
ACE Angiotensin-converting Enzyme 
ADE Adverse Device Effect 
AE Adverse Event 
ARB Angiotensin II Receptor Blockers 
ARNI Angiotensin Receptor Neprilysin Inhibitor 
BiPAP Bilevel Positive Airway Pressure 
BMD Bone Mineral Density 
BMI Body Mass Index 
CCC Clinical Coordinating Center 
CEA Clinical Event Ascertainment  
CFR Code of Federal Regulations 
CNS Central Nervous System 
CONSORT Consolidated Sta ndards of Reporting Trials 
COPD Chronic Obstructive Pulmonary Disease cOR Common Odds Ratio 
COVID-19 Coronavirus Disease 2019 CPAP Continuous Positive Airway Pressure 
C-SSRS Columbia-Suicide Severity Rating Scale DCC Data Coordinating Center 
DIC Disseminated Intravascular Coagulation 
DR Delayed-Release DUA Data Use Agreement 
ECMO Extracorporeal Membrane Oxygenation EDC Electronic Data Capture 
ESI Event of Special Interest 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
HbA1c Hemoglobin A1c HIPAA Health Insurance Portab ility and Accountability Act 
HIV Human Immunodeficiency Virus 
HR Hazard Ratio 
IA Interim Analysis 
IC
50 Half-Maximal Inhibitory Concentration 
ICF Informed Consent Form ICH International Council for Harmonisation ICMJE International Committee of Medical Journal Editors 
ICS Inhaled Corticosteroid ICU Intensive Care Unit IDMC Independent Data Monitoring Committee  IDS Investigational Drug Service IR Immediate-Release IRB Institutional Review Board KO Knockout LPS Lipopolysaccharide  MAOI Monoamine Oxidase Inhibitors 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 10 mITT Modified Intention to Treat 
MOP Manual of Procedures 
NCATS National Center for Adva ncing Translational Sciences 
NIH National Institute of Health 
OCD Obsessive Compulsive Disorder 
OHRP Office for Human Research Protections 
OR Odds Ratio 
PASC Post-Acute Sequelae of SARS-CoV-2 Infection 
PCORI Patient-Centered Outcomes Research Institute PCR Polymerase Chain Reaction 
PHI Personal Health Information 
PHQ Patient Health Questionnaire 
PI Principal Investigator 
PPOS Predicted Probability of Success 
PROMIS Patient-reported Outcomes Measurement Information System QOL Quality of Life 
RNA Ribonucleic Acid 
RRT Renal Replacement Therapy  
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SARS-CoV-1/2 Severe Acute Resp iratory Syndrome Coronavirus 1/2 
SD Standard Deviation 
sIA Screening Interim Analysis 
SNRI Selective Norepinephrine Reuptake Inhibitor 
SSRI Selective Serotonin Norepi nephrine Reuptake Inhibitor  
SUSAR Serious Unexpected Suspected Adverse Reaction 
UADE Unanticipated Adverse Device Effect UP Unanticipated Problems 
US United States 
WT Wildtype XR Extended-Release   
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 11 Table of Figures 
Figure 1: ACTIV-6 Study Schema ............................................................................................... 20Â 
Figure 2. ACTIV-6 Interim Analysis Schema .............................................................................. 21 Â 
Figure 3: Operational Structure Diagram ..................................................................................... 59 Â 
Figure 4: Survival curve of WT and S1R KO mice ...................................................................... 82 Â 
Figure 5: Summary of JAMA Randomization C linical Trial of Fluvoxamine for Early COVID-
19................................................................................................................................................... 83 Â 
Figure 6: Summary of study results for the pr ospective, nonrandomized  observational cohort 
study with fluvoxamine in participan ts diagnosed with COVID-19. ........................................... 83 Â 
Figure 7. Probability of efficacy for the primar y outcome in the ITT and mITT populations of 
TOGETHER ...................................................................................................................... ........... 93 Â 
Figure 8. Mean (SD) plasma metformin concentrat ions by treatment and time point after a single 
daily dose of metformin. ...................................................................................................... ....... 102 Â 
Figure 9. Metformin systemic (plasma) exposure ...................................................................... 103 Â 
 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 12 List of Tables 
Table 1: Schedule of Events ................................................................................................... ...... 35Â 
Table 2: ACTIV-6 Sample Size Estimates and Power ................................................................. 46 Â 
Table 3: Ivermectin Adverse Event Table for Doses â‰¥ 300 Âµg/kg ............................................... 73 Â 
Table 4: Ivermectin 400 Dosing Schedule .................................................................................... 75 Â 
Table 5. Fluvoxamine Adverse events occurring in 10-week studies of adult OCD or depression
....................................................................................................................................................... 78 Â 
Table 6. Fluvoxamine Adverse events that occu rred in COVID-19 study pa rticipants receiving 
300 mg/day for 15 days......................................................................................................... ........ 79Â 
Table 7. Fluticasone Adverse r eactions that occurred in â‰¥3% of adults and adolescents with 
asthma in a 24-week trial. .................................................................................................... ......... 85 Â 
Table 8. Ivermectin 600 Dosing Schedule .................................................................................... 90 Â 
Table 9. Montelukast sodium adverse reactions o ccurring at a higher incidence than placebo, in 
â‰¥1% of adults and adolescents â‰¥ 15 years of age. ........................................................................ 95 Â 
Table 10. Ongoing clinical tria ls with montelukast ...................................................................... 98 Â 
Â 
 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 13 1. Protocol Summary 
1.1. Synopsis 
 
Title ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate 
Efficacy of Repurposed Medications 
Clinical study phase III 
Rationale Coronavirus Disease 201 9 (COVID-19) is caused by a novel 
coronavirus, severe acute resp iratory syndrome coronavirus 2 
(SARS-CoV-2), that first emerge d in December 2019 and has since 
resulted in a global pandemic unseen  in almost a century in cases 
and mortality. Since 2020, advances have been made for treatment 
of COVID-19 and vaccination for prevention of SARS-CoV-2 
infection. However, the pandemic continues to evolve with new 
variants and surges of infections in different regions of the world, 
requiring an ongoing evidence-generati ng clinical trial platform, in 
particular for the treatment of COVID-19 in the outpatient setting. 
This platform protocol can serve as an evidence generation system 
for prioritized drugs, repurposed from other Food and Drug 
Administration (FDA) indications with  an established safety record 
in humans and preliminary data of efficacy. The ultimate goal is to 
evaluate if repurposed medications can  make participants feel better 
faster and reduce deat h and hospitalization. 
Primary Objective ï‚· To evaluate the effectiveness of  repurposed medications [(study 
drug(s)] in nonhospitalized particip ants with mild to moderate 
COVID-19 
Secondary Objectives ï‚· To evaluate the clinical outcome s in participants in a study drug 
arm versus those in the placebo arm 
ï‚· To describe symptom resolution in participants in a study drug 
arm versus those in the placebo arm 
ï‚· To describe the quality of life (QOL) in participants in a study drug arm versus those in the placebo arm 
ï‚· To compare illness severity trajecto ries in participants in a study 
drug arm versus those in the placebo arm 
ï‚· To compare the rate of Po st-Acute Sequelae of Covid 
(PASC) in participants in a study drug arm versus those in the placebo arm 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 14 Exploratory 
Objectives ï‚· To describe long-term COVI D-19-related symptoms in 
participants in a study drug arm versus those in the placebo arm  
Intervention All interventions will occur in addition to standard of care. Each 
study drug appendix describes a different study drug and 
matching placebo. The following arms will be included in each study appendix: 
ï‚· Study Drug Arm: repurposed medications (see 
Appendices) 
ï‚· Placebo Arm: placebo control  
While each appendix describes th e placebo that matches the 
study drug, for comparative anal ysis the control group will 
comprise eligible, concurrently enrolled participants from all study arms who were assigned to placebo.  
Study Design This study is a platform prot ocol designed to be flexible so that 
it is suitable for a wide range of settings within healthcare 
systems and in community settings where it can be integrated 
into routine COVID-19 testing programs and subsequent treatment plans. This platform protocol will enroll participants in 
an outpatient setting with a confirmed positive polymerase chain 
reaction (PCR) or antigen test for SARS-CoV-2. Each appendix 
will describe a repurposed medication (study drug) to meet the 
protocol objectives. 
When only one study drug/appendix is under study, allocation 
between study drug and placebo will be 1:1. If multiple study 
drugs/appendices are under study, participants will also be 
randomized among the study drugs for which eligibility is confirmed. Since the route of administration of each study drug 
may differ, the placebos may also differ. To achieve blinding and an equitable randomizati on probability, a two-step 
randomization process will be used. 
In the first step, the participant will be randomized m:1 active 
study drug to placebo, where m  is the number of active study 
drugs for which the participant is eligible (note, if the same 
study drug is tested at multiple doses, each dose will count as 
one study drug). Then, participan ts will be randomized among 
the m study drugs for which they ar e eligible. Participants will 
carry their â€˜study drugâ€™ versus  â€˜placeboâ€™ randomization with 
them into the study drug appendix. In this way, a participant allocated to placebo who is ra ndomized to study drug A will be 
given the placebo that matches study drug A. This achieves 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 15 equal probability of exposure among the placebo and active 
study drugs for which the particip ant is eligible, and equitable 
distribution among all study arms for which a participant is 
eligible. Sites will be informed to which study drug appendix the 
participant is randomized, but not whether they are allocated to 
the study drug arm or placebo ar m within that appendix.  
For analysis, concurrent placebo participants who were eligible for the study drug appendix will be pooled. This will result in approximately a 1:1 allocation ratio for any study drug to 
placebo. If a study drug appendix is stopped for efficacy and 
becomes standard of care, th e active study drug arm may serve 
as a concurrent placebo for other study drugs.  
Each study drug appendix will go through Screening Interim Analyses to assess efficacy/futility prior to evaluation of the primary objective. This Screening Interim Analysis provides an 
innovative approach to evaluate  the potential for repurposed 
drugs to reduce symptom burden and prevent disease progression in the outpatient sett ing at various points throughout 
enrollment. 
Participants will receive complete supply of repurposed 
medication (study drug) or placebo with length of treatment and 
amount of study drug/placebo depending on the study drug 
appendix and arm to which they are randomized. 
This study is designed so that it can be done completely 
remotely. However, screening and enrollment may occur in- 
person at sites and unplanned st udy visits may occur in-person 
or remotely, as deemed appropriate  by an investigator for safety 
purposes. Participants will be on-study for up to 180 days, during which they will comple te various questionnaires. 
Population Up to 15,000 adults   
Study Duration 24 months 
Study Location Up to 280 sites  
Inclusion Criteria 1.  Completed Informed Consent 
2. Age â‰¥ 30 years old 
3. Confirmed SARS-CoV-2 infec tion (or reinfection) by any 
authorized or approved PCR or an tigen test collected within 10 
days of screening 
4. Two or more current sympto ms of acute infection for â‰¤ 7 days. 
Symptoms include the following:  fatigue, dyspnea, fever, cough, 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 16 nausea, vomiting, diarrhea, body ache s, chills, headache, sore 
throat, nasal symptoms, new loss of sense of taste or smell. 
Exclusion Criteria 1.  Current or recent (within 10 days  of screening) hospitalization 
for COVID-19 infection 
2. Current or planned participation in  another interventional trial to 
treat COVID-19, at the discre tion of the study principal 
investigator (PI) 
3. Current or recent use (within th e last 14 days) of study drug or 
study drug/device combination*  
4. Known allergy/sensitivity or any hypersensitivity to 
components of the study drug or placebo* 
5. Known contraindication(s) to study drug including prohibited 
concomitant medications (see Appendices)* 
6.  Previous or current enrollment in the ACTIV-6 trial 
*If only one study drug appendix is op en at the time of enrollment. 
If multiple study drug appendices  are open, a participant may opt-
out of any study drug appendix or be excluded from any study drug 
appendix based on contraindicati ons listed in the study drug 
appendix, current use of  study drug, or known 
allergy/sensitivity/hypersensitivity and still remain eligible for the 
remaining study drug appendices. 
Sample Size Considerations This study will enroll up to 15,000 adults, depending on the number of study drug appendices th at are added and adjustments 
to sample size depending on the data.  
An estimated sample size of a pproximately 1200 participants per 
study drug appendix is expected to  be sufficient to conclude 
whether there is meaningful evid ence of benefit on the primary 
objective. A sample size of 3000 is needed for assessing the 
secondary objective of treatment benefit on the prevention of PASC. A screening interim analyses (sIA) will occur at n=300 
and n=600 to inform termination of the arm, continuation of 
enrollment, or transition to assessment of the primary objective. Formal interim analyses (IAs) of the primary objective are 
planned at n=300, n=600 and n=900. A futility analysis on the 
secondary objective of the prev ention of PASC will occur when 
600 participants have passed Da y 90. Review of emerging data 
will be done according to the schedule of DSMB meetings; no formal interim analyses ar e expected after n=900.  
As described in the statistical an alysis plan (SAP), the type I 
error for the primary objectiv e is controlled at < 0.05. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 17 General Statistical 
Consideration for Primary Analysis The primary objective of effectiveness will be determined based on the endpoints of hospitalization/deat h or time to recovery over 28 
days, the choice of which will be specified per appendix. The 
choice will be documented prior to interim analyses or prior to 
unblinding. The choice will be guided by emerging data on study 
drugs in the platform and on overall event rates in the trial, as well 
as external drivers, such as case ra tes, availability of other effective 
therapies, and vaccine effectiveness. 
The outcomes of interest for this platform (symptoms, 
hospitalization, and mortality) are collected using a web-assisted 
symptom diary according to the schedule in Table 1 . Symptoms 
will be graded on an ordinal scale as none, mild, moderate, or severe.  
The odds of hospitalization or death will be used to draw 
conclusions about clinical events. Time to recovery, measured as 
the time to achieving three cons ecutive days of self-reported 
symptom freedom, will be used to draw conclusions about symptom 
burden.  
The primary analysis will be impl emented separately for each study 
drug, where the matching placebo arm will consist of concurrently 
randomized participants that m eet the inclusion and exclusion 
criteria for that study drug appendix.  A modified intention to treat 
(mITT) approach will be used for primary analyses; all participants who receive study drug will be includ ed as assigned. It is possible 
that the delivery of medications (placebo or study drug) does not 
occur (failure of delivery, participant death, or participant withdrawal); this will result in ex clusion of the participant for the 
mITT analysis. All available data will be used to compare each study drug versus placebo control, regardless of post-randomization adherence to study protocols.  
Independent Data Monitoring 
Committee (IDMC)  Frequent IDMC reviews will be con ducted to ensure the safety of 
study participants and evaluate the accumulating endpoint data by 
treatment group. Regular IDMC meetings will monitor the 
following parameters at a minimum: 
ï‚· Recruitment progress 
ï‚· Enrollment overall and by subgroups 
ï‚· Adherence, retention, and st atus of data collection 
ï‚· Serious adverse events  
ï‚· Assessment for futility  
ï‚· Probability for benefit across endpoints 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 18 Interim Analysis Interim analyses (IA) will be performed per study drug appendix, 
after approximately every 300 part icipants (~150 in study drug arm 
and ~150 in placebo arm) have completed the Day 14 Visit. Placebo control participants contribu ting to this count will be drawn 
from across study drug appendices, and will include participants 
who were eligible for the study drug  appendix of interest regardless 
of final study drug arm allo cation.The following decision 
thresholds will be checked during IA(s): 
i) Screening IA (n=300):  
a. The study drug is found to have benefit (efficacy). 
Study drug appendix will proceed to primary objective IA at n=300. Note: this is also a check for 
harm as all assessments  are two-tailed.  
b. The study drug is not found to have benefit, 
enrollment continues in the study drug appendix and 
sIA is repeated at n=600.  
ii) Screening IA (n=600): a. It would be futile to attempt to show a benefit of the study drug based on the predicted probability of 
success (PPOS) and other factors. The study drug 
appendix will be terminated.  
b. Futility is not determined. Study drug appendix will proceed to primary objective IA at n=600. 
iii) Primary Objective IA (n= 300): if the criteria for 
proceeding to the primary objective are met when n=300, a primary objective IA will be conducted for the primary objective when n=300. The following decisions will be assessed: a. The study drug is found to have benefit (efficacy), the study drug appendix will be terminated as the 
primary endpoint has been met. 
b. It would be futile to attempt to show a benefit of the 
study drug based on the PPOS and other factors. The 
study drug appendix will be terminated.  
c. Efficacy/futility is undeterm inable, enrollment will 
continue in the study drug appendix and the primary 
objective IA will be assessed at n=600.  
iv) Primary Objective IA (n= 600, 900): if the criteria for 
proceeding to the primary objective IA are met when n=600 or n=900, a primary objective IA will be conducted. The following decisions will be assessed: 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 19 a. The study drug is found to have benefit (efficacy), 
the study drug appendix will be terminated as the primary endpoint has been met. 
b. It would be futile to attempt to show a benefit of the 
study drug based on the PPOS and other factors. The 
study drug appendix will be terminated.  
c. Efficacy/futility is undeterm inable, enrollment will 
continue in the study drug appendix and the primary 
objective will be assessed after another 300 
participants have been enrolled, or until n=900, and then again when n=3000. 
v) Secondary Objective IA (n=600 passing Day 90): A futility analysis on the PASC endpoint will be conducted 
when 600 participants have passed day 90 under the 
assumption of accrual to n=3000. 
vi) Interim analyses beyond n=900:  subsequent to planned 
interim analyses, the evalua tion of continuation of a 
study arm will consider achieving the primary objective, 
the secondary objective of preventing PASC, and any 
external stakeholder evidentiary needs with evaluation 
according to the schedule of DSMB meetings. 
A posterior probability of meaningf ul benefit for a study drug in 
comparison to the placebo control of greater than the appendix-
specified threshold will result in a declaration of ove rall superiority. 
A PPOS when n=3000 of less than th e appendix-specified threshold 
will result in a declaration of futility. 
Futility is a low probability of achieving any conclusions within a 
reasonable time frame or based on othe r factors for the trial. Prior to 
each IA, the target date for study completion will be specified, and 
accrual will be projected by that ta rget date. The PPOS of any study 
drug given expected accrual at a pr especified point in time will be 
provided to the IDMC. A statistica l model may be used to predict 
accrual. Futility assessment will use the lowest of either the planned 
accrual or predicted accrual at study closure. 
 
 
  
 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 20 1.2. Schema 
 
 
Figure 1: ACTIV-6 Study Schema 

CONFIDENTIAL ACTIV-6 Protocol [v11.0] 
 
 21  
Figure 2. ACTIV-6 Interim Analysis Schema 

CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 22 2. Introduction 
2.1. Study Rationale 
Severe acute respiratory syndrom e coronavirus 2 (SARS-CoV-2) is  a novel betacoronavirus that 
first emerged in December 2019 and has since ca used a global pandemic unseen in almost a 
century with respect to the number of cases a nd overall mortality.[1, 2] The clinical disease 
related to SARS-CoV-2 is referred to as  Coronavirus Disease 2019 (COVID-19). Since 2020, 
advances have been made for treatment of C OVID-19 and vaccinations for prevention of SARS-
CoV-2 infection, through emergency use author ization or FDA approval.[3-8] However, the 
pandemic continues to evolve with new variants a nd surges of infections in different regions of 
the world, requiring an ongoing evid ence-generating platform, in particular for the treatment of 
COVID-19 infection in the outpati ent setting. This platform prot ocol operates in addition to 
usual care and can serve as an evidence generati ng system for prioritized drugs repurposed from 
other indications with an established safety reco rd and preliminary evidence of clinical efficacy 
for the treatment of COVID-19. The ultimate goal is  to evaluate if repu rposed medications can 
make participants feel better faster  and reduce death and hospitalization. 
2.2. Background 
In December 2019, numerous patients in Wuhan, China were diagnosed with pneumonia caused 
by an unknown virus. By January 7, 2020, Chinese scie ntists had isolated SARS-CoV-2. This is 
a novel betacoronavirus closely related to severe acute resp iratory syndrome coronavirus 1 
(SARS-CoV-1).[2]  In the subsequent months th e spread of the virus led to a global pandemic. 
As of February 7, 2022 there were appr oximately 395,540,912 confirmed COVID-19 cases 
resulting in 5,741,726 deaths worldwide.[1] 
The virus continued to spread despite social  distancing and masking measures, vaccination 
campaigns/requirements, and travel restricti ons. As the pandemic progressed and social 
distancing, masking, and travel re strictions were lifted, the virus continued to spread. COVID-19 
vaccinations have been distributed and administered globally; how ever, new SARS-CoV-2 
strains continue to emerge, with potential for reduced monoclonal antibody therapeutic and 
vaccine efficacy.[9] As new strain s have emerged that confirm transmission, infection, and even 
severe disease after vaccination is possible, high lighting the need to esta blish treatment regimens 
despite vaccination availability. Furthermore,  acceptance and uptake of booster shots has been 
lower than uptake of the initial vaccination se ries, further justifying the need for safe and 
effective therapies. Thus, there remains a need to identify safe and efficacious treatments that can 
be administered in the outpatient setting.  As of February 2022, multiple clinical trials have  been reported, providing guidance to clinical 
providers on management of COVID-19, particularly in the hospital setting. Various drugs, 
including monoclonal antibodies an d antivirals, have been author ized or approved by the FDA 
for use in the inpatient and outpatient setting for treatment of COVID- 19.  Multiple repurposed 
immunomodulatory agents are clinically used for the treatment of severe COVID-19 in the 
inpatient setting. Thus, multiple medications have been reported to improve clinical disease and 
in some cases, mortality.[10, 11] Few of these are th erapies that can be administered at home.    
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 23 2.3. Benefit/Risk Assessment 
The risks for participation in this study include taking study drug (see Appendices) and loss of 
confidentiality. There may be some benefit to the participant if the therap y is effective against 
COVID-19. 
2.3.1. Risk Assessment 
Loss of confidentiality risks: There is a potential  risk of loss of confidentiality. Every effort will 
be made to protect the partic ipantâ€™s confidential medical in formation, but this cannot be 
guaranteed. Clinical informati on will not be released wit hout written permission of the 
participant, except as necessary for monitoring by the IRB, FDA, National Institutes of Health 
(NIH), Office for Human Research Protections  (OHRP), other local, US, and international 
regulatory authorities/entities as part of their duties. 
Risk lowering measures : Study procedures to manage a nd minimize risks include careful 
selection of the participants and monitori ng over time to check on participantsâ€™ health. 
Additional guidance to manage any risks or any change to the ri sk to the participant based on 
emerging data will be provided to the study teams,  as needed. In addition, an Independent Data 
Monitoring Committee (IDMC) will monitor safety  of the participants  throughout the study. 
2.3.2. Benefit Assessment 
Participants who randomize to a study drug arm may benefit fr om study drug administration.  
There is no direct benefit to participants random ized to the placebo arm apart from participating 
in generating evidence that may ultimately s upport treatment for SARS-CoV-2 infection. In 
addition, they will benefit from involvement with  the team following their health status during 
the study. The knowledge gained will be a benefit to others in the future.  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 24 3. Objectives and Endpoints 
Objectives Outcome Measurements  Reported Endpoints 
Primary   
To evaluate the 
effectiveness of repurposed 
medications [(study drug(s)] 
in nonhospitalized participants with mild to 
moderate COVID-19 ï‚· Hospitalization or death 
by Day 28 
ï‚· Time to recovery over 28 days, wherein time to recovery is the third day 
of  three consecutive days 
of self-reported symptom freedom Odds ratio (OR) for clinical events or hazard ratio (HR) 
for time to recovery will be 
used to estimate treatment effect. 
Secondary   
To evaluate the clinical outcomes in participants in a study drug arm versus 
those in the placebo arm ï‚· COVID Clinical 
Progression Scale on Day 7, Day 14, and Day 28 
(see Section 8.2) 
ï‚· Mortality through Day 28 
ï‚· Hospitalization, urgent care visit, emergency 
room visit through Day 28 The following model-assisted endpoints will be reported for the COVID 
Clinical Progression Scale: 
ï‚· The OR describing the 
difference in clinical 
progression at each 
measured time point 
ï‚· The HR describing the 
difference in time to 
hospitalization or death 
The following endpoints for 
the composite of medically 
assisted care will be directly assessed and reported: 
ï‚· Time to first urgent care, emergency care, hospitalization or death  
To describe symptom resolution in participants in 
a study drug arm versus 
those in the placebo arm Symptom resolution, defined as  three consecutive days without 
symptoms Time to symptom resolution 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 25 To describe the quality of 
life (QOL) in participants in a study drug arm versus 
those in the placebo arm Modified Patient-Reported 
Outcomes Measurement Information System (PROMIS)-
29 at baseline, Day 7, Day 14, 
Day 28, Day 90, and Day 120
1 
Follow-up ï‚· Odds ratios (ORs) specific to days 7, 14, 28, 90, and 120
1 
ï‚· The OR in QOL scores at each time point 
To compare illness severity trajectories in participants in 
a study drug arm versus 
those in the placebo arm Ordinal outcome including symptom severity, 
hospitalization, and death 
measured daily for 14 days ï‚· Difference in mean time unwell 
ï‚· Mean days of benefit 
To compare the rate of Post-Acute Sequelae of Covid (PASC) in participants in a 
study drug arm versus those 
in the placebo arm PASC score developed from the PASC Symptom Questionnaire and symptom reporting The OR for difference in PASC scores at 180 days 
Exploratory   
To describe long-term 
COVID-19-related 
symptoms in participants in a study drug arm versus 
those in the placebo arm Symptom occurrence, type, and severity at Day 90, Day 120
1, or 
Day 1801 Follow-up 
 Directly measured mean and median symptom count and 
QOL score at Day 90, Day 120
1, or Day 1801 in study 
drug arm(s) versus placebo. 
                                                 
1 Day 180 is applicable only for participants who were consented to the study after protocol v7.0 was implemented; 
Day 120 is applicable only for participants consented under protocol v6.0; Day 90 was the final follow-up day for 
Ivermectin 400, Ivermectin 600, Fluvoxam ine Maleate, and Fluticasone Furoate. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 26 4. Study Design 
Refer to Section 1.2 for the Study Schema. 
This study includes an innovative screening appr oach using sIAs to make decisions about 
dropping ineffective agents quickl y, or to accelerate study of poten tially effective agents. Each 
study drug appendix will go through sIAs to assess efficacy/futility prior to evaluation of the 
primary objective. This sIA provides an innovative approach to evalua te the potential for 
repurposed drugs to reduce symptom burden and prevent disease progression at various points 
throughout enrollment in a broad population. 
4.1. Overall Design 
This study is a platform protocol designed to be flex ible so that it is suita ble for a wide range of 
settings within healthcare systems and in comm unity settings where it can  be integrated into 
routine COVID-19 testing programs and subsequent treatment plans. The platform protocol will 
enroll participants with mild to moderate COVI D-19 in an outpatient setting with a confirmed 
positive polymerase chain reaction (PCR) or anti gen test for SARS-CoV-2 infection. Each 
appendix will describe a repurposed medication (study drug arm) that is sized to meet the master 
protocol objectives. 
Participants will be randomized to one of the st udy drug appendices that are actively enrolling at 
the time of randomization. Study drug appendices may be added or removed according to 
adaptive design and/or emerging evidence. Wh en there are multiple study drug appendices 
available, randomization will occur based on appropr iateness of each drug for the participant as 
determined by the study protocol and investigator  and participant equipoise. Each participant 
will be required to randomize to at least one study drug versus placebo. The probability of 
placebo to treatment will remain the same regardless of eligibility decisions.  
Eligible participants will be randomized (1:1), in a blinded fashion, to either the study drug 
arm or placebo arm in addition to standard of care, when one ac tive drug is on the platform or 
when a participant is only eligible for one of  the active drugs on the platform. As additional 
study drug appendices are added, the randomization will be altered to leverage placebo data 
across arms. If a study drug is offered at two dos es, each dose will be treated as separate study 
arm. If a participant is eligible for 1 study arm,  they have a 1:1 chance of receiving an active 
study drug. If a participant is eligible for two st udy arms, they have a 2:1 chance of receiving 
an active study drug, for 3 arms it is 3:1, for 4 arms it is 4:1, and so on. This is because each 
participant assigned to a place bo group is shared among all a ppendices, and the goal is that 
within appendices the allocation probability to study drug versus placebo is 1:1.  Participants 
will receive a complete supply of repurposed medication (study drug) or placebo with the 
quantity depending on the study drug/pla cebo to which they are randomized. 
All study visits are designed to be remote. Ho wever, screening and enrollment may occur in-
person at sites and unplanned st udy visits may occur in-person or remotely, as deemed 
appropriate by the site investigator for safety purposes. Participants will be asked to complete 
questionnaires and report safety events during the study, according to Table 1 . Participants will 
be prompted by the online system to report safe ty events and these will be reviewed and 
confirmed via medical records a nd site staff, as necessary.  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 27 4.2. End of Study Definition 
A participant is considered to have completed the study if he/she has co mpleted the applicable 
Long-term Follow-up assessments, refer to Table 1 . 
The end of the study is defined as the date of th e last follow-up of the last participant in the 
study. Data from interim analyses or recommen dations by the IDMC may result in protocol 
modifications or early termination of the study.  
 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 28 5. Study Population 
All Eligibility Criteria will be obtained per participant.   
5.1. Inclusion Criteria 
1. Completed Informed Consent 
2. Age â‰¥ 30 years old 
3.   Confirmed SARS-CoV-2 inf ection (or reinfection) by any authorized or approved PCR or 
antigen test collected with in 10 days of screening 
4. Two or more current sympto ms of acute infection for â‰¤7 days. Symptoms include the 
following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, 
headache, sore throat, nasal symptoms, new loss of sense of taste or smell  
5.2. Exclusion Criteria 
1. Current or recent (within 10 days of screen ing) hospitalization fo r COVID-19 infection 
2. Current or planned participation in another interventional trial to treat COVID-19, at the 
discretion of the study principal investigator (PI) 
3. Current or recent use (within  the last 14 days) of study drug or study drug/device 
combination*  
4. Known allergy/sensitivity or  any hypersensitivity to co mponents of the study drug or 
placebo* 
5. Known contraindication(s) to study drug incl uding prohibited concomitant medications 
(see Appendices)* 
6.  Previous or current enrollment in the ACTIV-6 trial 
*If only one study drug appendix is open at th e time of enrollment. If multiple study drug 
appendices are open, a participant may opt- out of any study drug appendix or be 
excluded from any study drug appendix based on contraindications listed in the study 
drug appendix, current use of study drug, or known allergy/sensitivity/hypersensitivity 
and still remain eligible for the remaining study drug appendices. 
5.3. Recruitment and Engagement 
5.3.1. Participant Recruitment 
Participants who are eligible based on positiv e SARS-CoV-2 PCR or antigen test will be 
identified by participating sites or  will self-identify to a central st udy hotline(s) and be referred to 
the closest site. Site investigator s, or their designee, may contact eligible particip ants to introduce 
the study and discuss st udy participation.  
5.3.2. Participant Engagement 
Participants will be engaged in the study through multiple channels. This includes, but is not 
limited to, ongoing participation in other registries partnering with ACTIV or healthcare systems.  
Additionally, participant engagement will include:  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 29 ï‚· compensation for participants who complete the applicable Final Visit (Day 90, 120, or 
180);  
ï‚· creating a study-wide ACTIV-6 Advisory Group;  
ï‚· developing participant-centered approaches that recognize the need s and preferences of 
COVID-19 survivors locally  and nationally; and 
ï‚· multifaceted approaches that combine engageme nt tools, leverage the online system, use 
of social media, and representative COVID-Participants. 
5.3.3. Participant Randomization Process 
This trial is a double-blind, placebo-controlled trial. Participants and investigators will be 
blinded. A participant who is eligible for m study drug arms/appendices will be randomized m:1 
study drug to placebo ( Figure 1 ). The participant will then be randomized with 1/m  probability 
to each of the study drug appendices. A partic ipant entering a study drug appendix carries their 
study drug or placebo designation with them a nd will get either the study drug or matching 
placebo. Participants who receiv e placebo will be pooled across study drug arms for those study 
drug arms/appendices that the pa rticipant is eligible. This reduces overall sample size by 
facilitating sharing of data from concurrent c ontrols while maintaining a 1:1 allocation to study 
drug or placebo within an appendix. Randomization sequences will not be pre-generated. Given 
the adaptive nature of the trial and th e unknown number of st udy drug appendices, arm 
assignment will be implemented at the time of confirming eligibility for randomization using a 
random number generator. The participant eligibil ity criteria will be checked for each study drug 
appendix, and the randomization probabilities will be set. The tw o step procedure will then 
occur, and the assignment to both study drug ap pendix and study drug versus placebo will be 
made. The participant and study teams will know which study drug appendix the participant is 
allocated to, but will be blinded to study drug versus placebo because they will be matching.  
The participant, treati ng clinicians, and study personnel will remain blinded to study drug versus 
placebo assignment until after the database is lock ed and blinded analysis is completed. Only the 
biostatistical team who is prepar ing closed IDMC interim reports will be unblinded. Specifically, 
study drug/placebo will be dispensed with packagi ng and labelling that would blind treatment 
assignment. Unblinding will occur only if require d for participant safety or treatment at the 
request of the treating clinician. Refer to the Manual of Procedur es (MOP) for further details. 
5.4. Screen Failures 
Screen failures are defined as participants who consent to participate in  the clinical study, who 
fulfill inclusion and exclusion crite ria, but are not subsequently randomized. Screen failures also 
include participants who consent, then on review by the site, are found to be ineligible for the 
study. A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure participants to meet the Conso lidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to que ries from regulatory authorities.  
Individuals who are considered scre en failures may not be re-screened. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 30 5.5. Enrollment 
Participants who are randomized and receive st udy drug/placebo will be considered enrolled. 
Participants who are randomized, but do not receive study drug/placebo for any reason (e.g., 
study drug lost in the mail, death prior to receipt  of study drug, participan t withdrawal prior to 
receipt of study drug), will not be  considered enrolled on the study and will be identified as 
randomized not enrolled . 
Receipt of study drug will be defined as evid ence that the study drug was delivered to the 
address of record. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 31 6. Study Drug(s) 
6.1. Repurposed Medication Treatments 
See Appendices 
6.2. Placebo 
See Appendices 
6.3. Study Drug Accountability  
Use of study drug will be tracked via the online sy stem, call center, or sites. Participants will 
dispose of any unused study drug as they would normally when stopping a medication. 
6.4. Concomitant Therapy 
Select concomitant me dications of interest  that the participant is receiving at the time of 
enrollment or receives during the course of the study will be recorded along with dosing 
information. Select concomitant medications of  interest include the following and will be 
verified at each remote visit by designated study personnel: 
ï‚· Any therapeutics that is thought to have pot ential or purported C OVID activity including 
hydroxychloroquine 
ï‚· Antibiotics  
ï‚· Antifungals  
ï‚· Antiparasitic 
ï‚· Antivirals including HIV proteas e inhibitors and ribavirin 
ï‚· Immunosuppressants in cluding steroids  
ï‚· Angiotensin-converting-enzyme (ACE )/angiotensin II receptor blockers 
(ARB)/angiotensin receptor neprilysin inhibitor (ARNI) 
ï‚· Statin 
ï‚· Anticoagulants and antiplatelets 
ï‚· COVID-19 vaccine (before, during, or after study intervention) 
Refer to the MOP for more details on conc omitant therapy. Refer to the appendices for 
contraindicated medications for each of the study drugs. 
6.5. Intervention After the End of the Study 
No additional study drug will be provided to th e participant following completion of the study.   
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 32 7. Participant Withdrawal/Termin ation and Study Termination 
7.1. Participant Withdrawal/Termination 
Participants will be followed until participant closeout, withdrawal of consent, or death. 
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the in vestigator for safety, be havioral, compliance, or 
administrative reasons. This is  expected to be uncommon. 
Those who request withdrawal from the study will  be asked to continue  on study follow-up with 
limited participation through the Final Visit (Section 8.1.4). Limited participation may include a 
call(s) to assess safety at st udy visits following withdrawal. 
If the participant withdraws consent for disclosure  of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. 
7.2. Premature Termination or Suspension of the Study 
The study may be temporarily suspended or prem aturely terminated if there is sufficient 
reasonable cause. Written notification will be provided documenting reason for study suspension 
or termination to the investigat ors, funding agency, a nd regulatory authorities, as appropriate. 
Circumstances that may warrant termination or suspension include, but are not limited to: 
ï‚· Determination of unexpected, significant, or unacceptable risk to participants 
ï‚· Insufficient compliance to protocol requirements 
ï‚· Data that are not sufficiently  complete and/or evaluable 
ï‚· Determination of futility after a sufficient time has passed for accrual of the primary and 
secondary outcomes 
ï‚· Recommendation by the IDMC 
7.3. Lost to Follow-up 
Participants will be asked for proxy contacts to a ssess vital status and/or other clinical events, 
including safety, if a participant fails to provi de the information. Provision of proxy information 
is not required for study participation. A participant will be considered lost to follow-up if he or 
she repeatedly fails to complete study assessments/procedures as outlined below and neither the 
participant nor the participantâ€™s proxy  can be contacted by the study site. 
The following actions must be taken if a participant fails to provide baseline information, if he or 
she fail to complete daily symp tom reporting by midnight the day af ter receiving the first dose of 
study drug/placebo (Day 2), if he or she miss one daily symptom reporting during Days 3 to 14, 
if he or she miss either the Day 14 or Day 28 Remote  Visits, and/or he or she fail to complete the 
applicable Final Visit assessments: 
ï‚· The site or call center must attempt to cont act the participant and counsel the participant 
on the importance of completing study assessments/procedures. 
ï‚· The site or call center will contact the part icipantâ€™s proxy to assess vital status and/or 
other clinical or safety events. 
ï‚· The site or call center will attempt to  collect all missing survey responses. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 33 ï‚· Before a participant is deemed lost to follo w-up, the investigator or designee must make 
every effort to regain contact  with the participant (where possible, three telephone calls 
and, if necessary, a certified letter to the participantâ€™s la st known mailing address or 
local equivalent methods). These contact  attempts should be documented in the 
participantâ€™s research record. 
ï‚· Online obituary search.    
ï‚· Should the participant continue to be unreach able, they will be considered lost to 
follow-up.  
 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 34 8. Study Assessments and Procedures 
Screening and eligibility confirmation will be pa rticipant-reported. A positive SARS-CoV-2 test 
result must be verified prior to randomization (refer to the MOP for details). Sites will be 
responsible for notifying the coor dinating center for participant withdrawals, lost to follow-up, 
permanent cessation of study drug, study drug dose modifications (if allowed, per Appendix), or 
change in vital status. Data will be collected  directly from the participant and supported by 
medical records, as needed. 
  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 35 8.1. Schedule of Events  
 
Table 1: Schedule of Events 
                                                 
2 Day 180 is applicable only for participan ts who were consented after protocol v7.0  was implemented; Day 120 is applicable 
only for participants consented on protoc ol v6.0; Day 90 was the final follow-up day for Ivermectin 400, Ivermectin 600, 
Fluvoxamine Maleate, and Fluticasone Furoate 
3 Refer to study drug appendix for le ngth of study drug administration. 
4 Only for enrollment in Study Drug Appendices that have pregnancy listed as a contraindication for females of childbearing 
potential. Participants will self-report pregnanc y using the Pregnancy Reasonably Excluded Guide. 
5 Review only during study drug/placebo admi nistration if contraindicated medications  provided for the study drug arm, per 
Appendix. 
6 Day 14 only. 
7 Daily symptom reporting; continued daily beyond day 14 through day 28 until sympto ms resolve for > 3 consecutive days. All 
participants will complete symptom reporting on Days 21 and 28, regardless of symptom resolution. 
8 Day 7 and 14 only. 
9 Day 3, 7, and 14 only. 
10 At Day 7 and 14 for participants enroll ed in Appendix E â€“ Fluvoxamine Maleate 100. 
11 At Day 14 for participants enrolled in Appendix G â€“ Metformin Hydrochloride Immediate-Release.  
12 Participantâ€™s medical record will be reviewed to confirm Serious Adverse Events (SAEs), Unanticipated Adverse Device 
Events (UADEs) [as applicable], and Events of Special Interest (ESIs).   Screening Intervention 
Period Follow-up Period 
 Final 
Visit Unplanned 
Study Visit 
Day 
Within 7 days
of Day 1 
Day 1 
Days 2 - 14 
Day 15 - 20 
Day 21 Â± 2 Day 22 - 27 Day 28 + 5  Day 90
2 + 5 
Day 1202 + 5 
Day 1802 + 7 
 
ACTIV-6 Trial            
Consent X           
Demographic Information X           
Eligibility criteria confirmed X           
Randomization X           
Receipt of study drug or placebo  X           
Continued use study drug   Continuous3         
Clinical Assessments            
Abbreviated medical history X           
Self-reported Pregnancy X4           
Concomitant Therapy X X5 X5         
Remote Visit   X6    X     
Drug Adherence  X X         
COVID-19 Outcomes  X X8  X  X X X X  
Symptom Reporting X7 X X7 X7 X7 X7 X7 X X X  
PASC Symptom Questionnaire          X  
QOL Questionnaire X  X8    X X X X  
At-home pulse oximetry   X9         
Columbia-Suicide Severity Rating 
Scale (C-SSRS)   X10         
Hypoglycemia Reporting   X11         
Safety Assessment12  Continuous via online system an d medical record review X 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 36 8.1.1. Screening 
The following events will occur at Screening: 
ï‚· Consent: Participants will be consented either via an e-consent proces s or paper process. 
The consent process should be done in accordan ce with local and central IRB regulations. 
Phone consenting may be facilitated th rough the e-consent or  paper process. 
ï‚· Demographic information will be collected including, but not limited to, age, sex, race, 
ethnicity, and occupation  
ï‚· Eligibility criteria confirmation by the participan t via the online system or by site staff via 
a paper process 
ï‚· Abbreviated medical history  
ï‚· Self-reported pregnancy, for wome n of childbearing potential ( only for enrollment in 
Study Drug Appendices that include  pregnancy as a contraindication )  
ï‚· Concomitant therapy  
ï‚· Symptom reporting, daily dur ing screening period 
ï‚· QOL questionnaire 
ï‚· Randomization (see Section 5.3.3) 
8.1.2. Intervention Period 
The following events will occur during the Interv ention Period, starting with receipt of study 
drug/placebo: 
Day 1: 
ï‚· Receipt of study drug or placebo 
ï‚· Study drug self-administration (see A ppendices for specifi c study drug/placebo 
administration) 
ï‚· Concomitant therapy  
ï‚· Drug adherence questionnaire 
ï‚· COVID-19 Outcomes 
ï‚· Symptom reporting 
ï‚· SAE, UADE (as applicab le), and ESI collection 
Days 2 â€“ 14: 
ï‚· Study drug self-administration (see A ppendices for specifi c study drug/placebo 
administration) 
ï‚· Concomitant therapy, including contraindicat ed medications provi ded for the study drug 
arm, per Appendix, during study drug/placebo administration. 
ï‚· Remote visit ( Day 14 only ) 
ï‚· Drug adherence questionnaire, daily 
ï‚· COVID-19 Outcomes ( Day 7 and 14 only ) 
ï‚· Symptom reporting, daily 
ï‚· QOL questionnaire (Day 7 and 14 only)  
ï‚· At-home pulse oximetry readings ( Day 3, 7, and 14 only )  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 37 ï‚· C-SSRS ( Day 7 and 14 for Appendix E â€“ Fluvoxamine Maleate 100 only ) 
ï‚· Hypoglycemia reporting (Day 14 for Appendix G â€“ Met formin Hydrochloride 
Immediate-Release only ) 
ï‚· SAE, UADE (as applicab le), and ESI collection 
8.1.3. Follow-up Period 
Day 15 â€“ 20:  
ï‚· Symptom reporting, daily from Day 14 for participants who have not yet reported three 
consecutive days of no symptoms. Partic ipants who experien ce three days of 
improvement before Day 14 but who then experience symptoms again will not be 
followed daily. 
ï‚· SAE, UADE (as applicab le), and ESI collection 
Day 21 Â± 2 days: 
ï‚· COVID-19 Outcomes 
ï‚· Symptom reporting 
ï‚· SAE, UADE (as applicab le), and ESI collection 
Day 22 â€“ 27:  
ï‚· Symptom reporting, daily from Day 14 for participants who have not yet reported three 
consecutive days of no symptoms. Partic ipants who experien ce three days of 
improvement before Day 14 but who then experience symptoms again will not be followed daily. 
ï‚· SAE, UADE (as applicab le), and ESI collection 
Day 28 + 5 days: 
ï‚· Remote visit 
ï‚· COVID-19 Outcomes 
ï‚· Symptom reporting 
ï‚· QOL questionnaire 
ï‚· SAE, UADE (as applicab le), and ESI collection 
Day 90 + 5 days:  
ï‚· COVID-19 Outcomes 
ï‚· Symptom reporting 
ï‚· QOL questionnaire 
ï‚· SAE, UADE (as applicab le), and ESI collection 
The Day 120 + 5 days Follow-up visit is only appli cable for participants consented on protocol 
v6.0 or later and will include the following:  
ï‚· COVID-19 Outcomes 
ï‚· Symptom reporting 
ï‚· QOL questionnaire 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 38 ï‚· SAE, UADE (as applicab le), and ESI collection 
8.1.4. Final Visit 
Depending on when the participant was consented, the Final Visit may have occurred at Day 90 
or Day 120. Following implementation of protocol  v7.0, Day 180 + 7 days will serve as the Final 
Visit. The Final Visit will include the following:  
ï‚· COVID-19 Outcomes 
ï‚· Symptom reporting 
ï‚· Post-acute Sequelae of SARS-CoV-2 In fection (PASC) Symptom Questionnaire ( Day 
180 participants only ) 
ï‚· QOL questionnaire 
ï‚· SAE, UADE (as applicab le), and ESI collection 
8.2. Clinical Assessments 
Abbreviated Medical History:  smoking status, estimated body mass index (BMI)/obesity, pre-
existing underlying lung disease (e .g., chronic obstructive pulmonary disease, asthma, idiopathic 
pulmonary fibrosis), underlying immunosuppression (transplant, malignancy, human 
immunodeficiency virus (HIV), autoimmune diseas e), medical conditions that may increase risk 
of COVID-19 infections or co mplications (e.g., diabetes, cardi ovascular disease, hypertension, 
chronic kidney disease), venous thromboembolism, chronic liver disease, COVID-19 vaccination 
status 
Concomitant Medications of Interest: Concomita nt medications of interest, including study drug 
specific contraindicated medications, will be collected. Refer to Section 6.4 for concomitant 
medications of interest and to the study drug specific appendices for contraindicated 
medications. Self-reported Pregnancy: Participants will be asked to self-report pregnancy, as needed, per 
Study Drug Appendix. The 3-item â€œPregnancy Re asonably Excluded Guideâ€ will be used to 
assess pregnancy at screening. The â€œPregnancy R easonably Excluded Guideâ€ uses traditional and 
World Health Organization criteria to exclude pr egnancy via participant se lf-report.[12] Refer to 
the MOP for details.  Remote Visit: Designated study personnel will contact  the participant directly via a phone call or 
other form of direct contact (e.g., text or e-ma il survey) in order to conduct study assessments, 
including, but not limited to, COVID-19 outcome s, drug adherence (at Day 14), and safety 
events. A missed remote visit will be consider ed a protocol deviation (non-major). If a 
participant misses a remote visi t, site study staff should take immediate action to contact the 
participant, per Section 7.3 follow-up processes. Refer to the MOP for details.  
Drug Adherence: Adherence to the study drug admi nistration schedule will be collected via the 
online system and confirmed at the Day 14 remote visit. 
COVID-19 Outcomes: The COVID-19 outcomes for th is trial are based on the World Health 
Organizationâ€™s Ordinal Scale for Clinical Impr ovement and will be collected via the online 
system and from the medical record.[13] The following outcomes will be assessed as part of the 
COVID Clinical Progression Scale:   
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 39 0. No clinical or virological evidence of infection 
1. No limitation of activities 
2. Limitation of activities 
3. Hospitalized, no oxygen therapy 
4. Hospitalized, on oxygen by mask or nasal prongs 
5. Hospitalized, on non-invasive ve ntilation or high-flow oxygen 
6. Hospitalized, on intubation and mechanical ventilation 
7. Hospitalized, on ventilation + additional organ support â€“ pressors, RRT, ECMO 
8. Death 
Symptom Reporting: Symptoms and symptom -related responses will be reported by the 
participant via the online system. Additional sy mptom reporting may occur from the sites, as 
available. Each of pre-defined symptoms will be  assessed on an ordinal severity scale of none, 
mild, moderate, and severe. The following symptoms will be collected:  
ï‚· Overall symptom burden 
ï‚· Fatigue 
ï‚· Dyspnea - shortness of breath or difficu lty breathing at rest  or with activity 
ï‚· Fever 
ï‚· Cough  
ï‚· Nausea  
ï‚· Vomiting 
ï‚· Diarrhea 
ï‚· Body aches 
ï‚· Sore throat 
ï‚· Headache 
ï‚· Chills 
ï‚· Nasal symptoms 
ï‚· New loss of sense of taste or smell 
ï‚· Other COVID-related symptom  
Post-acute Sequelae of SARS-CoV-2 Infection (PASC) Symptom Questionnaire: COVID-19 has 
affected many lives through lingering symptoms, often debilitating long after acute SARS-CoV-
2 infection. The syndrome of PASC is a chroni c condition present in up to 80% of infected, 
hospitalized patients and 40% to  70% of non-hospitalized patient s. [14-18] The PASC Symptom 
Questionnaire includes symptoms that are asso ciated with PASC and asks for severity 
(mild/moderate/severe) related to any symptoms identified by the participants. 
At-home pulse oximetry measurements: Participants will provide pulse oximetry readings using 
a study-provided FDA-approved pulse oximeter. Tw o consecutive pulse oximetry readings must 
be reported at each required time point. Day 3, 7, and Day 14 are study-required time points for 
pulse oximetry readings. Participants can repo rt pulse oximetry readings at other times 
throughout the study, at th eir own discretion.   
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 40 8.3. Quality of Life Questionnaires 
The following QOL questionnaire will be used in this study: 
ï‚· Modified PROMIS-29: PROMIS measures were developed through a collaborative 
process funded by the NIH.[19]  The PROMIS-29 consists of seven health domains with 
four 5-level items associated  with each and a pain inte nsity assessment using a 0-10 
numeric rank. The seven health domains include physical function, fatigue, pain 
interference, depressive symptoms, anxiety, ab ility to participate in social roles and 
activities, and sleep disturbance.[20] The PROMIS-29 measures will be modified for this 
study and will include select questions from each  of the seven health domains, refer to the 
MOP for details. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 41 9. Safety Assessments 
9.1. Adverse Events and Serious Adverse Events 
An AE is any untoward medical occurrence in hu mans, whether or not considered drug-related, 
which occurs during the conduct of a clinical trial. An AE can therefore be any change in clinical 
status, routine labs, x-rays, physical  examinations, etc., that is cons idered clinically significant by 
the study investigator.  
An SAE or serious suspected adverse reaction or serious  adverse reaction  as determined by the 
investigator or the sponsor is an AE that re sults in any of the follo wing serious outcomes:  
ï‚· Death  
ï‚· Life-threatening AE (â€œlife-threateningâ€ mean s that the study partic ipant was, in the 
opinion of the investigator or sponsor, at immediate risk of death from the reaction as it 
occurred and required immediate intervention)  
ï‚· Persistent or significant incapacity or subs tantial disruption of the ability to conduct 
normal life functions  
ï‚· Inpatient hospitalization or prolonga tion of existing hospitalization  
ï‚· Congenital abnormality or birth defect  
ï‚· Important medical event that may not result  in one of the above outcomes, but may 
jeopardize the health of the st udy participant or require medi cal or surgical intervention 
to prevent one of the outcomes listed in  the above definition of serious event 
Hospitalization for elective treatment of a preexisting condition that did not worsen from 
baseline does not meet the definition of an SA E. Hospitalization is defined as a stay in the 
hospital exceeding 24 hours.  
An unexpected AE is defined as any AE, the specificity or  severity of which is not consistent 
with the package insert. 
9.1.1. Adverse Device Effect (ADE) and Unanti cipated Adverse Device Effect (UADE) 
For those repurposed medications that are a part of a combination product, which includes a drug 
and a device, the following additional definitions will apply. 
An ADE is an AE related to the use of an inve stigational medical device. This includes any AE 
resulting from insufficiencies or inadequacies in  the instructions for use, the deployment, the 
implantation, the installation, the operation, or  any malfunction of th e repurposed medical 
device. This also includes any event that is a result of a use error or intentional misuse. 
ï‚· Device malfunction â€“ the failure of a de vice to perform in accordance with the 
instructions for use or clinical investigative plan. 
ï‚· User error or intentional misuse â€“ A device is used in a manner that is an act or omission 
of an act that results in a different me dical device response than intended by the 
manufacturer or expected by the user. 
A UADE is any SAE caused by, or associated wit h, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the investiga tional 
plan or applications (including a supplemental plan or application), or any other unanticipated 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 42 serious problem associated with a device that relates to the rights, safety, or welfare of 
participants. 
Unanticipated Adverse Device Effects (UADEs) w ill include events meeting either A or B as 
stated below: 
A. Events meeting ALL of the following criteria: 
ï‚· Not included in the relevant appendices or Product Label 
ï‚· Related to the device per s ite PI and/or IND sponsor 
ï‚· Serious (meets any of the following criteria): 
o Is life-threatening illness or injury 
o Results in permanent impairment of  a body function or a body structure 
o Necessitates medical or surgical intervention to prevent permanent 
impairment of a body function or a body structure 
o Results in hospitalization 
o Led to fetal distress, fetal death, or congenital abnormality or birth defect 
o Led to death 
(Permanent means irreversible impairment or dam age to a body structure or function, excluding 
trivial impairment or damage ). 
B. Any other unanticipated serious problem associ ated with the device that relates to the 
rights, safety, or welfare of participants. 
9.1.2. Collection Period for AE and SAE Information 
Study participants (and their designated emergency pr oxies) will be instructed  to report ESIs per 
appendix and Section 9.1.5, SAEs, and UADEs through their access to the studyâ€™s online system. 
Each day for 14 days, the participant will be asked to report on their symptoms and health state, 
including hospitalization and/or other change in health condition. The assessments include 
specific questions pertaining to ESIs, as well as symptoms and severity, health care visits, 
medications and a notification to the participant to contact the st udy team with any concerns or 
questions. If the participant is  still reporting symptoms at Da y 14, they will continue to be 
assessed until they have experi enced three consecutive days w ithout symptoms, or until Day 28, 
whichever is shorter. At Day 28, Day 90, Day 120, and Day 180, participants will complete 
assessments. Safety reporting will be available to the participant cont inuously throughout the 
study, but will only be required at the aforementioned collection points.   
The daily and follow-up assessments, as described in the paragraph above, will be monitored and sites will be actively notified of events requiri ng review, including for reporting that meets 
criteria for ESIs, SAEs, or UADEs. Refer to the MO P for details. In addition, participants will be 
invited during assessments to request contact from the study team, or to report any unusual 
circumstances that might be relevant, if they so  wish. Failure to complete daily assessments is 
also a trigger for review of a possible SAE. A missed assessment on the day after receiving the 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 43 first dose of study medication (Day 2) or any day of missed assessments up to Day 14 will 
prompt a notification to the site  to contact the participant. 
All participants will be instructed to self-report concerns either via an online event reporting 
system, by calling the site, or by calling a 24-hour ho tline. Participants will have access to event 
reporting via the online system from the signing of the informed consent form (ICF) until the 
Final Visit (Day 90, Day 120, or Day 180 depending on the time of consent). 
Events of special interest (ESIs) and SAEs will be extracted by site personnel from the 
participantâ€™s medical record if the participant seeks medical care or if  hospitalization occurs, 
each of which notifies the site to conduct follow up.  
Medical occurrences that begin before the start of study drug/placebo, but after obtaining 
informed consent, will not be considered an AE. Non-serious AEs (or ADEs, as applicable) may be reported by the participant, but will not be 
further assessed by the site or study personnel un less the event meets the criteria of an ESI.  
Events of Special Interest (ESIs), SAEs, and UA DEs (as applicable) will be collected from the 
start of study drug/device combination un til the Final Visit (Day 90, Day 120, or Day 180 
depending on the time of consent) or until 30 days after the last dose/use of device if participant 
terminates the study early. 
9.1.3. Assessing Causality of a Serious Adverse Event 
If an SAE occurs, the site investigator or me dical monitor will assess the relationship to study 
drug by using the following criteria: 
ï‚· Related:  
o Study drug â€“ there is a temporal relati onship between study drug and event onset 
or the event abates when study drug is discontinued or known to occur with study 
drug. 
o Device â€“ an event is due to the use of the device and cannot be reasonably 
explained by an alternative cause. 
ï‚· Not related: The event has no temporal rela tionship to study drug (or study device, as 
applicable) or the AE (or ADE, as applicable) has a much more likely alternate etiology 
or is due to an underlying or concurrent illness or effect of another drug (or device, as 
applicable). 
9.1.4. Reporting and Monitoring of SAEs 
All of the study drugs used in this platform protocol are re purposed medications that are 
approved for marketing in the US for another me dical condition. However, their investigational 
use for treatment of COVID-19 infection is not an approved indication and will be under an IND 
and subject to IND regulations in 21 CFR 312. Th e IND sponsor or designee will review SAEs 
weekly, and will perform aggregat e reviews of SAEs every two weeks. The IND sponsor or her 
designee will be responsible for determining if the safety reporting crit eria are met per 21 CFR 
312.32(c)(1)(i)(C) and 21 CFR 312.32(c)(1)(iv) and will notify the Data Coordinating Center 
(DCC) to prepare an aggregate report for submi ssion to the FDA. An aggregate safety report will 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 44 be submitted to FDA as soon as possible, but in no case later than 15 calendar days after the IND 
sponsor determination. If the IND sponsor determines that an unexpected fatal or life-threatening 
suspected adverse reactio n occurs markedly more frequently in a study drug arm than in the 
placebo arm, an aggregate safety report will be submitted to the FDA as soon as possible, but in 
no case later than 7 calendar days after the IND sponsor determination. Information on individual SAEs will be available upon request from the Agency following the submission of any 
aggregate reports. 
Any UADE(s) that the IND sponsor determines is/a re reportable will be submitted to the FDA, 
manufacturer, all reviewing IRBs, and all particip ating investigators within 10 working days of 
when the sponsor makes that determination. If the IND sponsor determines that a UADE presen ts an unreasonable risk  to participants, all 
investigations or parts of investigations presen ting that risk shall be terminated as soon as 
possible. Termination shall occu r not later than 5 working days  after the sponsor makes this 
determination and no later than 15 working days after the sponsor first received notice of the 
effect. 
All hospitalization and death events will be adjudicated (see Section 10.9), any event that is 
determined to be COVID-19-related will not be reportable as an e xpedited SAE, with the 
exception of events that are related to study drug and unexpected, which will be reportable 
regardless of relatedness to COVID-19. All events that are not COVID-19-related per the 
adjudication process will be reviewed by the DCRI  Safety Medical Monitor to determine if the 
event is a reportable SAE. Individual SAEs and UADEs must be entered in to the data system within 24 hours of site 
awareness. The DCRI Safety Surveillance team  will notify pharmaceutical partners of SAEs 
within 1 business day of their receipt that oc cur involving the specific appendix of the supplied 
study drug/placebo, as required. Serious Adverse Even ts that are related and confirmed unlisted 
by the DCRI Safety Medical Monitor will be repo rted to the FDA as SUSARs; as 7-day reports 
for unexpected fatal or life-threatening advers e reactions and 15-day re ports for serious and 
unexpected adverse reactions. If  the IND sponsor, IDMC, or F DA note a clinically important 
increase in the rate of a SUSAR, the IND s ponsor or her designee will notify investigators no 
later than 15 calendar days af ter determining that the inform ation qualifies for reporting. The 
investigator will follow all reportable events until resolution, stabiliza tion or the event is 
otherwise explained. The DCRI Safety Surveillance Team will follow all SAEs until resolution, 
stabilization, until otherwise explained. Pregnancies that occur while on-study will be co llected and will not be followed to outcome if 
outcome occurs beyond the participantâ€™s Final Study Visit, however, any associated ESI or SAE 
should be reported if information can be collected  and entered into the EDC. The DCRI Safety 
Surveillance team will notify pharmaceutical partne rs of a pregnancy within 1 business day of 
receipt that occur involving the specific appendix of the supplied study drug/placebo, as 
required. 
9.1.5. Events of Special Interest  
The following are also considered ESIs to the study and will be collect ed by study personnel via 
medical record review when concern for ESIs  are observed for hospitalized participants:  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 45 ï‚· Hypoxia, defined as two consecutive pulse oximetry readings â‰¤ 93% 
Each study drug may have a unique list of possi ble related ESIs. Refer to the relevant 
appendices. 
9.2. Unanticipated Problem (UP) and Terminations 
9.2.1. Definition of Unanticipated Problem  
The OHRP considers UPs involving ri sks to participants or others  to include, in general, any 
incident, experience, or outcome that meets all of the following criteria: 
ï‚· Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the prot ocol-related documents, such as the IRB-approved research 
protocol and informed consent document; and (b) the characteristics of the participant 
population being studied. 
ï‚· Related or possibly related to participation in the research (â€œpossibly relatedâ€ means there 
is a reasonable possibility that the incident , experience, or outcome may have been 
caused by the procedures i nvolved in the research). 
ï‚· Suggests that the research places participants or  others at a greater risk of harm (including 
physical, psychological, economic, or social  harm) than was previously known or 
recognized. 
9.2.2. Reporting of an Unanticipated Problem  
The site investigator will report UPs for their pa rticipants to the DCC. The site may also be 
required to inform their reviewing IRB about a UP occurring at the local institution. The UP 
report to the DCC will include the following: 
ï‚· A detailed description of the event, incident, experience, or outcome  
ï‚· An explanation of the basis for determining that the event, incident, experience, or 
outcome represents an UP  
ï‚· A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP 
ï‚· The DCC will document and review all UPs.  De tails of the UP reporting process will be 
located in the MOP. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 46 10. Statistical Considerations 
10.1. Statistical Hypotheses 
10.1.1. Primary Hypothesis 
The primary hypothesis in this trial is that part icipants who receive study drug will have reduced 
disease progression to ho spitalization or death and/or more rapid resolution of symptoms as 
compared to those who receive placebo. 
10.2. Sample Size Determination 
This study is designed to be analyzed using a Bayesian approach, accepting the possibility of 
adding and dropping of arms as the trial progres ses. There is also th e potential for extending 
accrual in a study drug appendix if there is the potential to de monstrate benefit. Detailed 
simulations will be used to demonstrate th e operating characteristics common to each study 
drug appendix. Decision thresholds will be set to  balance overall power with control of the 
Type I error rate in the contex t of the appendix-specific goal.  
To aid planning for this trial, symptom count and clinical event data were estimated from 
participants in a clinical trial w ith similar inclusion criteria. Data were not collected daily in that 
study, but evaluations were completed on Day 10 after randomization, which is considered a 
clinically meaningful point in time. Based on the observed distribution, it is estimated that 
studies of about n=600 (300 study drug and 300 placebo) will be sufficiently sized to determine 
whether there is evidence of mean ingful benefit with > 85% power ( Table 2 ). Moreover, when 
a study drug demonstrates overall effectiveness, the planned adaptations to increase targeted 
accrual for the purpose of demonstrating benefit on  clinical events is a reasonable extension 
within the context of this platform. The final decision thresholds and operating characteristics 
selected for each appendix, if deviating from the common approach described in the SAP, will 
be customized in an appendix-specific SAP.  An estimated sample size of approximately 1200  
participants per study drug appendix is expected to be sufficient to conclude whether there is 
meaningful evidence of benefit on the primary objective. A sample size of 3000 is needed for 
assessing the secondary obj ective of treatment bene fit on the prevention of PASC. It is expected 
that this study will enroll up to 15,000 adults, depending on the number of study drug appendices that are added and adjustments to sample size depending on the data.
[21]  
Table 2: ACTIV-6 Sample Size Estimates and Power 
OR Corresponding 
difference in mean symptom burden Power Corresponding Risk Difference in clinical events Power 
80% 85% 90% 80% 85% 90% 
0.4 2.10 75 86 101 0.025 343 392 459 
0.5 1.98 132 150 176 0.021 455 520 608 
0.6 1.86 242 277 324 0.017 675 772 903 
0.7 1.74 496 567 664 0.012 1004 1148 1343 
0.8 1.61 1267 1449 1696 0.009 1652 1889 2211 
The sample sizes given are the sample size for the study dr ug arm only. Placebos will be borrowed across study drug 
appendices. The total size of the placebo arm will be equal to the size of the study drug  arm. The total number of 
placebos in the trial will depend on eligibility of particip ants among the study drug appendices and the number of study 
drugs. The calculations are based on symptom burden, hospitalization, and death at Day 10. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 47 10.3. Randomization 
See Section 5.3.3 for additional details.  
10.4. Blinding 
The investigators, treatin g clinicians, and study participants will all remain blinded to study drug 
versus placebo assignment until after the database is locked and blinded analysis is completed. 
Only the Investigational Drug Service (IDS) a nd staff who are handling randomization codes and 
unblinded members of the biostatistical team wh o are preparing closed IDMC interim reports 
will be unblinded. The statistical staff responsible for preparing IDMC reports will not directly 
interact with the clinic al team that delivers care to the study participants. Specifically, study 
medication will be dispensed with packaging and labelling that would blind treatment assignment. Unblinding will occur only if require d for participant safety or treatment at the 
request of the treating clinician.  
The web-based randomization system will include b lind-breaking instructions. Participant safety 
must always be the first consid eration in making an unblinding de termination. If the investigator 
decides that unblinding is warrant ed, the investigator should complete an unblinding request, 
which will immediately notify the Medica l Monitor (see MOP for details).  
10.5. Populations for Analyses 
Modified Intention to Tr eat (mITT) Population:  
â— All participants who r eceive study drug/placebo. 
â— Participants who do not receive study drug, for any reason, wi ll be excluded; while this 
modifies the intention to treat principle, the fa ilure of delivery of medications from site to 
participant is not under the contro l of either investigator nor participants and is expected 
to occur infrequently and randomly. Similarly, ea rly death of a participant or withdrawal 
prior to the study drug being received is po ssible, but unlikely and expected to occur 
randomly between study drug appendices. All other participants will be included, and 
they will be analyzed according to whic h arm they were assigned. Thus, the mITT 
analysis set includes all part icipants who were randomize d and received the study drug. 
Safety Population: 
â— The safety population will include those persons in the mITT population who report 
taking at least one dose of study drug or matching placebo. In the unlikely case a participant receives the incorre ct study drug, participants will be grouped according to the 
treatments that they received.  
10.6. Statistical Analyses 
The main trial SAP will be finalized  prior to the primary analysis.  It will include a description of 
the statistical analyses and detailed simulations used to inform the sample size estimates. Appendix-specific decisions, such as choice of c ovariates for the model, and context specific 
decisions such as deviations in decision making th resholds or in targeted accrual, will be made 
blinded to data and prior to analyses. Such decisi ons will be documented in the trial master file.  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 48 This section is a brief summary of the planned approach to statistical analyses of the most 
important endpoints including prim ary and secondary endpoints. 
10.6.1. General Considerations 
Baseline demographic and clinical variables will  be summarized for each randomized arm of the 
study. Descriptive summaries of the distribution of continuous variables will be presented in 
terms of percentiles (e.g., median, 25th and 75t h percentiles) along with means and standard 
deviations. Categorical variables will be summarized in terms of  frequencies and percentages. 
Histograms and boxplots may be used to visualize the data. 
If an efficacy signal is observed at n=300 or n=600 following sIA, the trial will enter assessment 
of the primary objective. At th at time, the pre-determined pr imary clinical endpoint for the 
appendix will be evaluated as either  clinical events (hospitalization or death) or time to recovery. 
The unselected endpoint will be re ported as part of the secondary objective. Both clinical 
endpoints will be analyzed using a covariate-adjusted statistical model.  
10.6.2. Statistical modeling 
Estimation and inferences about the effect of  each study drug versus matching placebo will be 
made using Bayesian regression methods. At leas t 30 events must occur in order to perform 
inference, if fewer than 30 events occur, the analysis will only be descriptive. For each study 
drug, the matching placebo arm will consist of conc urrently randomized participants that meet 
the inclusion and exclusion criteria for that study drug. The statistical models are described in 
detail in the SAP. Briefly, a longitudinal ordina l regression model will be used for the sIA, a 
logistic regression model will be used for clini cal events, and proportional hazards models will 
be used for time to event analyses. All models will be adjusted for covariates, including baseline symptom severity and time from symptom onset. Covariates will be formally specified prior to 
an analysis, taking into account emer ging data and changing context.   
10.6.3. Assessing Effectiveness (Primary Objective) 
The overall effect of each study drug versus matc hing placebo will be quantified using one of the 
following two primary endpoints, unless otherwise sp ecified in the appendix: composite clinical 
events (hospitalization or death) or time to r ecovery. The primary endpoint will be defined and 
documented per study drug appendi x prior to the initial IA. 
The primary analysis will be implemented se parately for each study drug appendix where the 
matching placebo arm will consist of concurrent ly randomized participants that meet the 
inclusion and exclusion cr iteria for that study drug. Decision thresholds, priors, and meaningful 
effect sizes may change during the course of th e pandemic, as vaccination rates, case rates, and 
new therapies continue to evolve . Thresholds, effect sizes and pr iors, that vary during the trial 
from those described in the main SAP will be documented in the trial master file or other 
designated document. Prior to any interim or fina l analysis, all decision thresholds, priors and 
effect sizes will be confirmed and evaluated using extensive simulations to demonstrate the 
overall Type I error rate remains below 0.05.  
CONFIDENTIAL ACTIV-6 Protocol [v11.0] 
 
 49 An mITT approach will be used for primary analys es. All available data will be used to compare 
each study drug versus placebo control, regardle ss of post-randomization adherence to study 
protocols.  
10.6.4. Interim Analyses (IA), Early Sto pping, and Type-I Error Control 
Individual study drugs may require different sample  sizes, and the sample sizes may be adjusted 
based on the results of IA. Therefore, fixed enrollment triggers will be used for IA. An IA will 
occur after enrollment and completion of 14 day follow-up of approximately every 300 
participants in a study arm (150 in study dr ug arm and 150 in placebo arm). Beyond n=900, IA 
will occur according the DSMB meeting schedul e. Study drug appendices may be stopped early 
for efficacy or futility (see 
Figure 2). Thresholds are described in the SAP to guide stopping of each appendix if there is 
clear evidence of benefit or if there is sufficient evidence to declare futility.  
The following schedule and decision thresholds will be followed for IAs: 
i) Screening IA (n=300):  
a. The study drug is found to have bene fit (efficacy). Study drug appendix will 
proceed to primary objective IA at n=300. Note: this is also a check for harm as 
all assessments are two-tailed.  

CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 50 b. The study drug is not found to have benef it, enrollment continues in the study 
drug appendix and sIA is repeated at n=600.  
ii) Screening IA (n=600): 
a. It would be futile to attempt to show  a benefit of the study drug based on the 
predicted probability of success (PPOS)  and other factors. The study drug 
appendix will be terminated.  
b. Futility is not determined. Study drug a ppendix will proceed to primary objective 
IA at n=600. 
iii) Primary Objective IA (n=300): if the criter ia for proceeding to the primary objective 
are met when n=300, a primary objectiv e IA will be conducted. The following 
decisions will be assessed: a. The study drug is found to have benefit (efficacy), the study drug appendix will 
be terminated as the primary endpoint has been met. 
b. It would be futile to attempt to show a benefit of the study drug within the PPOS 
and other factors. The study drug appendix will be terminated.  
c. Efficacy/futility is undeterminable, enro llment will continue in the study drug 
appendix and the primary objective IA will be assessed at n=600.  
iv) Primary Objective IA (n= 600, 900): if the criteria for proceeding to the primary 
objective IA are met when n=600 or n=900, a primary objective IA will be conducted. The following decisions will be assessed: 
a. The study drug is found to have benefit (efficacy), the study drug appendix will be terminated as the primary endpoint has been met. 
b. It would be futile to attempt to show  a benefit of the study drug based on the 
PPOS and other factors. The study dr ug appendix will be terminated.  
c. Efficacy/futility is undeterminable, enro llment will continue in the study drug 
appendix and the primary objective will be assessed after another 300 participants 
have been enrolled, or until n=900, and then again at n=3000.  
v) Secondary Objective IA (n=600 passing Day 90): A futility analysis on the PASC 
endpoint will be conducted when 600 part icipants have passed day 90 under the 
assumption of accrual to n=3000. 
vi) Interim analyses beyond n=900: subseque nt to planned interim analyses, the 
evaluation of continuation of a study arm will consider achieving the primary 
objective, the secondary object ive of preventing PASC, and any external stakeholder 
evidentiary needs with evaluation accord ing to the schedule of DSMB meetings. 
The analysis for the sIA will use a covariate adjust ed statistical model. The outcome is an ordinal 
variable, which is the overall symptom burden measured on a none / mild / moderate / severe 
scale with hospitalization and death added as the 5
th and 6th level of the ordinal scale. The 
outcome is measured daily for 14 days. The outcome  is compared between participants receiving 
study drug and participants receiving placebo each of  the 14 days using a longitudinal statistical 
model that takes into account th e repeated measurements on each  participant. The statistical 
model can be used to estimate the days of be nefit â€“ the number of days for which being on an 
active study drug results in a better outcome than being on a comparator. Da ys benefit, restated 
in terms of concordance and discordance proba bilities, is the difference between (a) the 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 51 probability that the intervention is better and (b ) the probability that the non-intervention is 
better, summed over all the days of follow-up. This is the main quantity, or estimand, that will be 
used to make early go/no-go decisions for each appendix.  
The primary objective IA will follow processes described in Section 10.6.3 for assessment of 
efficacy. The primary endpoint used for the prim ary objective IA will be selected per appendix 
prior to the initial IA.  
A posterior probability of meaningful benefit for a study drug in comparison to the placebo 
control of greater than the specifi ed threshold will result in a d eclaration of overall superiority. A 
PPOS when n=3000 is less than the specified threshold will result in a declaration of futility. 
Futility is a low probability of achieving any conclusions within a reasonable time frame or 
within the context of the trial. Prior to each IA, the target date for study completion will be 
specified, and accrual will be projec ted by that target date. A stat istical model may be used to 
predict accrual. Futility assessmen t will use the lowest of either the planned accrual or predicted 
accrual at study closure. 
The combination of decision thresholds and effect sizes have been selected to balance the ability 
to observe a meaningful effect on symptoms, to observe the potential for an effect on clinical 
outcomes, and to maximize power while controll ing the Type 1 error rate. For each appendix, 
decision making thresholds will be set to achieve appendix-specific goals and simulations will be 
used to demonstrate that the operating characteristic s are consistent with a Type I error control of 
at least 5%, as described in the SAP. 
10.6.5. Sensitivity and Supplementary Analyses 
The sensitivity analyses described in the SAP ar e designed to test robustn ess of the results to 
assumptions in the statistical models. In addi tion to checking assumptions about the modeling 
approach, association of adherence with outcomes will also be ascertained. In the main statistical 
model, the number of doses of study drug consumed  or weight adjusted dose will be added as a 
covariate to investigate a po ssible dose response curve. 
10.6.6. Differential Treatment Eff ects and Subgroup Analyses 
Differential treatment effect, also referred to as  heterogeneity of treatme nt effect, refers to 
differences in treatment efficacy as a function of pre-existing participant ch aracteristics such as 
baseline variables. This is often assessed by forming subgroups. However, these subgroups do 
not inherit the baseline covari ate adjustment of the full participant outcome model, and are 
problematic because of improper subgrouping when a continuous variable is used. For example, 
dichotomizing age at 65 years is arbitrary and it is very unlikely that any study drug effect has a 
discontinuity in effect at 65 years old. Also, subgroup estimates and stat istical assessments of 
them are unreliable and are often taken out of c ontext when a more system atic analysis does not 
find evidence for an interaction between the covariate and study drug.  
For these reasons, analysis of differential study dr ug effect will be prespecified and model based.  
For example, effectiveness variability can be estimated with continuous age by adding a smooth 
age by study drug interaction into  the model and using this mo del and using this model to 
estimate treatment contrast and their uncertainties acro ss age = 10, 11, â€¦, 100. Differential 
treatment effects by sex, body mass index, and age w ill be examined. Prior to the final analysis, 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 52 additional important subgrouping va riables will be defined and listed in the SAP. Knowledge 
about concomitant therapies, risk factors, and v accinations are expected to continue to evolve 
and inform the final decision on thei r inclusion in these analyses.  
Studies under this master protocol will be si zed only for assessing overall study drug effects. 
Thus, there may be inadequate power to (1) exam ine interactions and to (2) estimate covariate-
specific treatment effects (e.g., odds ratio at age 70 or for females). 
10.6.7. Secondary Clinical Endpoint 
The COVID Clinical Progression Scale score on Day 14 will be compared between participants 
in each study drug arm and the placebo arm using a covariate adjusted proportional odds model. 
A similar approach will be used for QOL a nd PASC score outcomes. Covariates will be 
prespecified and will include at a minimum: age, baseline severity, and duration of illness. The 
proportional odds assumption will mainly be examined using graphical methods . If 
proportionality is clearl y violated, a partial proportional odd s or non-proportional odds models 
will be considered. As before, a Bayesian approach to model interpretation will be used. For estimating time to symptom resolution based on the definition of at least three consecutive days 
without symptoms, a proportional hazards model will be used. Since death is a competing risk, 
cause-specific hazards will be estimated. Obse rvations will be censored at 28 days. 
10.6.8. Exploratory Analysis 
Exploratory analyses involve the same outcome  variables, measured at 90, 120, or 180 days. 
Exploratory analysis will focus on describing long term outcomes, particularly symptoms and severity, clinical status , and QOL. Statistical models will use a similar form as for the main 
analysis. As well as simple analysis that consid er the effect of treatm ent on long term outcomes, 
the SAP will describe how participant state durin g the intervention period will be used to inform 
longer term outcomes.  
10.6.9. Adherence and Retention Analysis 
Withdrawals from study drug and consent withdraw als will be tracked via the online system.  
Participants will be asked about their use of study drug. Those reporting discontinuation or 
switching will be asked about the reas ons for discontinuation/switching.   
Measures of study retention to inform follo w-up time will be based on several measures, 
including web-based check-ins for symp toms and COVID-19 outcome reporting. 
10.7. Interim Reporting  
In addition to routine evaluation of decision thres holds pursuant to the statistical design of this 
study, regular IDMC reviews will be conducted to ensure the safety of study participants.  
Regular IDMC meetings will monitor the following parameters at a minimum: 
ï‚· Recruitment progress 
ï‚· Enrollment overall and by subgroups 
ï‚· Adherence, retention, and st atus of data collection 
ï‚· Events of special interest (ESIs) 
ï‚· Unanticipated problems 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 53 ï‚· Serious adverse events (SAEs) 
Interim examination of clinical endpoints will be based on the accrual of primary endpoint data.  
It is expected that reviews of  the data will occur approximately after each 300 participants are 
enrolled in each study drug appendix (150 in study drug arm and 150 in placebo arm).  
For ethical reasons, interim examinations of key safety and process data will be performed at 
regular intervals during the course of the trial. The DCC will create reports to track participant 
enrollment, rates of adherence with the assigne d treatment strategy, and frequency of protocol 
violations. Prior to each meeti ng, the DCC will conduct any request ed statistical analyses and 
prepare a summary report along with the following  information: participant enrollment reports, 
rates of adherence with the assigned tr eatment, and description of SAEs.  
Safety reports will be prepared for the IDMC approximately weekly once enrollment begins. The 
prespecified stopping thres holds are intended to guide the interpretation of interim analyses and 
are not a strict rule for early termination. It is expected that both internal and ex ternal factors will 
influence the decisions of the IDMC. The SAP w ill describe the planned interim analyses and 
futility monitoring in detail. 
10.8. Independent Data Monitoring Committee (IDMC) 
The IDMC will monitor participant safety and st udy performance. An IDMC charter that outlines 
the operating guidelines for the committee and the procedures for the interim evaluations of 
study data will be developed and agreed upon by the IDMC. Reports will be prepared by the 
DCC in accordance with the plan outlined in the ch arter, or as requested by the IDMC chair, and 
will include interim analyses of primary and secondary endpoints, additional safety events, and 
other information as requested by the committ ee. After each scheduled closed meeting, the 
IDMC will send a recommendation to the IND sponsor to continue, modify, or terminate the study. After approval, the recommen dations will be forwarded by the clinical coordi nating center 
(CCC) to investigators for submission to th eir local, regional a nd national IRB/Ethic 
Committees, as applicable. Please refer to the IDMC Charter for further details. 
10.9. Adjudication Committee 
The medical records will be requested for all part icipants reporting a hosp italization and/or death 
at any point during the study. For each participan t-reported hospitalization or death event, the 
DCRI Clinical Event Ascertainment (CEA) group will review the medical records and confirm 
the occurrence and root cause of  the event as part of an ad judication process. The CEA group 
includes specialists relevant to the hospitalization or death events of interest, additional details 
about review procedures will be prov ided in an adjudication charter.  
 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 54 11. Ethical Standards 
11.1. Institutional Review Board (IRB) 
The protocol, ICF(s), recruitment materials, and all participant materials will be submitted to the 
IRB(s) of record for review and approval. This approval must be obtained before any participant 
is enrolled. Any amendment to the protocol wi ll require review and approval by the IRB(s) 
before being implemented in the study. All changes to the consent form will also be IRB-
approved and a determination will be made regarding whether prev iously consented participants 
need to be re-consented. 
11.2. Informed Consent Process 
All consenting will occur either via an electroni c consent process or a paper process. Consent 
forms describing in detail the study drug/placebo, study procedures, and risks will be given to the 
participant and documentation of informed consen t is required prior to starting study procedures. 
Informed consent is a process that is initiated pr ior to the individualâ€™s agreement to participate in 
the study and continues throughout the individualâ€™ s study participation. A description of risks 
and possible benefits of participation will be prov ided to the participants. A description of the 
current available therapies as part of usual care  outside of this trial will be provided to the 
participants and clarification that receipt of such  therapies are not part of exclusion criteria will 
also occur. Consent forms will be IRB-approved a nd the participant will be asked to read and 
review the document. The participant will be provided a phone number and email in the event 
they have questions about study participation. This will allow them to communicate with the 
investigators (or their delegate), for further expl anation of the research study and to answer any 
questions that may arise, as necessary. Participan ts will have the opportunity to carefully review 
the consent form and ask questions prior to signing. 
The participants should have th e opportunity to discuss the st udy and think about it prior to 
agreeing to participate. The participant will si gn the informed consent document prior to any 
procedures being done specifically for the study. The participants may withdraw consent at any 
time throughout the course of the study. A copy of the informed consent document will be 
provided to the participants for their records. Th e rights and welfare of the participants will be 
protected by emphasizing to them that the quality of their medical care will not be adversely 
affected if they decline to  participate in this study. 
The study team will distinguish be tween the desire to discontinue study drug and the desire to 
withdraw consent for study follow-up. In the even t that a participant withdraws consent, the 
investigator or his/her design ee will clarify with the participant and document whether the 
withdrawal is temporary or permanent,  and if a full or partial withdrawal. 
11.3. Participant and Data Confidentiality 
Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological 
samples in addition to the clinical and private information relating to participants. Therefore, the study protocol, documentation, data, and all other in formation generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 55 third party without prior written approval of  the sponsor. The study participantâ€™s contact 
information will be securely stored  in the clinical study database. 
Study participant research data, which is for pur poses of statistical analysis and scientific 
reporting, will be transmitted to and stored at the DCC. The study data entry and study 
management systems used by clinical sites and by research staff will be secured and password 
protected. At the end of the study, all study-rela ted data storage systems will be archived 
according to local processes. 
11.4. Site Management and Quality Assurance 
The study team will work in tandem to ensure that the data collected in this study are as complete 
and correct as possible. A four-step, multi-func tional approach to quality control will be 
implemented: 
ï‚· Training: Prior to the start of enrollment , the clinician invest igators and key study 
personnel at each site will be trained with the clinical protocol and data collection 
procedures, including how to use the Electronic Data Capture (EDC) system. Follow-up 
training and training for new st udy personnel or new versions of the protocol will be 
conducted as needed. 
ï‚· Monitoring: The CCC, along with the DCC, will ensure that data collection is handled properly, will provide in-service training, and will address questi ons from site investigators 
and coordinators. Electronic review of da ta quality and completeness will occur on a 
regular and ongoing basis. Any issues will be addressed. At a minimum, source document verification will occur, as needed, for confirmation of COVID-19 diagnosis and hospitalization(s). 
ï‚· Managing data: After the data have been tr ansferred for statistical summarization, data 
description, and data analysis, further crossc hecking of the data will be performed with 
discrepant observations bei ng flagged and appropriately re solved through a data query 
system. 
ï‚· Reviewing data: Data regarding events of interest will be reviewed to ensure appropriate documents are collected for IDMC revi ew. The DCC will monitor standardized 
classification of symptoms and contact site study teams when events comprising the primary endpoint are not complete. 
11.5. Site Monitoring 
This study will employ a centralized risk-based appr oach to monitoring with  routine and periodic 
review of participant-submitted data to validate the informed consent process, select eligibility 
criteria, hospitalization, identify  and follow-up on missing data, inco nsistent data, data outliers, 
etc. and ensure completion of administrative and regulatory processes. The study team will 
facilitate regular communicat ion through training sessions, tel econferences, videoconferencing, 
email, etc. Using quality-by-design principles, steps will be taken at the study design stage to 
foresee and limit problems that might occur du ring the study conduct. Follow-up from the online 
system and call center is expected to keep par ticipants engaged. Minimal levels of intervention 
and a focus on observing rather than influenci ng the study participants greatly increases the 
likelihood that Good Clinical Practices will be  followed. Central statistical monitoring is 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 56 particularly useful for identifyi ng unusual patterns in data. An in tegrated approach to quality 
surveillance will be deployed, whic h will be detailed in the appropriate study management plans. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 57 12. Data Handling and Record Keeping 
12.1. Data Collection and Manage ment Responsibilities 
Minimizing research activities a nd conducting the trial in a pragma tic manner will increase the 
ability to complete the trial in the face of strained clinical and research resources during the 
COVID-19 pandemic. Data will be collected by electronic methods, supplemented by telephone 
or videophone follow-up and from th e electronic health record.  
Data will be collected directly from participants using REDCap  through text messaging or email 
with a survey link, or phone call as back up. Th e process for using text  messaging is Health 
Insurance Portability and Accountability Act (HIPAA) compliant.  
Site personnel or participants will enter study da ta into a secure online database. Data will be 
maintained in a secure online database until th e time of study publica tion. At the time of 
publication, the DCC will generate a de-identified version of the database for archiving (see 
Section 12.4). 
12.2. Study Records Retention 
Study documents should be retained for a minimum of six years after the study has ended. However, if required by local regulations, thes e documents should be retained for a longer 
period. No records will be destro yed without the written consent of  the sponsor, if applicable. It 
is the responsibility of  the sponsor to inform the investig ator when these documents no longer 
need to be retained. 
12.3. Protocol Deviations 
A protocol deviation is define d as non-compliance with  the clinical study protocol, GCP, or 
MOP requirements. The non-compliance may be on th e part of the participant, site investigator, 
or the site staff.  
A major protocol deviation is a significant di vergence from the protocol that may have 
significant effect on the participan tâ€™s safety, rights, or welfare a nd/or on the integrity of the study 
data. Major protocol deviations must be sent to the study IRB a nd local IRB per th eir guidelines, 
recorded in source documents, and reported to th e coordinating center. Major protocol deviations 
will be tracked. For this study, any missed or dela yed survey completion will not be considered a 
major protocol deviation. Refer to the MOP for details. 
12.4. Publication and Data Sharing Policy 
This study will comply with th e NIH Public Access Policy, wh ich ensures that the public has 
access to the results of NIH-funded research. Met hods of data sharing will include 1) archiving 
de-identified data in a data repository and 2) sharing of lim ited datasets under a Data Use 
Agreement (DUA) and IRB approval. Data will be made available to qualified investigators by 
archiving a fully de-identified dataset in a platform to be determined at the end of the trial. Both 
repositories allow users to search, view study in formation, and then submit an application to 
receive data. Prior to archiving study data, the DCC will produce a final dataset that will be 
stripped of all personal health  information (PHI) in compliance with the HIPAA privacy rule. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 58 The relative timing of an event w ill be retained in the dataset converting to study days instead of 
dates.  
The study result will be returned, in cluding some participant specific results, to enhance value from 
participation. Study results will be disseminated to the public and the me dical community through 
presentations at scientific meetings and publis hing manuscripts in high impact peer-reviewed 
journals. The International Committee of Medical Journal Editors (ICMJE) member journals have 
adopted a clinical studies regist ration policy as a condition for publication. The ICMJE defines a 
clinical study as any research project that prospectively assigns human participants to 
intervention or concurrent comparison or co ntrol groups to study the cause-and-effect 
relationship between a medical intervention and a health outcome. The ICMJE policy, and the 
Section 801 of the Food and Drug Administrati on Amendments Act of 20 07, requires that all 
clinical studies be registered in  a public registry such as Clin icalTrials.gov, which is sponsored 
by the National Library of Medici ne. For interventional clinical trials performed under NIH IC 
grants and cooperative agreements, it is the grante eâ€™s responsibility to register the study in an 
acceptable registry, so the research results may be considered for publication in ICMJE member 
journals.  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 59 13. Study Leadership 
The Steering Committee is a multi-stakeholder committee that oversees the study and includes 
representatives from clinical sites, the trial coordinating center, the NIH, PCORI, Operation 
Warp Speed, the FDA, National Center for Adva ncing Translational Scie nces (NCATS), ACTIV 
representatives with no conf lict of interest, and academic and industry advocates.  
The CCC and DCC are each overseen by PI(s). The CCC is responsible for study coordination, 
site management, communication, and financial administration. The DCC is responsible for 
treatment allocations, receipt and processing of data, quality control programs, and statistical 
analysis and reporting.   
An independent IDMC will oversee the safety and welf are of trial participants as well as provide 
recommendations for continuation, discont inuation or revision of the trial. 
 
 
Figure 3: Operational Structure Diagram 

CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 60 14. Summary of Changes 
Protocol 
Version (version 
#, date) Summary of Changes 
Version 1.0, 
01APR2021 N/A, Version 1.0 
Version 2.0, 
25MAY2
021 ï‚· Added current use of study drug or study drug/device combination as an 
exclusion criterion (Sections 1.1 and 5.2); 
ï‚· Added a phone call follow-up the day af ter first study drug dose, clarified 
that follow-up will occur if two consecutive days of reporting are missed during Days 3-14, and added that si tes/call center will collect missing 
survey information during follow-up calls (Section 7.3); 
ï‚· Added at-home pulse oximetry readings and description of at-home pulse oximetry reading collection (Table 1  and Section 8.2); 
ï‚· Added symptom severity scale (Section 8.2); 
ï‚· Added Adverse Device Effect and Un anticipated Adverse Device Effects 
definitions, collection/reporting period details, and causality assessment details (Sections 9.1.1, 9.1.2, 9.1.3, 9.1.4); 
ï‚· Clarified that hypoxia ESI will only be collected from hospitalized 
participants (Section 9.1.5 ); 
ï‚· Clarified that any missing or delayed survey completion will not be considered a major protocol deviation (Section 12.3); 
ï‚· Updated Ivermectin and matched placebo information and packaging (Sections 16.3, 16.3.1, 16.3.3, 16.4.1); 
ï‚· Added Appendix B â€“ Fluvoxamine maleate (Section 17); 
ï‚· Added Appendix C â€“ Fluticasone Furoate (Section 18); 
ï‚· Changed symptom freedom to symptom resolution for consistency throughout; 
ï‚· Other administrative changes throughout. 
Version 
3.0, 
06JUL20
21 ï‚· Clarified that the sample size increa se will include 1:1 active study drug to 
placebo (Section 1.1); 
ï‚· Added footnote 6 to COVID-19 Outcom es during Intervention Period to 
clarify that these will be  assessed on Day 7 and 14 ( Table 1 ); 
ï‚· Added that events that are COVID-19 related AND study drug related and 
unexpected will be considered reportable (Section 9.1.4); 
ï‚· Updates made to fluvoxamine appe ndix: excluded linezolid, use of 
fluoxetine within 45 days of consen t, and bipolar disorder per FDA 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 61 feedback (Section 17.2); added precautions of additional drugs including 
tramadol, buspirone, fentanyl, lithium, amphetamines, St. Johnâ€™s Wart, 
carbamazepine, quinidine, and tacrine per FDA feedback (Section 17.2.1 ); 
ï‚· Updates made to fluticasone furoate appendix: brand name Arnuity Ellipta 
replaced with fluticasone furoate throughout (Section 18); changed liver 
failure exclusion criteria to â€œmodera te to severe hepatic impairment, 
defined as Child-Pugh B or Câ€ (Section 18.2); removed hepatic 
impairment precautions as it was ad ded to exclusion criteria (Section 
18.2.1); 
ï‚· Other minor administrative changes throughout. 
Version 
4.0, 
20DEC20
21 ï‚· Removed protocol number as no protocol number will be assigned; 
ï‚· Changed primary objective from symptom reduction to effectiveness 
based on clinical outcome endpoints of  hospitalization/death or time to 
recovery (Sections 1.1 and 3);  
ï‚· Removed unnecessary â€œe.g., hospitali zation and deathâ€ from first 
secondary objective (Sections 1.1 and 3);  
ï‚· Added rationale for sIA (Sections 1.1  and 4);  
ï‚· Inclusion criterion #3: ad ded reinfection (Sections 1.1 and 5.1); 
ï‚· Exclusion criteria updates: Remove d â€œprior diagnosis of COVID-19 
infection (>10 days from screening)â€ as it was causing confusion for sites 
and is already covered by Inclusion criterion #3; specified that current or recent hospitalization for COVID-19 in fection is exclusionary, not all 
hospitalizations; added a time window for current or recent use of study 
drug or combination for within the last  14 days; added â€œcur rent or planned 
participation in another interventi onal trial to treat COVID-19, at the 
discretion of the study PIâ€ (Sections 1.1 and 5.2); 
ï‚· Sample size considerations updated to include sIA (Sections 1.1 and 10.2); 
ï‚· Statistical considerations for Primary Analysis updated to align with change in primary objective and IAs (Sections 1.1, 10.6.1, and 10.6.3); 
ï‚· Interim Analysis updated to specif y that IA will occur ~ every 300 
participants instead of every 200, in cluded sIA, and primary objective IA 
(Sections 1.1, 10.6.4, and 10.7); 
CONFIDENTIAL ACTIV-6 Protocol [v11.0] 
 
 62 ï‚· Added 
Figure 2 to portray IA process (Section 1.2); 
ï‚· Updated study background and ration ale based on new data (Sections 2.1 
and 2.2); 
ï‚· Updated secondary outcome measures  and reported endpoints (Section 3);  
ï‚· Added additional information regardi ng arm eligibility depending on the 
number of arms open to provide clarity for sites (Section 4.1); 
ï‚· Added that screen failures also incl ude participants who consent, then on 
review by the site, are found to be  ineligible for the study (Section 5.4); 
ï‚· Added additional reasons why pa rticipant may not receive study 
drug/placebo and specified that these participants would be identified as 
randomized not enrolled, instead of consented not enrolled (Section 5.5); 
ï‚· Specified that participants will be contacted directly if the miss one daily symptom reporting during Days 3 to 14 (Sections 7.3 and 9.1.2); 
ï‚· Clarified that all participants will be asked to complete symptom reporting on Days 21 and 28, regardless of symptom resolution ( Table 1 , Section 
8.1.3); 
ï‚· Added that â€œoverall symptom burdenâ€ is collected as part of Symptom Reporting (Section 8.2); 

CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 63 ï‚· Updated primary hypothesis to ali gn with updated primary objective 
(Section 10.1.1); 
ï‚· Model priors section removed and Sta tistical modeling simplified to refer 
to detailed description in SAP as models will be adjusted per appendix 
(Section 10.6.2); 
ï‚· Removed details of sensitivity anal ysis and referred to SAP (Section 
10.6.5); 
ï‚· Clarified that additional subgrouping variables may be added to the SAP 
prior to final analysis (Section 10.6.6 ); 
ï‚· Changed Appendix A â€“ Ivermectin title to Ivermectin 400 (Section 16); 
removed CYP3A4 and P-gp precautions as not noted in the IB for the ivermectin study drug (Section 16.2.1 ); in Section 16.2, deleted â€œuse of 
warfarin, CYP3A4, P-gp inhibitor drugs, or CYP3A4 substratesâ€ appendix-level exclusion criteria and added â€œCurrent or planned use of the following drugs: 
o Antiarrhythmic/antihypertens ive drug class: quinidine, 
amiodarone, diltiazem, spironolactone, verapamil 
o Antibiotic-macrolides drug class: clarithromycin, erythromycin 
o Antifungal drug class: itrac onazole, ketoconazole 
o Immunosuppressant drug class:  cyclosporine, tacrolimus 
o Anti-HIV drug class: indinavir, ritonavirâ€; 
ï‚· Added Appendix D â€“ Ivermectin 600 (Section 19); 
ï‚· Other administrative changes throughout. 
Version 
5.0, 
17MAR2
022 ï‚· Added illness severity objective (Sections 1.1 and 3); 
ï‚· Removed reference to appendix-specific  SAP, only significant deviations 
from the main SAP analysis will require appendix-specific SAPs. Choice 
of primary objective, covariates, etc. will be documented outside of the 
SAP (Sections 1.1, 10.2, 10.6, 10.6.3, 10.6.4); 
ï‚· Clarified that primary objective occurs at 28 days (Sections 1.1 and 3); 
ï‚· Updated COVID-19 status, vaccination, and treatment options background (Sections 1.1  and 2.1); 
ï‚· Defined â€œreceipt of study drugâ€ (Section 5.5); 
ï‚· COVID-19 vaccination added to abbr eviated medical history (Section 
8.2); 
ï‚· Updated instructions for unblinding (Section 10.4 ); 
ï‚· Specified that covariates will take into account emerging data and changing context (Section 10.6.2); 
ï‚· Added that this study operates in addition to usual care in additional 
protocol locations (Sections 11.2 and 2.1); 
ï‚· Appendix A closed to enrollment on 04FEB2022; 
ï‚· Appendix C closed to enrollment on 08FEB2022; 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 64 ï‚· Added Appendix E â€“ Combination Fluvoxamine Maleate and Fluticasone 
Furoate; 
ï‚· Added Appendix F â€“ Montelukast (Section 21); 
ï‚· Other administrative changes throughout. 
Version 
6.0, 
17JUN20
22 ï‚· Appendix B closed to enrollment on 27FEB2022; 
ï‚· Removed appendix for combination fl uvoxamine maleate and fluticasone 
furoate arm;  
ï‚· Added Appendix E â€“ Flu voxamine Maleate 100;  
ï‚· Added neuropsychiatric events of special interest in Montelukast 
appendix; 
ï‚· Updated the final visit from 90 to 120 days, effective only for arms 
Fluvoxamine Maleate 100 and Montelukast (footnotes added throughout for Day 120); 
ï‚· Other administrative changes throughout.  
Version 
7.0, 
08DEC20
22 ï‚· Added C-SSRS collection to the Fluvoxamine Maleate 100 Appendix on 
Day 7 and Day 14 and included in the Schedule of Events (Section 8.1.2, 
20.5, and Table 1 ); 
ï‚· Changed the Final Visit to Day 180 for participants consented to protocol 
v7.0 (Section 3, 5.3.2, 8.1.3, 8.1.4, 9.1.2, 10.6.8, and Table 1 ); 
ï‚· Added PASC Symptom Questionnaire (Section 8.1.4, 8.2, and Table 1 );  
ï‚· Added C-SSRS and PASC as abbreviations; 
ï‚· Other administrative changes throughout. 
Version 
8.0, 
19APR20
23 ï‚· Updated maximum participation durati on to align with changes made in 
the previous amendment (Section 1.1); 
ï‚· Added exclusion of previous or curr ent enrollment in the ACTIV-6 trial 
(Sections 1.1 and 5.2); 
ï‚· Updated specifics of study endpoints (Section 3); 
ï‚· Clarified statistical details (Section 10) and added the number of events 
required to perform inference (Section 10.6.2); 
ï‚· Added closure date of Appendix E â€“ Fluvoxamine Maleate 100 (Section 
20); 
ï‚· Clarified that the C-SSRS will only be done on participants enrolled in the 
fluvoxamine maleate 100 arm on pr otocol v7.0 or higher (Section 20.5); 
ï‚· Excluded ACTIV-6 study team members from enrollment on the 
montelukast appendix (Section 21.2); 
ï‚· Added details of the additional montelukast study drug provider and removed debossing details from the montelukast tablet description (Sections 21.3.1, 21.3.2, and 21.4.1); 
ï‚· Added Appendix G â€“ Metformin Hy drochloride Immediate-Release 
(Section 22); 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 65 ï‚· Other administrative changes throughout. 
Version 
9.0, 
16JUL20
23 ï‚· Expanded screening window to 7 days due to operational challenges with 
shipping drug within 2 days (Section 8.1); 
ï‚· Added hypoglycemia reporting at Day 14 for Appendix G only (Section 
8.1 and 8.1.2); 
ï‚· Added enrollment closure dates for Appendix D and F; 
ï‚· Updated exclusion criteria for Appendix G based on FDA feedback 
(Section 22.2); 
ï‚· Added lactic acidosis and hypoglycemia  as ESIs to Appendix G based on 
FDA feedback (Section 22.5); 
ï‚· Other administrative changes throughout.  
Version 
10.0, 
02AUG20
23 ï‚· Updated exclusion criteria for Appendix G based on FDA feedback 
(Section 22.2). 
Version 11.0, 26DEC20
23 ï‚· Added secondary objective (Section 3, synopsis) 
ï‚· Adjusted main analysis sample size to 3000 (Section 10.6) 
ï‚· Clarified between the analayses fo r acute COVID and PASC (Sections 
10.6.4, 22.6) 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 66 15. References 
1. COVID-19 Map FAQ . 2020  [cited 2020; Available from: 
https://coronavirus.jhu.edu/map-faq.html . 
2. McIntosh, K. Coronavirus disease 2019 . 2020  [cited 2020 March 24]. 
3. Beigel, J.H., et al., Remdesivir for the Treatment of Covid-19 â€” Final Report.  New 
England Journal of Medicine, 2020. 383(19): p. 1813-1826. 
4. Dexamethasone in Hospitalized Patien ts with Covid-19 â€” Preliminary Report.  New 
England Journal of Medicine, 2020. 
5. Gordon, A.C., et al., Interleukin-6 Receptor Antagonists in Critically Ill Patients with 
Covid-19 â€“ Preliminary report.  medRxiv, 2021: p. 2021.01.07.21249390. 
6. Baden, L.R., et al., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.  New 
England Journal of Medicine, 2020. 384(5): p. 403-416. 
7. Polack, F.P., et al., Safety and Efficacy of the BN T162b2 mRNA Covid-19 Vaccine. New 
England Journal of Medicine, 2020. 383(27): p. 2603-2615. 
8. Voysey, M., et al., Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) 
against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, 
South Africa, and the UK.  The Lancet, 2021. 397(10269): p. 99-111. 
9. Wang, Z., et al., mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating 
variants.  bioRxiv, 2021: p. 2021.01.15.426911. 
10. Grein, J., et al., Compassionate Use of Remdesivir fo r Patients with Severe Covid-19.  
New England Journal of Medicine, 2020. 382(24): p. 2327-2336. 
11. Beigel, J.H., et al., Remdesivir for the Treatment of Covid-19 â€” Preliminary Report.  New 
England Journal of Medicine, 2020. 
12. Wyatt, M.A., et al., Implementation of the â€œPregnancy Reasonably Excluded Guideâ€ for 
Pregnancy Assessment: A Qua lity Initiative in Outpatient Gynecologic Surgery.  
Obstetrics & Gynecology, 2018. 132(5): p. 1222-1228. 
13. Print, W.H.O.R.D.B. Novel Coronavirus COVID-19 Therapeutic Trial Synopsis . 2020. 
14. Cabrera Martimbianco, A.L., et al., Frequency, signs and symptoms, and criteria adopted 
for long COVID-19: A systematic review.  Int J Clin Pract, 2021. 75(10): p. e14357. 
15. Huang, C., et al., 6-month consequences of COVID- 19 in patients discharged from 
hospital: a cohort study.  The Lancet, 2021. 397(10270): p. 220-232. 
16. Hirschtick, J.L., et al., Population-Based Estimates of Po st-acute Sequelae of Severe 
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence 
and Characteristics.  Clin Infect Dis, 2021. 73(11): p. 2055-2064. 
17. Bell, M.L., et al., Post-acute sequelae of COVID-19 in  a non-hospitalized cohort: Results 
from the Arizona CoVHORT. PLOS ONE, 2021. 16(8): p. e0254347. 
18. Davis, H.E., et al., Characterizing long COVID in an inte rnational cohort: 7 months of 
symptoms and their impact.  eClinicalMedicine, 2021. 38. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 67 19. Cella, D., et al., The Patient-Reported Outcomes Me asurement Information System 
(PROMIS): progress of an NIH Roadmap coope rative group during its first two years.  
Med Care, 2007. 45(5 Suppl 1): p. S3-S11. 
20. Hays, R.D., et al., PROMIS(Â®)-29 v2.0 profile physical and mental health summary 
scores.  Quality of life research : an internati onal journal of quality  of life aspects of 
treatment, care and rehabilitation, 2018. 27(7): p. 1885-1891. 
21. Whitehead, J., Sample size calculations for ordered categorical data.  Stat Med, 1993. 
12(24): p. 2257-71. 
22. Boussinesq, M., et al., Clinical picture, epidemiology  and outcome of Loa-associated 
serious adverse events related to mass iver mectin treatment of onchocerciasis in 
Cameroon. Filaria journal, 2003. 2 Suppl 1(Suppl 1): p. S4-S4. 
23. Makenga Bof, J.C., et al., Onchocerciasis control in the Democratic Republic of Congo 
(DRC): challenges in a post-war environment.  Trop Med Int Health, 2015. 20(1): p. 48-
62. 
24. Chandler, R.E., Serious Neurological Adverse Events after Ivermectin-Do They Occur 
beyond the Indication of Onchocerciasis?  Am J Trop Med Hyg, 2018. 98(2): p. 382-388. 
25. Barkwell, R. and S. Shields, Deaths associated with iver mectin treatment of scabies.  
Lancet, 1997. 349(9059): p. 1144-5. 
26. MERCK & CO., I. TABLETS STROMECTOL (R) (IVERMECTIN) Product Label . 2009  
[cited 2021 February 12]; Available from: 
file:///U:/Personal/My%20Document s/Medical%20Writing/COVID/ACTIV-
6/Study%20Drugs/Ivermectin.pdf. 
27. Nicolas, P., et al., Safety of oral iverm ectin during pregnancy: a systematic review and 
meta-analysis.  The Lancet Global Health, 2020. 8(1): p. e92-e100. 
28. PacquÃ©, M., et al., Pregnancy outcome after inadverte nt ivermectin treatment during 
community-based distribution. The Lancet, 1990. 336(8729): p. 1486-1489. 
29. Addiss, D.G., et al., Randomised placebo-controlled  comparison of ivermectin and 
albendazole alone and in combination for <em>Wuchereria bancrofti</em> 
microfilaraemia in Haitian children.  The Lancet, 1997. 350(9076): p. 480-484. 
30. Dreyer, G., et al., Treatment of bancroftian filariasis  in Recife, Brazil: a two-year 
comparative study of the efficacy of si ngle treatments with ivermectin or 
diethylcarbamazine.  Trans R Soc Trop Med Hyg, 1995. 89(1): p. 98-102. 
31. Heukelbach, J., S. Franck, and H. Feldmeier, Therapy of tungiasis: a double-blinded 
randomized controlled tria l with oral ivermectin.  Mem Inst Oswaldo Cruz, 2004. 99(8): 
p. 873-6. 
32. Martin-Prevel, Y., et al., Tolerance a
nd efficacy of single high-dose ivermectin for the 
treatment of loiasis.  Am J Trop Med Hyg, 1993. 48(2): p. 186-92. 
33. Smit, M.R., et al., Safety and mosquitocidal efficacy of high-dose ivermectin when co-
administered with dihydroartemisinin-piperaqu ine in Kenyan adults with uncomplicated 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 68 malaria (IVERMAL): a randomised, double- blind, placebo-c ontrolled trial.  Lancet Infect 
Dis, 2018. 18(6): p. 615-626. 
34. LLC, E.P., Ivermectin Tablets USP, 7mg, 14mg Investigator's Brochure . 2021. 
35. Yang, S.N.Y., et al., The broad spectrum antiviral iver mectin targets the host nuclear 
transport importin Î±/Î²1 heterodimer.  Antiviral Res, 2020. 177: p. 104760. 
36. Caly, L., et al., The FDA-approved drug ivermectin inhi bits the replication of SARS-CoV-
2 in vitro. Antiviral Research, 2020. 178: p. 104787. 
37. Lehrer, S. and P.H. Rheinstein, Ivermectin Docks to the SA RS-CoV-2 Spike Receptor-
binding Domain Attached to ACE2.  In Vivo, 2020. 34(5): p. 3023-3026. 
38. Guzzo, C.A., et al., Safety, tolerability, and pharmacokinetics of escalating high doses of 
ivermectin in healthy adult subjects.  Journal of clinical pharmacology, 2002. 42(10): p. 
1122-1133. 
39. Chaccour, C., et al., Ivermectin and COVID-19: Keepi ng Rigor in Times of Urgency.  Am 
J Trop Med Hyg, 2020. 102(6): p. 1156-1157. 
40. Arshad, U., et al., Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities 
Based on Plasma and Target Site Concentratio ns Derived from their Established Human 
Pharmacokinetics.  Clin Pharmacol Ther, 2020. 108(4): p. 775-790. 
41. Bray, M., et al., Ivermectin and COVID-19: A report in Antiviral Research, widespread 
interest, an FDA warning, two letters to the editor and the authors' responses.  Antiviral 
research, 2020. 178: p. 104805-104805. 
42. Zhang, X., et al., Ivermectin inhibits LPS-induced pr oduction of inflammatory cytokines 
and improves LPS-induced survival in mice.  Inflamm Res, 2008. 57(11): p. 524-9. 
43. Ci, X., et al., Avermectin exerts anti-inflammatory e ffect by downregulating the nuclear 
transcription factor kappa-B and mitogen-ac tivated protein kinase activation pathway.  
Fundam Clin Pharmacol, 2009. 23(4): p. 449-55. 
44. DiNicolantonio, J.J., J. Barroso-Arranda, and M. McCarty, Ivermectin may be a clinically 
useful anti-inflammatory age nt for late-stage COVID-19.  Open Heart, 2020. 7(2): p. 
e001350. 
45. Ahmed, S., et al., A five-day course of ivermectin for the treatment of COVID-19 may 
reduce the duration of illness.  Int J Infect Dis, 2021. 103: p. 214-216. 
46. Chachar, A.Z.K., et al., Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients.  
International Journal of Sciences, 2021. 
47. Abu Taiub Mohamm
ed Mohiuddin, C., et al., A Randomized Trial of Ivermectin-
Doxycycline and Hydroxychloroquine-Azithr omycin therapy on COVID19 patients.  
Research Square, 2021. 
48. Soto-Becerra, P., et al., Real-World Effectiveness of Hy droxychloroquine, Azithromycin, 
and Ivermectin Among Hospitalized COVID-19 Patients: Results of a Target Trial 
Emulation Using Observational Data from a Nationwide Healthcare System in Peru.  
SSRN Electronic Journal, 2020. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 69 49. Hashim, H.A., et al., Controlled randomized  clinical trial on using Ivermectin with 
Doxycycline for treating COVID-19 patients in Baghdad, Iraq.  medRxiv, 2020: p. 
2020.10.26.20219345. 
50. Khan, M.S.I., et al., Ivermectin Treatment May Impro ve the Prognosis of Patients With 
COVID-19.  Arch Bronconeumol, 2020. 56(12): p. 828-830. 
51. Morgenstern, J., et al., The use of compassionate Ivermectin in the management of 
symptomatic outpatients and hospitalized patient s with clinical diagnosis of COVID-19 at 
the Medical Center Bournigal and the Me dical Center Punta Cana, Rescue Group, 
Dominican Republic, from may 1 to august 10, 2020.  medRxiv, 2020: p. 
2020.10.29.20222505. 
52. Krolewiecki, A., et al., Antiviral Effect of High-Dose I vermectin in Adults with COVID-
19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial . 2020, SSRN. 
53. Podder, C.S., et al., Outcome of ivermectin treated mild to moderate COVID-19 cases: a 
single-centre, open-label, r andomised controlled study.  IMC Journal of Medical Science, 
2020. 14(2). 
54. Ravikirti, et al., Ivermectin as a potential treatment for mild to moderate COVID-19 â€“ A 
double blind randomized pla cebo-controlled trial.  medRxiv, 2021: p. 
2021.01.05.21249310. 
55. Morteza Shakhsi, N., et al., Research Square, 2021. 
56. Espitia-Hernandez, G., et al., Effects of Ivermectin-az ithromycin-cholecalciferol 
combined therapy on COVID-19 infected patients: A proof of concept study.  Biomedical 
Research, 2020. 
57. Babalola, O., et al., Ivermectin shows clinical benefits in mild to moderate COVID19: A 
randomised controlled double bli nd dose response study in Lagos.  medRxiv, 2021: p. 
2021.01.05.21249131. 
58. NIH. COVID-19 Treatment Guidelines Fluvoxamine . 2021  [cited 2021 April 23]; 
Available from: 
https://www.covid19treatmentguidelines .nih.gov/immunomodulators/fluvoxamine/ . 
59. Apotex, Higlights of Fluvoxamine Maleate Tablets Prescribing Information . 
60. Lenze, E.J., et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients 
With Symptomatic COVID-19: A Randomized Clinical Trial.  JAMA, 2020. 324(22): p. 
2292-2300. 
61. Rosen, D.A., et al., Modulation of the sigma-1 receptorâ€“ IRE1 pathway is beneficial in 
preclinical models of inflammation and sepsis.  Science Translati onal Medicine, 2019. 
11(478): p. eaau5266. 
62. Rafiee, L., V. Hajhashemi, and S.H. Javanmard, Fluvoxamine inhibits some inflammatory 
genes expression in LPS/stimulated hum an endothelial cells, U937 macrophages, and 
carrageenan-induced paw edema in rat. Iran J Basic Med Sci, 2016. 19(9): p. 977-984. 
63. Seftel, D. and D.R. Boulware, Prospective Cohort of Fluvoxam ine for Early Treatment of 
Coronavirus Disease 19.  Open Forum Infectious Diseases, 2021. 8(2). 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 70 64. GlaxoSmithKline, Highlights of Prescribing Info rmation for Arnuity Ellipta . 2018: 
Online. 
65. Yamaya, M., et al., Inhibitory effects of glycopyrr onium, formoterol, and budesonide on 
coronavirus HCoV-229E replication and cyt okine production by primary cultures of 
human nasal and tracheal  epithelial cells.  Respir Investig, 2020. 58(3): p. 155-168. 
66. Peters, M.C., et al., COVID-19-related Genes in Sputum Cells in Asthma. Relationship to 
Demographic Features and Corticosteroids.  Am J Respir Crit Care Med, 2020. 202(1): p. 
83-90. 
67. Finney, L.J., et al., Inhaled corticosteroids downregulat e the SARS-CoV-2 receptor ACE2 
in COPD through suppression of type I interferon.  J Allergy Clin Immunol, 2021. 147(2): 
p. 510-519.e5. 
68. Kern, C., et al., Modeling of SARS-CoV-2 Treatm ent Effects for Informed Drug 
Repurposing.  Front Pharmacol, 2021. 12: p. 625678. 
69. Krolewiecki, A., et al., Antiviral effect of high-dose iver mectin in adults with COVID-19: 
A proof-of-concept randomized trial.  EClinicalMedicine, 2021. 37. 
70. Navarro, M., et al., Safety of high-dose ivermectin: a systematic review and meta-
analysis.  J Antimicrob Chemother, 2020. 75(4): p. 827-834. 
71. Smit, M.R., et al., Safety and mosquitocidal efficacy of high-dose ivermectin when co-
administered with dihydroartemisinin-piperaqu ine in Kenyan adults with uncomplicated 
malaria (IVERMAL): a randomised, double- blind, placebo-c ontrolled trial.  The Lancet 
Infectious Diseases, 2018. 18(6): p. 615-626. 
72. Reis, G., et al., Effect of early treatment with fluvoxa mine on risk of emergency care and 
hospitalisation among patients with COVID- 19: the TOGETHER randomised, platform 
clinical trial.  The Lancet Global Health, 2022. 10(1): p. e42-e51. 
73. BarrÃ©, J., J.-M. Sabatier, and C. Annweiler, Montelukast Drug May Improve COVID-19 
Prognosis: A Review of Evidence.  Frontiers in Pharmacology, 2020. 11(1344). 
74. Copertino, D.C., et al., Montelukast drug activity and potential against severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2).  J Med Virol, 2021. 93(1): p. 187-
189. 
75. Sanghai, N. and G.K. Tranmer, Taming the cytokine storm: repurposing montelukast for 
the attenuation and prophylaxis of severe COVID-19 symptoms.  Drug Discov Today, 
2020. 25(12): p. 2076-2079. 
76. Al-Kuraishy, H.M., et al., Role of leukotriene pathway and montelukast in pulmonary and 
extrapulmonary manifestations of Covid-19: The enigmatic entity.  Eur J Pharmacol, 
2021. 904: p. 174196. 
77. Mao, L., et al., 
Neurologic Manifestations of Hosp italized Patients With Coronavirus 
Disease 2019 in Wuhan, China.  JAMA Neurology, 2020. 77(6): p. 683-690. 
78. Marschallinger, J., et al., Structural and functional rejuve nation of the aged brain by an 
approved anti-asthmatic drug.  Nat Commun, 2015. 6: p. 8466. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 71 79. Khan, A.R., et al., Montelukast in hospitalized pa tients diagnosed with COVID-19.  The 
Journal of asthma : official journal of the Association for the Care of Asthma, 2021: p. 1-
7. 
80. Kerget, B., et al., Effect of montelukast therapy on clinical course, pulmonary function, 
and mortality in patients with COVID-19.  J Med Virol, 2022. 94(5): p. 1950-1958. 
81. Inzucchi, S.E., et al., Metformin in patients with type 2 diabetes and kidney disease: a 
systematic review.  Jama, 2014. 312(24): p. 2668-75. 
82. Salpeter, S.R., et al., Risk of fatal and nonfatal lactic ac idosis with metformin use in type 
2 diabetes mellitus.  Cochrane Database Syst Rev, 2010. 2010(4): p. Cd002967. 
83. Eurich, D.T., et al., Comparative safety and effectivene ss of metformin in patients with 
diabetes mellitus and heart failur e: systematic review of observational studies involving 
34,000 patients.  Circ Heart Fail, 2013. 6(3): p. 395-402. 
84. Ponikowski, P., et al., 2016 ESC Guidelines for the diagnos is and treatment of acute and 
chronic heart failure: The Task Force for the diagnosis and tr eatment of acute and 
chronic heart failure of the European Socie ty of Cardiology (ESC)Developed with the 
special contribution of the Heart Fa ilure Association (HFA) of the ESC.  Eur Heart J, 
2016. 37(27): p. 2129-2200. 
85. Chang, L.L., G.E. Umpierrez, and S.E. Inzucchi, Management of Hyperglycemia in 
Hospitalized, Non-Critically Ill Adults.  N Engl J Med, 2022. 387(11): p. 1040-1042. 
86. Haltmeier, T., et al., Insulin-Treated Patients with Diabetes Mellitus Undergoing 
Emergency Abdominal Surgery Have Worse Ou tcomes than Patients Treated with Oral 
Agents.  World J Surg, 2016. 40(7): p. 1575-82. 
87. Pasquel, F.J. and G.E. Umpierrez, Web Exclusive. Annals for Ho spitalists Inpatient Notes 
- How We Treat Hyperglycemia in the Hospital.  Ann Intern Med, 2021. 174(8): p. Ho2-
ho4. 
88. Reitz, K.M., et al., Association Between Preope rative Metformin Exposure and 
Postoperative Outcomes in Adults With Type 2 Diabetes.  JAMA Surg, 2020. 155(6): p. 
e200416. 
89. Brand, K.M.G., et al., Metformin in pregnancy and risk of  adverse long-term outcomes: a 
register-based cohort study.  BMJ Open Diabetes Res Care, 2022. 10(1). 
90. Hosey, C.M., K. Halpin, and Y. Yan, Considering metformin as a second-line treatment 
for children and adolescents with prediabetes.  Journal of Pediat ric Endocrinology and 
Metabolism, 2022. 35(6): p. 727-732. 
91. Hyer, S., J. Balani, and H. Shehata, Metformin in Pregnancy: Mechanisms and Clinical 
Applications.  Int J Mol Sci, 2018. 19(7). 
92. Kalafat, E., et al., Metformin for prevention of hypert ensive disorders of pregnancy in 
women with gestational diabe
tes or obesity: systematic review and meta-analysis of 
randomized trials.  Ultrasound Obstet Gynecol, 2018. 52(6): p. 706-714. 
93. Masarwa, R., et al., Efficacy and Safety of Metformin fo r Obesity: A Systematic Review.  
Pediatrics, 2021. 147(3). 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 72 94. Warnakulasuriya, L.S., et al., Metformin in the Management  of Childhood Obesity: A 
Randomized Control Trial.  Child Obes, 2018. 14(8): p. 553-565. 
95. Prevention;, C.f.D.C.a. Alcohol and Public Health 2022 April 19, 2022 [cited 2022 
August 25]; Available from: 
https://www.cdc.gov/alcohol/faqs.htm#:~ :text=What%20does%20moderate%20drinking
%20mean,women%2C%20when%20alcohol%20is%20consumed . 
96. Chen, X., et al., Immunomodulatory and Antiviral Activity of Metformin and Its Potential 
Implications in Treating Coronav irus Disease 2019 and Lung Injury. Front Immunol, 
2020. 11: p. 2056. 
97. Ventura-LÃ³pez, C., et al., Treatment with metformin glycinate reduces SARS-CoV-2 viral 
load: An in vitro model and randomized, double-blind, Phase IIb  clinical trial.  Biomed 
Pharmacother, 2022. 152 : p. 113223. 
98. Buse, J.B., et al., The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, 
Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-
Ranging Studies.  Diabetes Care, 2016. 39(2): p. 198-205. 
99. Henry, R.R., et al., Improved glycemic control with  minimal systemic metformin 
exposure: Effects of Metformin Delayed-Re lease (Metformin DR) targeting the lower 
bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.  PLoS One, 
2018. 13(9): p. e0203946. 
100. Bramante, C.T., et al., Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for 
Covid-19. New England Journa l of Medicine, 2022. 387(7): p. 599-610. 
 
  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 73 16. Appendix A (Enrollment Closed  04FEB2022) â€“ Ivermectin 400  
16.1. Risk Assessment 
The most commonly reported adverse events for ivermectin are pruritus (25.3%), headache 
(13.9%), and dizziness (7.5%) (ICH working group, 2003). Since the 1980s, the use of 
ivermectin in humans for the treatment of f ilariasis, especially onchocerciasis, has been 
associated with SAEs, including coma, seizure and death only when admi nistered in regions 
where onchocerciasis  and loiasis are co-endemic.[22] 
The issue of SAEs due to ivermectin is a threat to adherence to mass drug administration and the 
control and elimination of disease in communities co-endemic with O. volvulus  and Loa. Mass 
drug administration were suspended from 2004 to 2006 in some health zones in the Equateur, 
Bas Congo, and Oriental provinces in the De mocratic Republic of the Congo because of 
ivermectin-associated SAEs in the Bas Congo a nd Oriental provinces in  2003.[23] It has been 
thought that co-infection with L. loa is a risk factor for the deve lopment of thes e reactions.[24] 
Additionally, a study investigating escalating high doses of iverm ectin in healthy adults was 
performed to explore the safety of  its use in the treatment of head lice. The authors documented 
no evidence of Central Nervous System (CNS) toxi city in doses up to 10 times the highest FDA-
approved dose of 200 Âµg/kg.[25] 
Table 3  shows safety events that occurred in greate r than 5% of the clin ical trial population who 
received â‰¥ 300 Âµg/kg of ivermectin.[26]  For a detailed list of the adverse r eactions that occurred 
during clinical trials with iver mectin, refer to the product label and the Investigatorâ€™s Brochure. 
Ivermectin is pregnancy category C and is not contraindicated per FDA.  Analyses of outcomes 
of pregnancies in women inadvertently exposed to ivermectin through mass administration 
campaigns show no evidence of increased birth de fects, neonatal deaths , maternal morbidity, 
preterm births, or low birthwei ght over baselin e rates.[27, 28] 
Table 3: Ivermectin Adverse Event Table for Doses â‰¥ 300 Âµg/kg 
Indication (dose) 
Wuchererua bancrofti 
(200-400 Âµg/kg) [29] 
Wuchererua bancrofti 
(200 Âµg/kg, then 400 
Âµg/kg on day 4) [30] 
Stage II or III tungiasis 
lesions (300 Âµg/kg, 
days 1 & 2) [31]  
Loa loa infection (300 
or 400 Âµg/kg) [32] 
Symptomatic 
Plasmodium 
falciparum  malaria 
(600 Âµg/kg) [33] 
Adverse Reactions 
Abdominal Pain   7%   
Cough 42%     
Diarrhea    6.5%  
Eye disorders     9% 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 74 Fever 69% 46%  8%  
Gastrointestinal   18%    
Headache 75%  11% 16%  
Local Inflammation  9%    
Local Pain  9%    
Lumber myalgia    6.5%  
Malaise  27%    
Myalgia 37%     
Neurological  15%    
Pneumonia     9% 
Pruritus    60%  
Renal  33%    
Respiratory  33%    
16.2. Additional Appendix-Leve l Exclusion Criteria 
1. End-stage renal disease on renal replacement therapy 
2. Liver failure or decompensated cirrhosis 
3. Current or planned use of the following dr ugs during the study, listed by drug class: 
a. Antiarrhythmic/antihypertensive drug class: quinidine, amiodarone, diltiazem, 
spironolactone, verapamil 
b. Antibiotic-macrolides drug class: clarithromycin, erythromycin 
c. Antifungal drug class: itrac onazole, ketoconazole 
d. Immunosuppressant drug class:  cyclosporine, tacrolimus 
e. Anti-HIV drug class: indinavir, ritonavir 
4. Nursing mothers 
5. Pregnancy*  
*Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after thei r final dose of study drug. Effective methods 
include any of the following: absti nence, partner vasectomy, bila teral tubal ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
16.2.1. Precautions 
While rare, post-marketing reports indicate an in creased International Normalized Ratio (INR) 
when ivermectin was co-administered with warfarin. With a 3-day dosing period this is unlikely 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 75 to be a significant issue, but INR monitoring can  be recommended to the care provider if felt 
warranted by site investigator.   
16.3. Ivermectin Information  
Ivermectin is a semisynthetic oral agent used prim arily as an anti-parasitic agent. It is derived 
from highly active, broad-spectrum, an ti-parasitic agents isolated from Streptomyces avermitilis  
fermentation products. It binds se lectively, and with high affinit y, to glutamate-gated chloride 
ion channels, therefore increasing cell membrane permeability to chloride ions resulting in death 
of the parasite.[34] It is currently FDA-approve d for the following indica tions: strongyloidiasis 
of the intestinal tract due to the nematode parasite Strongyloides stercoralis  and onchocerciasis 
due to the nematode parasite Onchocerca volvulus.[26] Per the FDA-approved labelling of 
ivermectin, the recommended dose is 200 Âµg/kg/da y to treat strongyloidias is and 150 Âµg/kg/day 
to treat onchocerciasis in the form of a 3 mg tablet.    
16.3.1. Formulation, Appearance, Packaging, and Labeling 
Ivermectin is a white to yellowish-white, nonhyg roscopic, crystalline powder. For this study, 
ivermectin will be supplied as fifteen 7-mg tablet s in a bottle with a single panel label. The 
tablets are white, round, biconvex ta blets with â€œ123â€ over the scor ing on one side. All packaging 
will be labeled to indicate that the product is for investigational use. 
16.3.2. Drug Dispensing, Storage, and Stability 
Ivermectin will be supplied as 7-mg tablets and must be stored at temperatures below 30Â°C. 
16.3.3. Dosing and Administration 
Ivermectin should be taken on an empty stomach with water (30 minutes before a meal or 2 
hours after a meal). Each partic ipant will receive a bottle of fi fteen 7-mg tablets and will be 
instructed to take a pre-specified number of ta blets for 3 consecutive days based on their weight 
(see Table 4 ) for a daily dose of approximately 300-400 Âµg/kg. 
Table 4: Ivermectin 400 Dosing Schedule 
Weight (kg) Day 1 (# of 7-
mg tablets) Day 2 (# of 7-
mg tablets) Day 3 (# of 7-
mg tablets) Daily Dose 
(Âµg/kg) 
35-52 2 2 2 269-400 
53-69 3 3 3 304-396 
70-89 4 4 4 315-400 
> 90 5 5 5 â‰¤ 389 
16.3.4. Rationale for Selection of Dose 
Pre-clinical studies: 
Reports from in vitro studies suggest that ivermectin acts  against ribonucleic acid (RNA) viruses 
such as SARS-CoV-2 by inhibiting the host importin Î±/Î²-mediated nuclear transport that prevent 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 76 viral proteins from entering the nucleus to alte r host cell function.[35] A single dose addition of 
ivermectin to Vero-hSLAM cells 2 hours post inf ection with SARS-CoV-2 was able to effect a 
5000-fold reduction in viral RNA at 48 hours  and may interfere with the attachment of SARS-
CoV-2 spike protein to the human cell membrane.[36, 37] 
Ivermectin has been shown to inhibit the replic ation of SARS-CoV-2 in  cell culture. However, 
pharmacokinetic and pharmacodynamic studies sugge st that ivermectin doses up to 100-fold 
higher than those approved for use in humans  would be required to achieve the plasma 
concentrations necessary to dupli cate the drugâ€™s antiviral efficacy in vitro.[38, 39] Even though 
ivermectin appears to accumulate  in lung tissue, with the doses used in most clinical trials, 
predicted systemic plasma and lung tissue concentrations are mu ch lower than 2 ÂµM, the half-
maximal inhibitory concentration (IC 50) against SARS-CoV-2 in vitro .[40, 41] 
Ivermectin demonstrates potential an ti-inflammatory properties in some in vitro 
studies, properties which have been postulated to be benefici al in the treatment of COVID-
19.[42-44]  The dose range for an anti-inflammatory effect may be lower than for the anti-viral 
effects.[44]   
Clinical studies: 
A number of retrospective cohort studies and the results of several randomized trials of 
ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or 
made available as preliminary, non-peer-reviewed  reports. Some clinical studies showed no 
benefits after ivermectin use, whereas others reported shorter time to resolution of disease 
manifestations attributed to COVID-19, greater reduction in infl ammatory markers, shorter time 
to viral clearance, or lower mortality rates in pa tients who received ivermectin than in patients 
who received comparator drugs or placebo.[45-50] 
Most of the studies reported to date are limited by their small sample size, varying dosing 
schedules and the adjunctive use of various concomitant medications (e.g., doxycycline, 
hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true efficacy or safety of ivermectin. Clinical studi es in outpatients with COVID-19 did not always 
describe the severity of COVID-19 and the stud y outcome measures were not always defined. 
Nonetheless, while some have shown no difference,  most clinical trials of outpatients with 
mild/moderate COVID-19 have shown clinical improvement with even a single dose
 or a short 
two to five-day course of ivermectin given orally shortly after sy mptom onset.[39, 49, 51, 52]  
There is a dose-dependent relationship between ivermectin dose and clinical efficacy. Trials 
using lower doses of ivermectin tend to show  no or minimal clinical benefit in COVID-19 
patients treated in the outpatient or hospita l setting.[53, 54] Higher dos es, at least 0.4 mg/kg, 
particularly when administered in multiple doses , have been shown to significantly reduce time 
to recovery and mortality as compared with lower doses or placebo/standard care.[51, 55-57] 
There is a concentration-depende nt virologic response seen usi ng higher-than-usual doses of 
ivermectin (600 Î¼ g/kg vs 200 Î¼ g/kg once daily for 5 days) that ha ve been shown to significantly 
reduce the time to PCR viral positivity over standard doses with minimal associated 
toxicities.[52]  
The safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin was tested 
in healthy adult subjects.[ 38] Doses from 30 mg/day (347-571 Âµg/kg)  to 120 mg/day  (1404-2000 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 77 Âµg/kg)  given for 3 days were all well tolerated.[38] These data coupled with evidence of superior 
clinical efficacy of doses in the lower of this  range provide the rationale for the 300-400 Âµg/kg 
dose given for 3 days in the proposed trial. 
16.4. Placebo Information  
16.4.1. Formulation, Appearance, Packaging, and Labeling 
Placebo will match the appearance of the 7-mg iv ermectin tablets: white, round, biconvex tablets 
with â€œ123â€ over the scoring on one  side. A total of fifteen tabl ets will be provided in a bottle 
with a single panel label. The placebo formula tion includes the following ingredients in a 210 mg 
tablet: microcrystalline cellulose, NF (MC-102;  pregelatinized starch, NF (Starch 1500); 
croscarmellose sodium, NF (Vivasol, GF Grade); colloidal silicon dioxide, NF (Aerosil 200) and 
magnesium stearate, NF (2257). All packaging will be labeled to i ndicate that the product is for 
investigational use. 
16.4.2. Drug Dispensing, Storage, and Stability 
Placebo must be stored at temperatures below 30Â°C. 
16.4.3. Dosing and Administration 
Dosing and administration will occur according to Section 16.3.3 in order to maintain blinding.  
16.5. Events of Special Interest 
None 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 78 17. Appendix B (Enrollment Closed 27MAY2022) â€“ Fluvoxamine Maleate  
17.1. Risk Assessment 
The most common adverse effects of fluvoxamine described in the setting of treatment of 
psychiatric conditions include ga strointestinal effects, neurological effects, dermatological 
reactions, and in rare cases suic idal ideation.[58] In two 10-week controlled trials in Obsessive 
Compulsive Disorder (OCD) a nd depression at doses ranging from 100-300 mg/day, the most 
commonly observed adverse reactions associated with the use of fluvoxamine maleate tablets 
(incidence of 5% or greater a nd at least twice that for placebo) were nausea, somnolence, 
insomnia, asthenia, nervousness, dyspepsia, a bnormal ejaculation, swea ting, anorexia, tremor, 
and vomiting (see Table 5 ).[59]   
Table 6 lists the complete set of a dverse events identif ied in a randomized clinical trial of 
fluvoxamine (300 mg/day for 15 days) versus placebo in 152 COVID- 19 participants.[60] 
Adverse events and serious adverse events were more common in the placebo arm and the single 
SAE in the fluvoxamine arm was dehydration and the study medication was not interrupted.[60]  
Table 5. Fluvoxamine Adverse events occurrin g in 10-week studies of adult OCD or 
depression 
 *Table shows events that occurred in â‰¥ 5% of adult OCD and depression study 
participants receiving 100- 300 mg/day for 10 weeks of fluvoxamine maleate versus 
placebo. [59] 
Adverse Reaction Fluvoxamine, 
n=892 (%) Placebo, 
n=778 (%) 
Headache 22 20 
Asthenia 14 6 
Nausea 40 14 
Diarrhea 11 7 
Constipation 10 8 
Dyspepsia 10 5 
Anorexia 6 2 
Vomiting 5 2 
Somnolence 22 8 
Insomnia 21 10 
Dry Mouth 14 10 
Nervousness 12 5 
Dizziness 11 6 
Tremor 5 1 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 79 Anxiety 5 3 
 
Table 6. Fluvoxamine Adverse events that occurred in COVID-19 study participants 
receiving 300 mg/day for 15 days. 
Adverse Reaction [60] 
 Fluvoxamine, n=80 
(%) Placebo, n=72 
(%) 
Pneumonia 3.8 8.3 
Shortness of breath 2.5 5.6 
Headache or head pain 2.5 1.4 
Gastroenteritis, nausea, or vomiting 1.3 6.9 
Muscle aches 1.3 0 
Bacterial infection 1.3 0 
Vasovagal syncope 1.3 0 
Teeth chattering 1.3 0 
Dehydration 1.3 0 
Low oxygen saturation or hypoxia 0 8.3 
Chest pain or tightness 0 2.8 
Fever 0 2.8 
Acute respiratory failure 0 1.4 
Serious adverse events 1.3 6.9 
Other adverse events 13.8 8.3 
17.2. Additional Appendix-Leve l Exclusion Criteria 
1. Use of selective serotonin (or norepinephrine)  reuptake inhibitors (SSRIs/SNRIs), 
including fluvoxamine, or monoamine oxi dase inhibitors (MAOIs) within 2 
weeks of consent including triptans and tryptophan. Use of fluoxetine within 45 
days of consent.  
2. Co-administration of tizanidine, thiori dazine, alosetron, pimozide, diazepam, 
ramelteon, linezolid 
3. Bipolar Disorder 
4. Nursing mothers 
5. Pregnancy* 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 80 *Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after thei r final dose of study drug. Effective methods 
include any of the following: absti nence, partner vasectomy, bila teral tubal ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
17.2.1. Precautions 
Fluvoxamine is a potent inhibitor of CYP1A2 and 2C19 and a moderate inhibitor of CYP2C9, 
2D6, and 3A4, as such, it may enhance anticoagulan t effects of antiplatelets and anticoagulants 
as well as other medications. It is recommended that concomitant medications listed below be 
discussed with participants and potential e ffects of increased drug exposure reviewed and 
monitored by the participant and/or their prescribing clinician. 
ï‚· Tricyclic antidepressants: monitor for side effects with amitriptyline, clomipramine, 
imipramine 
ï‚· Antipsychotic drugs: neuroleptic malignant  syndrome or similar; particularly 
clozapine (hypoten sion, seizure) 
ï‚· Benzodiazepines: particularly alpr azolam; recommend dose reduction  
ï‚· Tramadol, buspirone, fentanyl, lithiu m, amphetamines, St. Johnâ€™s Wart, 
carbamazepine, quinidine, and tacrine 
ï‚· Methadone: opioid intoxication 
ï‚· Mexiletine: monitor for side effects 
ï‚· Theophylline: recommend dose reduction and monitor for side effects 
ï‚· Warfarin: monitor INR 
ï‚· NSAIDS or aspirin: monitor for signs of bleeding 
ï‚· Diltiazem, propranolol, metoprol ol: monitor for bradycardia 
Participants should be warned about fluvoxa mine inhibition of caffeine metabolism. A 
description is 1 cup of coffee has the eff ects of 4 cups while taking fluvoxamine.  
Caution should be used in participants with  hepatic dysfunction due to approximately 30% 
increase in exposures.  
17.3. Fluvoxamine Information  
Fluvoxamine is an FDA-approved SSRI for the treatme nt of OCD. Clinically  it is also used for 
other conditions such as depression.[58] The active ingredient in fluvoxamine is fluvoxamine 
maleate.  17.3.1. Formulation, Appearance, Packaging, and Labeling 
Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has â€œAPOâ€ 
and the other side has â€œF50â€ with a partial bisect. All packaging will be la beled to indicate that 
the product is for investigational use. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 81 17.3.2. Drug Dispensing, Storage, and Stability 
Drug will be supplied by Apotex and distribut ed by Belmar Pharmacy. Study drug should be 
stored in controlled room temperature (20Â°C to 25Â°C); excursions are permitted to 15Â°C to 30Â°C. 
17.3.3. Dosing and Administration 
Fluvoxamine will be self-administered orally by each participant at a dos e of 50 mg BID for 10 
days. 
17.3.4. Rationale for Selection of Dose 
The recommended starting dose of fluvoxamine for OC D in adults is 50 mg daily dose to be 
titrated up to a maximum of 300 mg/day divided in to BID doses. Clinical data from the placebo-
controlled, randomized trial in nonho spitalized adults with mild C OVID-19 demonstrated that a 
50 mg BID fluvoxamine dose was we ll-tolerated and effective (see Figure 5 ).[60] In the same 
study, doses of 100 mg BID in COVI D-19 participants resulted in additional side effects over a 
14-day period. The 300 mg daily dose is for se rotonin receptor activity, whereas the postulated 
dose for sigma-1 receptor activity as an anti-inf lammatory is lower. Therefore, the proposed 
dosing regimen of 50 mg BID for 10 days will use the anticipated minimal effective dose to 
maximize efficacy and minimize toxicity. 
Pre-Clinical Studies: 
Pre-clinical studies have indica ted that the anti-inflammatory e ffects of fluvoxamine may support 
its use for treating COVID-19. Systemic inflamma tion as a result of infection can damage 
vasculature which may lead to tissue hypoperfus ion and multiple organ failure.[61] Reducing 
systemic inflammation thereby may avoid or mitigate the aforementioned serious clinical 
outcomes. In murine studies, administration of  fluvoxamine significantly increased survival of 
S1R wildtype (WT) mice and S1R knoc kout (KO) mice challenged with ligand 
lipopolysaccharide (LPS) as compared  to mice that received saline ( Figure 4 ).[61] Fluvoxamine 
also reduced production of in flammatory cytokines in ex vivo  and in vitro murine and human 
cells (HEK293mTLR4/MD2/CD14, primary lung fibroblasts, and mouse bone marrow-derived 
macrophages) and inflammatory genes in human endothelial cells.[61, 62] 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 82  
Figure 4: Survival curve of WT and S1R KO mice  
Figure note: Mice were treated wi th vehicle (33% Kolliphor in sa line) or STF (30 mg/kg) after 
administration of LPS (2 mg/kg) as indicated in (B) (n = 15 to 16 mice per group; **P < 0.01, 
***P < 0.001, log-rank test). [61] 
Clinical Studies: 
A placebo-controlled, randomized tr ial in nonhospitalized ad ults with mild COVID-19 tested the 
efficacy and safety of fluvoxamine (50 mg oral one-time dose, followed by 100 mg orally twice 
daily for 2 days, followed by 100 mg orally three times daily through day 15) versus placebo 
[60]. Results of the study reported that 8.3% (6/7 2) of participants who received placebo 
experienced clinical deteriorati on within 15 days of randomization, as opposed to 0% (0/80) in 
the fluvoxamine arm (absolute difference 8.7%;  95% CI, 1.8% to 16.5%; P = 0.009) .[60]  
Clinical deterioration was defined as shortness of breath/pneumonia with hypoxia ( Figure 5 ). 
Concomitant SSRI/SNRI dosing was not allowed pe r the trial protocol thus the participantâ€™s 
SSRI/SNRI was held for the study dosing period if reported at baseline.  

CONFIDENTIAL ACTIV-6 Protocol [v11.0] 
 
 83  
Figure 5: Summary of JAMA Randomization Clinical Trial of Fluvoxamine for Early 
COVID-19.  
A prospective, nonrandomized observational co hort study that evaluated fluvoxamine showed 
that on Day 14, 0/65 participants had persistent symptoms as oppos ed to 19/48 participants who 
did not receive fluvoxamine (P < 0.001) [63] . Additionally, by Day 14, none of the participants 
who received fluvoxamine were hospitalized as  compared to 6 participants who were 
hospitalized who did not receive the drug (see Figure 6 ). In this study, a ll participants were 
offered fluvoxamine and decided whether or not to take the study drug. Participants who chose to 
receive the study drug received 50 mg of fluvoxami ne two times a day following an upfront 100 
mg loading dose.[63]  
 
Figure 6: Summary of study results for the prospective, nonrandomized observational 
cohort study with fluvoxamine in participants diagnosed with COVID-19.   

CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 84 17.4. Placebo Information  
The placebo will be a fluvoxamine-matched place bo containing mannitol, magnesium stearate, 
hydroxyethyl cellulose, polyethylene glycol, titan ium dioxide, yellow ferr ic oxide, and purified 
water. The appearance and packaging will match that of the study drug (as described in Section 
17.3.1). All packaging will be labeled to indicate th at the product is for investigational use.  
17.4.1. Formulation, Appearance, Packaging, and Labeling 
Placebo will match the appearance of the fluvoxamine  tablets: round golden 50 mg tablet that is 
scored on both sides - one side has â€œAPOâ€ and the other side has â€œF50â€ with a partial bisect. All 
packaging will be labeled to indicate that the product is for investigational use. 
17.4.2. Drug Dispensing, Storage, and Stability 
Placebo will be supplied by Apotex  and distributed by Belmar Pharmacy. Placebo should be 
stored in controlled room temperature (20Â°C to 25Â°C). 
17.4.3. Dosing and Administration 
Participants will self-administer one place bo tablet orally, twice daily for 10 days. 
17.5. Events of Special Interest 
None 
 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 85 18. Appendix C (Enrollment Closed 08FEB2022) â€“ Fluticasone Furoate 
18.1. Risk Assessment 
The most common adverse reactions reported in â‰¥ 5% of adults and adolescents with lung 
disease include nasopharyngitis, bronchitis, uppe r respiratory tract infection, and headache. 
Long-term use of systemic and local  corticosteroids may also result  in the following side effects: 
Candida albicans  infection, immunosuppression, hype rcorticism and adrenal suppression, 
reduction in bone mineral density (BMD),  or glaucoma and cataracts.[64] 
There are insufficient data on the use of fluticasone furoate in pregnant women. There are 
clinical considerations with use of fluticas one furoate in pregnant women to inform drug-
associated risk and benefit. In animal reproduc tion studies, fluticasone furoate administered by 
inhalation to rats and rabbits during the period of organogenesi s produced no fetal structural 
abnormalities. The highest fluticasone furoate doses in the rat and rabbit studies were 4 times and 
1 times the maximum recommended human daily inhalation dose, respectively. The estimated 
risk of major birth defects and miscarriage for the indicated populati ons is unknown. In the US 
general population, the estimated risk of major birth defects and miscarriage in clinically 
recognized pregnancies is 2% to 4%  and 15% to 20%, respectively.[64] 
Disease-Associated Maternal a nd/or Embryofetal Risk: In women with poorly or moderately 
controlled asthma, there is an increased risk of several perinatal outcomes such as pre-eclampsia 
in the mother and prematurity, low birth weight, a nd small for gestational age in the neonate.[64]  
Table 7. Fluticasone Adverse reactions that occurred in â‰¥3% of adults and adolescents 
with asthma in a 24-week trial.  
Adverse Reaction [64] Fluticasone furoate,  
fluticasone 200 Âµg, n=119 
(%) Fluticasone furoate, 
fluticasone 100 Âµg, 
n=119 (%) 
Nasopharyngitis 13 12 
Headache  13 10 
Bronchitis 7 12 
Influenza 7 4 
Upper Respiratory tract infection 6 2 
Sinusitis 4 7 
Oropharyngeal pain  4 3 
Pharyngitis 3 6 
Back pain 3 3 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 86 Dysphonia 3 2 
Oral candidiasis 3 <1 
Procedural pain 3 <1 
Rhinitis 3 <1 
Throat irritation 3 <1 
Abdominal pain 3 0 
Cough 3 0 
18.2. Additional Appendix-Leve l Exclusion Criteria 
1. Severe hypersensitivity to milk proteins  
2. Currently prescribed or use within 30 days of inhaled or systemic steroids 
3. Moderate to severe hepatic impairment, defined as Child-Pugh B or C 
4. Nursing mothers 
5. Pregnancy* 
*Participants must agree to use an effective method of contraception during study drug 
administration and for at least 3 days after thei r final dose of study drug. Effective methods 
include any of the following: absti nence, partner vasectomy, bila teral tubal ligation, intrauterine 
device, progestin implants, or barrier (condom, diaphragm, cervical cap) plus spermicide.  
18.2.1. Precautions 
While not contraindicated, the following should be considered while taking fluticasone furoate: 
ï‚· Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, 
conivaptan, indinavir, itr aconazole, lopinavir, nefazodone, nelfinavir, saquinavir, 
telithromycin, troleandomycin, voriconazole ) should be used with caution as 
increased systemic corticosteroid adverse effects may occur in combination with fluticasone furoate. Generally, due to the limited study drug administration length, 
clinically significant interactions are unlikely.  
ï‚· Paradoxical Bronchospasm may occur with an immediate increas e in wheezing after 
dosing. Fluticasone furoate should be disc ontinued immediately if this occurs.  
18.3. Fluticasone Furoate Information  
Inhaled fluticasone furoate will be provided by GlaxoSmithKline. It  is a synthetic trifluorinated 
inhaled corticosteroid (ICS) w ith anti-inflammatory activity. In vitro  and in vivo  models have 
shown that fluticasone furoate demonstrates anti-inflammatory actions by activating the 
glucocorticoid response element, inhibiting pre-inflammatory tr anscription factors such as 
NFkB, and inhibiting antigen-induc ed lung eosinophilia, which may contribute to its efficacy in 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 87 the approved indications. It is FDA-approved for once-daily maintenance treatment of asthma as 
prophylactic therapy in patient s 5 years and older.[64]  
18.3.1. Formulation, Appearance, Packaging, and Labeling 
Fluticasone furoate is an inha led powder drug product. It is  a synthetic trifluorinated 
corticosteroid that is insoluble in water. Fl uticasone furoate is a white powder. Fluticasone 
furoate will be provided in a tw o tone grey inhaler with a mouthpiece cover and separate foil 
blister strips. The blister strips used for this  study will contain a white powder mix with a 
mixture of 200 Âµg micronized fluticasone furoat e and lactose monohydrate. The inhaler will be 
packaged in a moisture-protective foil tray with  a desiccant and a peelab le lid.[64] All packaging 
will be labeled to indicate that the product is for investigational use. 
18.3.2. Drug Dispensing, Storage, and Stability 
The study drug should be stored at room temperature (20Â°C to 25Â°C) with excursions permitted 
from 15Â°C to 30Â°C. It should be stored in a dry environment away from direct heat or sunlight. 
Unopened fluticasone furoate should be stored in side the unopened moisture-protective foil tray 
and only removed immediately before use. An y unused study product should be discarded 6 
weeks after opening the foil tray or when the counter reads â€œ0â€ (after all blisters have been used), 
whichever comes first. The inhaler is not reus able.[64] The study product has a shelf life of 24 
months when stored at â‰¤ 25Â°C. After removal of the secondar y package and the desiccant packet 
from the inhaler, the product ma y be stored up to 6 weeks at â‰¤ 25Â°C.  
18.3.3. Dosing and Administration 
Fluticasone furoate is a self-administered inha led drug. Participants will self-administer 200 Âµg 
(1 blister) of fluticas one furoate once daily for 14 days. After inhaler activ ation, the powder 
within the blister is exposed and the particip ant inhales the study drug through the mouthpiece.  
18.3.4. Rationale for Selection of Dose 
Inhaled corticosteroids (ICS) have been shown to be effective in improving asthma and as a 
combination therapy in chroni c obstructive pulmonary  disease (COPD) a nd thus are commonly 
prescribed medications world-wide. Corticosteroid s have been shown to have a broad range of 
pharmacologic activity on multiple cell types in cluding mast cells, eosinophils, neutrophils, 
macrophages and lymphocytes, as well as other me diators of inflammation such as histamine, 
eicosanoids, and leukotrienes. In addition to the anti-inflammatory role of ICS, there is also 
potential for regulation of gene transcription in  epithelial cells.[65-67] Th is regulation of gene 
transcription may result in inhi bition of SARS-CoV-2 replication. Furthermore, in asthmatic 
patients, ICS may lower gene expression of ACE2 and TMPRSS2. The ACE2 receptor is 
expressed on epithelial cells and binds SARS-CoV -2 for entry and the serine protease TMPRSS2 
primes the SARS-CoV-2 spike protein for bi nding. Lowering gene expression of ACE2 and 
TMPRSS2 may reduce binding and entry into cells therefore reducing or preventing infection.  
Clinical Studies: 
The PRINCIPLE (Platform Randomized trial of  Interventions against COVID-19 in Older 
People) trial is a multicenter, open-label, multi-arm, adaptive randomized, platform trial. The 
trial is ongoing and released an interim analysis  after the Trial Steering Committee advi sed the 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 88 Trial Management Group that the pre-specifie d superiority criterion wa s met on the time to 
recovery in the overall study population and the s ubgroup of participants with confirmed positive 
SARS-CoV-2 testing. Part icipants were eligible  if aged >65 years, or >50 years with 
comorbidities and had ongoing symptoms from PCR confirmed or suspected COVID-19 with 
symptoms starting within the past 14 days. Pa rticipants were randomi zed to any open active 
intervention arm including inhaled budesonide and usual care. Participants were followed 
through an online, daily symptom diary for 28 days. Participants received us ual care plus inhaled 
budesonide 800 Âµg daily for 14 days or usual care alone. The primary outcome of the trial at the 
start was hospitalization or death within 28 days ; however, the rate of hospitalization was lower 
than initially expect ed thus the Trial Management Gr oup and the Trial Steering Committee 
recommended amending the primary outcome to in clude a measure of illness duration. The trial 
was completed with two co-primary endpoints m easured within 28 days of randomization: 1) 
time to first reported recovery defined as the first day that a participant reported feeling 
recovered; and 2) hospitalization or death related to COVID-19.  
The interim analysis included eligible SARS-C oV-2 positive participants who were randomized 
to inhaled budesonide (N=751) or usual care  alone (N=1028). The mean age was 62.8 years and 
83% of participants had co-morbidities. The medi an days from symptom onset to enrollment was 
6 days. There was evidence of a benefit in time-to- first-recovery in the budesonide arm with an 
estimated median benefit of 3 days. The point  estimate of the proportion of COVID-19 related 
hospitalizations or deaths was lower in the bude sonide group (8.5%) versus  usual care (10.3%), 
but this did not meet statisti cal significance (95% BCI -0.7 â€“ 4.8 %). There were two SAEs for 
hospitalization unrelated to COVI D-19, both in the budesonide group.  
A smaller trial of 146 nonhospitalized adults with mild COVID-19 reported that inhaled 
budesonide at the same dose reduced COVI D-19 related emergency assessments and 
hospitalization.  
The dose of ICS studied is PRINCIPLE is consistent with a high dose of inhaled steroid. The 
equivalent high dose of fluticasone furoate is 200 Âµg/day. Inhaled fluticasone furoate has a 
greater anti-inflammatory potency per microgram than budesonide, thus fluticasone furoate is 
administered at a lower daily dose and used onl y once daily to achieve a similar high dose.  
18.4. Placebo Information  
18.4.1. Formulation, Appearance, Packaging, and Labeling 
The placebo will be a fluticasone furoate-matche d placebo containing lactose for inhalation in 
the same two tone grey inhaler that is used  for the study drug. The appearance and packaging 
will match that of the study drug (as described in Section 18.3.1). All packaging will be labeled 
to indicate that the product is for investigational use. 
18.4.2. Drug Dispensing, Storage, and Stability 
Placebo will be stored in the same conditions as study drug, room temperature (20Â°C to 25Â°C) 
with excursions permitted from 15Â°C to 30Â°C in a dry environment away from direct heat or 
sunlight. The placebo has a shelf life of up to 36 months when stored at â‰¤ 30Â°C. 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 89 18.4.3. Dosing and Administration 
Participants will self-administer one blister of placebo via inhalation from the inhaler once daily 
for 14 days.  
18.5. Events of Special Interest 
None 18.6. Safety Reporting for Fluticasone Furoate 
Sponsor will promptly notify GlaxoSmithKlin e of all SAEs, UADEs, and pregnancies (if 
applicable), and medical device deficiencies that have occurred for participants enrolled in this 
Study Drug Appendix, in accordance with the ti melines and procedures specified in the 
Protocol/appendix. In addition, the sponsor will reasonably obtain and provide follow-up 
information as available, to GSK upon request.  
 
  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 90 19. Appendix D (Enrollment Closed  22JUL2022) â€“ Ivermectin 600 
19.1. Risk Assessment 
Refer to Section 16.1. 
19.2. Additional Appendix-Leve l Exclusion Criteria 
Refer to Section 16.2. 
19.2.1. Precautions 
Refer to Section 16.2.1. 
19.3. Ivermectin Information  
Refer to Section 16.3. 
19.3.1. Formulation, Appearance, Packaging, and Labeling 
Refer to Section 16.3.1. 
19.3.2. Drug Dispensing, Storage, and Stability 
Refer to Section 16.3.2. 
19.3.3. Dosing and Administration 
Ivermectin should be taken on an empty stomach with water (30 minutes before a meal or 2 
hours after a meal). Each particip ant will receive a bottle containi ng the number of 7-mg tablets 
they require based on their weight and will be inst ructed to take a pre-specified number of tablets 
for 6 consecutive days based on their weight (see Table 8 ) for a daily dose of approximately 
400-600 Âµg/kg. 
Table 8. Ivermectin 600 Dosing Schedule 
Weight 
(kg) Day 1 (# 
of 7-mg 
tablets) Day 2 (# 
of 7-mg 
tablets) Day 3 (# 
of 7-mg 
tablets) Day 4 (# 
of 7-mg 
tablets) Day 5 (# 
of 7-mg 
tablets) Day 6 (# 
of 7-mg 
tablets) Daily Dose 
(Âµg/kg) 
35-52 3 3 3 3 3 3 403-600 
53-69 4 4 4 4 4 4 406-528 
70-89 6 6 6 6 6 6 470-600 
90-109 7 7 7 7 7 7 450-540 
110-129 8 8 8 8 8 8 434-509 
> 129 10 10 10 10 10 10 < 540 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 91 19.3.4. Rationale for Selection of Dose 
Refer to Section 16.3.4. 
Additional relevant pre-clinical studies : 
Modeling studies have supported high dose and longer duration of ivermectin. One modeling 
study reported 600 Âµg/kg daily for 3 days may have  clinical effect while 300 Âµg/kg for 3 days 
was unlikely to have efficacy.[68] Following th is modeling study, a recen tly published proof-of-
concept randomized controlled clinical trial in ho spitalized patients showed that 600 Âµg/kg 
ivermectin for 5 days, a dose still well within the range for safety, was associated with IC 50 for 
anti-viral activity in vitro  while lower doses (300 Âµg/kg) were not.[69] The anti-viral activity was 
identified in the subgroup of patients on ivermec tin with higher mean plasma concentrations. 
When the ivermectin group was further divide d into subgroups with 160 ng/mL as the plasma 
concentration cutoff, the median Cmax ach ieved was 202 ng/mL in those with plasma 
concentration >160 ng/mL and this group had greater reduction in viral load at day 5. These data 
argue for the use of higher dosing regimens in clinical trials. 
The safety of higher doses of ivermectin is well understood. At least six published trials have 
administered ivermectin at doses above 400 Âµg/kg.[70] These include over 2,500 independent 
administrations of cumulative 800 Âµg/kg within one week an d over 2,000 single dose 
administrations of 800 Âµg/kg. The primary side effect of higher doses, usually due to peak 
concentrations, is transient and mild visual dist urbances not found to be structural and found to 
self-resolve. One such study randomized 47 patien ts with malaria to receive ivermectin 600 
Âµg/kg daily for 3 days versus 300 Âµg/kg daily for 3 days versus placebo.[71] The 600 Âµg/kg group had more adverse events than the other gro ups. Treatment-related adverse events exhibited 
a dose-response relationship, with predominantly tr ansient minor visual disturbances that were 
deemed non-severe.  
19.4. Placebo Information  
Refer to Section 16.4. 
19.4.1. Formulation, Appearance, Packaging, and Labeling 
Refer to Section 16.4.1. 
19.4.2. Drug Dispensing, Storage, and Stability 
Refer to Section 16.4.2. 
19.4.3. Dosing and Administration 
Dosing and administration will occur according to Section 19.3.3 in order to maintain blinding. 
19.5. Events of Special Interest
 
ï‚· Photophobia 
ï‚· Blurred vision 
ï‚· Visual impairment 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 92 20. Appendix E (Enrollment Closed 20JAN2023) â€“ Fluvoxamine Maleate 100  
20.1. Risk Assessment 
Refer to Section 17.1. 
20.2. Additional Appendix-Leve l Exclusion Criteria 
Refer to Section 17.2.  
20.2.1. Precautions 
Refer to Section 17.2.1.  
20.3. Fluvoxamine Information  
Refer to Section 17.3.  
20.3.1. Formulation, Appearance, Packaging, and Labeling 
Refer to Section 17.3.1. Fluvoxamine tablets remain 50 mg.  
20.3.2. Drug Dispensing, Storage, and Stability 
Refer to Section 17.3.2. 
20.3.3. Dosing and Administration 
Fluvoxamine will be self-administe red orally by each participant at  a dose of 50 mg BID for one 
day (first two doses at 50 mg), followed by 100 mg (two 50 mg tablets) BID for 12 days 
(remaining 24 doses at 100 mg), for a total of 13 days (26 doses, 50 tabl ets) of fluvoxamine.  
20.3.4. Rationale for Selection of Dose 
Refer to Section 17.3.4. 
Additional relevant rationale : 
The recommended starting dose of fluvoxamine for OCD in adults is 50 mg daily to be titrated 
up to a maximum of 300 mg/day divided into BI D doses. The 300 mg daily dose is for serotonin 
receptor activity, whereas the postulated dose for sigma-1 receptor activity as an anti-
inflammatory is lower. The TOGETHER tria l is a randomized, placebo-controlled, adaptive 
platform trial that demonstrated a 100 mg BID fluvoxamine dose for 10 days was well-tolerated 
and effective (see Figure 7) in nonhospitalized a dults with mild COVID-19.[72] This is a 
multicenter study conducted in Brazi l. Participants were > 18 y ears old and with symptomatic 
confirmed COVID-19 within 7 days of the screeni ng date or a positive rapid antigen test done at 
the time of screening. Participants were required to have at least one risk factor for severe 
disease. Participants were randomized to activ e drug versus placebo, and due to the concurrent 
enrollment into multiple active arms, pooled placebo was used for each active arm. The primary outcome was a composite endpoint of medical  admission to the hospital due to COVID-19, 
which was defined as more than 6 hours in an em ergency care setting (acu te care areas set up to 
respond to capacity) or referral for hospitaliz ation, within 28 days of randomization. Key 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 93 secondary outcomes included viral clearance, time to clinical improvement, and all-cause 
mortality. The planned accrual, based on an assu mption of 15% event rate in the placebo group, 
was 681 participants per arm.  
The study randomized 741 participants to fluvoxam ine and 756 to placebo. In the fluvoxamine 
group 79 (11%) participants had a primary outco me event versus 119 (16%) in the pooled 
placebo arm (relative risk 0.68 [95% Bayesian credible interv al, 0.52-.88]). Secondary outcomes 
including viral clearance at day 7, hospitalization, and mortality we re not different between arms. 
There was no significant difference in the number of treatment-emergent adverse events in the 
two arms. Thus, this large randomized, double-blind, controlled trial is suggestive of safety and 
efficacy of fluvoxamine dosed 100 mg twice daily in people with mild-to-moderate COVID-19.  
 
Figure 7. Probability of efficacy for the prim ary outcome in the ITT and mITT populations 
of TOGETHER 
20.4. Placebo Information  
Refer to Section 17.4.  
20.4.1. Formulation, Appearance, Packaging, and Labeling 
Refer to Section 17.4.1. 
20.4.2. Drug Dispensing, Storage, and Stability 
Refer to Section 17.4.2. 
20.4.3. Dosing and Administration 
Participants will self-administer one placebo ta blet orally BID for one day, followed by two 
placebo tablets orally BID (four total per day) for 12 days, for a total of 13 days of placebo 
tablets. 

CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 94 20.5. Events of Special Interest 
For participants enrolled in the Fluvoxamine Maleate 100 appe ndix on protocol v7.0 or later, 
suicidal ideation and behavior will be assessed at Day 7 and Da y 14 via the Columbia-Suicide 
Severity Rating Scale (C-SSRS) Screener Since Last Asked Self-Report. The C-SSRS asks a 
total of up to six questions and a minimum of th ree questions. Sites will follow local policies in 
response to high risk screen cases . In addition, high risk screen cas es will be advised to dial 988 
to access the 988 Suicide & Crisis Lifeline.     
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 95 21. Appendix F (Enrollment Closed 23JUN2023) â€“ Montelukast  
21.1. Risk Assessment 
The most common adverse reactions that occurred at a greater frequency in montelukast than in 
placebo and at an incidence rate â‰¥ 5% include upper respiratory infection, fever, headache, 
pharyngitis, cough, abdominal pain, diarrhea, otitis  media, influenza, rhinorrhea, sinusitis, and 
otitis. 
Post-market reports of neuropsychiatric events associated with montel ukast have included 
agitation, hostility, anxiousness, depression, sl eepwalking, suicidal thinking/behavior, and 
tremors. 
Table 9. Montelukast sodium adverse reactio ns occurring at a higher incidence than 
placebo, in â‰¥1% of adults and adolescents â‰¥ 15 years of age. 
Adverse Reaction Montelukast sodium  
10 mg/day, n=1955 (%) Placebo, n=1180 
(%) 
Pain, abdominal  2.9 2.5 
Asthenia/fatigue 1.8 1.2 
Fever 1.5 0.9 
Trauma 1.0 0.8 
Dyspepsia 2.1 1.1 
Pain, dental 1.7 1.0 
Gastroenteritis, infectious 1.5 0.5 
Headache 18.4 18.1 
Dizziness 1.9 1.4 
Influenza 4.2 3.9 
Cough 2.7 2.4 
Congestion, nasal 1.6 1.3 
Rash 1.6 1.2 
ALT Increase 2.1 2.0 
AST Increase 1.6 1.2 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 96 Pyuria 1.0 0.9 
21.2. Additional Appendix-Leve l Exclusion Criteria 
1. Currently participating as a study team member in support of the ACTIV-6 trial 
21.2.1. Precautions 
Participants with known aspiri n sensitivity should continue to avoid aspirin and other non-
steroidal anti-inflammatory agents while taki ng montelukast. Care should be taken with the 
reduction of oral corticostero id therapy while on monteluka st as systemic eosinophilia, 
sometimes presenting with clinical features of  vasculitis consistent with Churg-Strauss 
syndrome, has been reported. 
21.3. Study Drug Information  
The primary active ingredient in montelukast tabl ets is montelukast sodium, which is an orally 
active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor. It 
is indicated for prophylaxis and chronic treatme nt of asthma, acute prevention of exercise-
induced bronchoconstriction, relief of seasonal allergic rhinitis, a nd relief of perennial allergic 
rhinitis in patients â‰¥ 15 years of age. 
21.3.1. Formulation, Appearance, Packaging, and Labeling 
Montelukast sodium is a white to off-white pow der. The 10 mg montelukast tablets are beige, 
rounded square-shaped, biconvex, film-coated ta blets. Each tablet contains 10.4 mg of 
montelukast sodium, which is equi valent to 10 mg montelukast. All packaging will be labeled to 
indicate that the product is for investigational use. 
21.3.2. Drug Dispensing, Storage, and Stability 
A US commercial supply of m ontelukast tablets will be supplied by Accord Healthcare Inc. or 
Camber Pharmaceuticals and distributed by Be lmar Pharmacy and Womenâ€™s International 
Pharmacy. Montelukast tablets should be stored at 25Â°C with excursions permitted from 15Â°C to 30Â°C, protected from moisture and light. 
21.3.3. Dosing and Administration 
Montelukast will be self-administered orally by each participant at a dose of 10 mg (1 tablet) 
once daily for 14 days. 
21.3.4. Rationale for Selection of Dose 
Preclinical Studies: 
Montelukast is a potent cysteinyl leukotriene receptor antagonist with anti-inflammatory effects 
and has been proven to significantly suppress oxidative stress and cytokine production. 
Pre-clinical in vitro  studies demonstrate montelukastâ€™s ability to act as an anti-viral agent against 
RNA viruses such as Zika, Influenza A, and He patitis C, among others.[73] A virtual screening 
tool, using an in silico molecular docking an alysis, was used to simulate the binding of 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 97 montelukast to catalytically active sites within the SARS â€CoVâ€2 main protease and RNA 
dependent RNA polymerase. The results indicated that the Protein-Ligand ANT System chemplp 
docking score of montelukast against the main protease was âˆ’105.71, and the RNA dependent 
RNA polymerase was âˆ’104.75. These docking scores suggest that  montelukast is likely to dock 
to both the main protease and the RNA dependent RNA polymerase of SARS â€CoVâ€ 2, therefore 
demonstrating the potential to inhibit the enzyma tic activity of the proteins and subsequently 
disrupting the substrate binding site.[74]   
Montelukast inhibits the signaling of NF-Îº B, such as interleukin-6,8,10, TNF-alpha, MCP-1, and 
other proinflammatory mediators, which may result in a corresponding reduction of 
proinflammatory mediators, thereby attenuating cy tokine production and th e cytokine storm.[75] 
Pulmonary and extra-pulmonary manifestations in C OVID-19 are attributed to a direct effect of 
SARS-CoV-2 on expressed ACE2 recep tors or indirectly through NF- ÎºB dependent induction of 
a cytokine storm. Montelukast may ameliorate  extra-pulmonary manifestations of COVID-19 
either directly through blocking of cysteinyl le ukotriene receptors in different organs or 
indirectly through inhibition of the NF-Îº B signaling pathway.[76] 
In addition, 36.4% of patients with COVID-19 experience CNS involvement, and although the 
majority of these events include headache, anosmi a, and dysgeusia; more serious events such as 
stroke, delirium, and seizures ha ve been reported.[77] In a 6-w eek treatment of young (4 months) 
and old (20 months) rats with montelukast, a redu ction of neuroinflammation was seen; elevation 
of hippocampal neurogenesis and improvement in learning and memory in old animals was seen. 
By using gene knockdown and knockout approaches, the authors demonstrated that the effect 
was mediated through inhibition of the GPR17 receptor.[78] 
Clinical studies: 
One published retrospective analys is of hospitalized patients w ith confirmed COVID-19 treated 
with or without montelukast (10 mg orally, once daily, at the discretion of  the treating provider) 
included ninety-nine patients not previously on montelukast in th e analysis (30 montelukast/62 
non-montelukast). Inclusion requir ed hospitalization for at least 3 days. Montelukast was started 
on day 1 of hospitalization and all patients but  1 were on hydroxychloro quine. Steroids were 
used by 16-23% of patients duri ng the first 3 days of hospita lization and 33-40% of patients 
during the entire hospitalization. A un ivariate logistic regression reve aled a lower risk of clinical 
deterioration in patients who we re receiving montelukast, defined as any increase in ordinal scale 
from day 1 to day 3 of hospitalization, (OR, 0.23;  P =.029); however, in a multivariable logistic 
regression, the results in patient s 60 years or older demonstrat ed that montelukast was not 
significantly associated with a reduced risk of clinical deterioration (OR, 0.28; P =.058).[79] 
A recent prospective, randomized, controlled, single-blinded, single-center study investigated 
standard of care treatment versus two doses of montelukast (10 mg/day or 20 mg/day) in addition 
to standard of care treatment in  hospitalized patients with co nfirmed COVID-19 at the Erzurum 
Regional Training and Research Hospital in Turk ey.[80] To be considered for enrollment, 
patients were required to have a PaO2/FiO2 ra tio above 200 at adm
ission and to be starting on 
standard of care treatment (per Turkish Ministry of Health this was favipiravir for a total of 5 
days). The primary outcome was a composite of progression to ARDS and/or macrophage 
activation syndrome (MAS). MAS was assessed at  Day 5 of treatment. Clinical outcomes of 
disease progression were capture d during hospitalization. Based on an assumption of a 20% or 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 98 greater reduction in the primary outcome, the samp le size was determined to be total accrual of 
180 participants enrolled (60 in each group). Th e two montelukast arms were combined for the 
clinical outcome analysis. The standard of care arm had more MAS or ARDS events (8 vs 3, p = 
0.001) and mortality (4 vs 0) th an the pooled active treatment arms. There was no adverse event 
reporting in this manuscript, and there ar e numerous weaknesses to the study design.  
Although the preclinical montelukast data available for SARS â€CoVâ€2 is quite provoking, data 
from randomized clinical trials is lacking and the efficacy of montelukast for the treatment of 
COVID-19 warrants further studies. Ongoing clinical trials with montelukast propose a range of 
doses for testing (10 mg orally daily for 28- 60 days; 60 mg orally daily for 14 days), see Table 
10. One completed observational study (NCT 047145515) has not posted study results. The 
proposed dose (Section 21.3.3) of 10 mg orally daily  for 14 days fills a gap for a shorter course 
of therapy at the FDA-approved dose for wh ich comprehensive safety data exists. 
Table 10. Ongoing clinical trials with montelukast 
Study  Study Design  Proposed 
Montelukast Dose NCT Identifier 
The COvid-19 
Symptom MOntelukast 
Trial (COSMO) Phase 3, randomized, 
blinded, placebo-
controlled trial with 600 participants 10 mg daily for 60 
days [STUDY_ID_REMOVED] 
Efficacy of 
Montelukast in Mild-
moderate Respiratory 
Symptoms in Patients With Long-COVID-
19: (E-SPERANZA) Phase 3, double-blind, 
randomized, placebo-
controlled trial with 
284 participants 20 mg daily for 28 days [STUDY_ID_REMOVED] 
A National, Multi-
Center, Open-Label, 
Three-Arm, Phase II Study to Investigate 
the Effect of 
Montelukast Between Emergency Room 
Visits and 
Hospitalizations in COVID-19 Pneumonia 
in Comparison With 
Standard Treatment Phase 2, 3 arm 
(montelukast, 
montelukast plus favicovir, and 
favicovir), open-label, 
randomized trial with 380 participants Montelukast arm 
dosing: 6x10 mg 
montelukast daily for 14 days [STUDY_ID_REMOVED] 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 99 21.4. Placebo Information  
The placebo will match, in appearance, an FDA-approved, US commercial supply of 
montelukast sodium. The final packaging of th e placebo will match that of the study drug (as 
described in Section 21.3.1). 
21.4.1. Formulation, Appearance, Packaging, and Labeling 
Placebo will be tablets with the following app earance: beige, rounded square-shaped, biconvex, 
film-coated tablets. All packaging will be la beled to indicate that the product is for 
investigational use. 
21.4.2. Drug Dispensing, Storage, and Stability 
Placebo will be supplied by Almac Pharma Servi ces and distributed by Belmar Pharmacy and 
Womenâ€™s International Pharmacy. Placebo should be  stored at controlled room temperature 
25Â°C, excursions permitted from 15Â°C to 30Â°C. 21.4.3. Dosing and Administration 
Participants will self-administer one placebo tablet orally daily for 14 days. Dosing and 
administration will occur according to Section 21.3.3 in order to maintain blinding. 
21.5. Events of Special Interest 
Neuropsychiatric events including agitation, hos tility, anxiousness, depression, sleepwalking, 
suicidal thinking/behavior, and tremors. 
  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 100 22. Appendix G â€“ Metformin Hydrochl oride Immediate-Release   
22.1. Risk Assessment 
The most common adverse reactions (> 5%) with  metformin hydrochloride include diarrhea, 
nausea/vomiting, flatulence, asthenia, indiges tion, abdominal discomfort, and headache. 
Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with 
postmarketing use of metformin. 
Safety concerns around metformin have centered around a risk of lactic acidosis, however the 
historical concern was driven by experience w ith other biguanides. Se veral large studies and 
Cochrane reviews have demonstrated no increased ri sk of lactic acidosis, a nd in fact fewer cases 
of lactic acidosis, in persons on metformin compar ed to other diabetes treatments.[81, 82] This 
includes in adults with heart failure.[83, 84] Metformin is also safe in adults with kidney disease 
and should not be withheld from persons with  glomerular filtration rates >30 mL/min/1.73m2 (or 
lower) because of associations with improved ma crovascular outcomes in persons with chronic 
kidney disease.[81] Guidelines recommend metf ormin should no longer be stopped upon hospital 
admission or for surgery.[85-88] Metforminâ€™s safe ty has been demonstrated in children and 
during lactation and pregnancy.[89-94] 
22.2. Additional Appendix-Leve l Exclusion Criteria 
1. Chronic kidney disease including end-stage renal disease on renal replacement therapy 
(dialysis) 
2. Chronic liver disease with ascites  
3. History of metabolic acidosis and/or cu rrent use of bicarbonate supplementation  
4. Current or recent use (within 14 days) of ranolazine, dolutegravir, cimetidine, pacritinib, 
erdafitinib, fexinidazole, pati romer, risdiplam, tafenoquine,  vandetanib, zonisamide, 
acetazolamide, dichlorphenamide 
5. Type 1 diabetes mellitus or type 2 diabetes mell itus, currently taking insulin or a sulfonylurea  
6. Does not agree to less than moderate alcohol consumption* during the Intervention Period  
*Â Defined as greater than 2 drinks a day fo r men and 1 drink a day for women. A drink is 
equivalent to 12 ounces of b eer (5% alcohol content), 8 ounces of malt liquor (7% alcohol 
content), 5 ounces of wine (12% alcohol cont ent), 1.5 ounces or a â€œshotâ€ of 80-proof (40% 
alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). [95]  
7. Breastfeeding or planning to breastfeed a premat ure infant (born at < 37 weeks of gestation) 
or an infant with renal impairm ent during the Intervention Period 
8. Currently participating as a study team member in support of the ACTIV-6 trial 
22.2.1. Precautions 
Postmarketing reports have indicated that metformin-associated lactic acidosis could result in 
death, hypothermia, hypotension, and resistant bradya rrhythmias. Symptoms of lactic acidosis 
include malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Risk factors of 
lactic acidosis include significant renal impa irment, concomitant use of carbonic anhydrase 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 101 inhibitors, age > 65 years old, ra diological studies with contrast , surgery and other procedures, 
hypoxic states, excessive alcohol intake, and hepa tic impairment. Laboratory abnormalities from 
postmarketing cases included elevated blood lact ate levels, anion gap acidosis, increased 
lactate/pyruvate ratio, and metformi n plasma levels generally >5 Âµg/mL. Steps to reduce the risk 
of and manage metformin-associat ed lactic acidosis in high risk  groups are provided in the Full 
Prescribing Information. If lact ic acidosis is suspected, st udy drug will be discontinued.  
Additional precautions include Vitamin B12 Defici ency with long-term use (> 1 year), and 
increased risk of hypoglycemia with concomitant use with insulin and insulin secretagogues.  
Alcohol can theoretically potentiat e the effect of metformin on l actate metabolism, participants 
should be warned to avoid exces sive alcohol intake. Drugs such  as vandetanib may increase the 
accumulation of metformin; as such, concomitant use of these drugs is not allowable in the 
study. Excessive use of alcohol is also not allowable.  
22.3. Study Drug Information  
Metformin hydrochloride is a biguanide and is indi cated, in combination with diet and exercise, 
to improve glycemic control in adults and pediatri c patients 10 years of age and older with type 2 
diabetes mellitus. Metformin is an antihyperglycemic hydrochloride that is a white to off-white 
crystalline compound. Metformin decreases hepa tic glucose production, decreases intestinal 
absorption of glucose, and improves insulin sens itivity by increasing peripheral glucose uptake 
and utilization. This study will use the immedi ate release (IR) formulation of metformin. 
22.3.1. Formulation, Appearance, Packaging, and Labeling 
Metformin IR tablets contain the active metformin hydrochlor ide and inactive ingredients 
including povidone and magnesium  stearate. Commercially availa ble metformin 500 mg tablets 
will be provided.   
Participants will be provided with one bottle cont aining thirty-six 500 mg ta blets.  All packaging 
will be labeled to indicate that the product is for investigational use. 
22.3.2. Drug Dispensing, Storage, and Stability 
Metformin IR will be dispensed in  light-resistant containers and s hould be stored at 20Â° to 25Â°C 
(68Â° to 77Â°F); excursions permitted to 15Â°â€“30Â°C (59Â°â€“86Â°F). 
22.3.3. Dosing and Administration 
Metformin IR tablets will be self-administered or ally according to the following dosing schedule:  
ï‚· 500 mg on Day 1;  
ï‚· 500 mg in the morning and 500 mg in the evening on Day 2 through Day 5; and 
ï‚· 500 mg in the morning and 2 x 500 mg (a total of 1000 mg) in the evening on Day 6 
through Day 14.  
22.3.4. Rationale for Selection of Dose 
Preclinical data suggests metformin has immuno modulatory activity that reduces the production 
of proinflammatory cytokines while stimulating the formation of neutr ophil extracellular traps 
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 102 that may directly inhibit SARS -CoV-2.[96, 97] The hypothesis is that the primary mechanism of 
action for metformin against SARS-CoV-2 relies on metforminâ€™s availability in the plasma. The 
systemic exposure of IR metformin is higher than for extended-releas e (XR) metformin. Anti-
viral medications are also consider ed more effective when started ea rly in the course of infection, 
and IR metformin is faster to reach systemic levels above 500 ng/mL. 
While the preclinical data shown in Figure 8  and Figure 9  use a dose of 2000 mg per day of IR, 
2000 mg per day is also the dose at which the ri sk of side effects in creases significantly ( Figure 
9). Rapidly increasing the dose to 2000 mg per day within 2 weeks appeared to increase the risk 
of side effects. The proposed dose of 1500 mg da ily balances the need to achieve a consistent 
dose and an effective dose without  causing side effects. A dose ti tration is typically important 
when starting metformin, to avoid side  effects and study dr ug discontinuation. 
Preclinical Studies: 
Preclinical data supports the use of the IR formulation to achie ve systemic exposure. One study 
with samples from 19 evaluable patients receiv ing a single dose  of metformin demonstrated 
higher plasma metformin levels in those who received IR as opposed to de layed-release [DR] 
(Figure 8 ). A randomized, phase 2, parallel-group, multicenter, placebo-controlled study of 
double-blind placebo or 4 doses of metformin DR and single-blind metformin IR (2000 mg) 
similarly showed higher systemic metformin plasma levels following dosing of an IR formulation as opposed to DR (Figure 9 ). 
 
Figure 8. Mean (SD) plasma metformin concentr ations by treatment and time point after a 
single daily dose of metformin. 
Figure Note: Treatments were administered at t = 0 h (8:00 p.m.) and at t = 12 h (8:00 a.m.) 
except for metformin (Met) XR, which wa s administered as a single dose at t = 0 (black arrows). 
Meals were administered at t = âˆ’0.42, 2.08, 11.5, 18.08, and 24.08 hours rela tive to the first dose 
(dotted vertical lines).[98] 

CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 103  
Figure 9. Metformin systemic (plasma) exposure 
Figure Note: (A) observed at trough (median) and (B) steady state AUC 0-24h (geometric mean 
[95% CI]) estimated from trough and post-dose sampling. Efficacy presented as (C) Hemoglobin 
A1C (HbA1c) change at Week 16 (Least squares mean + sta ndard error) and (D) Average 
concentration Week 4â€“16 change in fasting gl ucose from baseline (Least Squares mean + 
standard error). Data are fr om the mITT population (n = 542), with the exception of modeled 
steady-stated metformin AUC 0-24h (ITT population; n = 571). * p<0.05 vs. Placebo. The ITT 
population consisted of participants randomized on Day 1 who received at least one dose of 
randomized study medication. The mITT population cons isted of ITT participants with at least 
one post-baseline value for HbA1c that was collected no more than 1 week after discontinuing 
study medication and prior to taking a new anti -diabetic concomitant medication that could 
reasonably be expected to influen ce subsequent glycemic data.[99] 
Clinical Studies: 
Metformin IR is more widely available and less expensive than XR or DR metformin. Metformin 
IR is over the counter in some countries, like Brazil and Spain, but XR a nd DR formulations are 
not.  
While several studies have investigated metf ormin in the SARS-CoV-2 population, the IR 
formulation appears to result in improved out comes as opposed to other formulations. The 
TOGETHER Trial performed in Brazil compared metformin DR (750 mg twice daily for 10 
days) to placebo in a total of  418 participants with confirme d SARS-CoV-2 infection, including 

CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 104 symptoms within 7 days of Screening and one additional high-risk criterion. The results showed 
no difference in the primary outcome of hospitali zation or > 6 hours of re tention in a COVID-19 
emergency setting between metformin DR and placebo. Additionally, no clinical improvement 
(according to the World Health Organization clin ical worsening scale) was identified at 28 
days.[72]  The TOGETHER Trial did not have a dose titration, and starting at 1,500 mg per day 
would be expected to cause side  effects in a large portion of pa rticipants. Thus, the per-protocol 
results might be more informative from the TOGETHER Trial, and the per-protocol results do suggest a benefit for metformin. In the per-proto col analysis, 4.76% (8 of 168) in the metformin 
group versus 7.82% (14 of 179) of  controls were hospitalized. 
Another trial performed in Mexico compared metf ormin IR (620 mg twice daily for 14 days) to 
placebo in a total of 20 participants with type  2 diabetes mellitus who presented with severe 
acute respiratory syndrome secondary to SA RS-CoV-2 infection. The results showed a 
significant reduction in the viral load of those who received me tformin IR (93.2%) as opposed to 
those on placebo (78.3%) and lower supplementa l oxygen intake on days 2, 5, and 7 in those 
who received metformin IR (5.9 points) ve rsus those on placebo (10.6 points).[97] 
One trial of metformin IR for outpatient treatme nt of COVID-19 has been completed in the US, 
COVID-OUT. Metformin IR prevented over 40% of emergency department visits, 
hospitalizations, and death due to COVID-19 (OR 0.58, 95% CI, 0.35 to 0.94) by Day 14. By 
Day 28, those in the metformin IR group were also less likely to be hospitalized, 1.34% (8/596) 
versus 3.16% (19/601) of those receiving placeb o. Treatment with metformin IR during acute 
COVID-19 infection prevented over 40% of Long COVI D cases, with 6.3% of participants in the 
metformin IR group and 10.6% in the placebo group receiving a diagnosis of Long COVID from a medical provider.[100] 
22.4. Placebo Information 
22.4.1. Formulation, Appearance, Packaging, and Labeling 
Placebo tablets will be provided by The Univers ity of Iowa Pharmaceuticals and Almac Pharma. 
One bottle of 36 placebo tablets will be provided to participants who are randomized to receive 
placebo. All packaging will match that of the activ e drug supply and will be labeled to indicate 
that the product is for investigational use. 
22.4.2. Drug Dispensing, Storage, and Stability 
Placebo will be stored in the same conditions as study drug, room temperature (20Â°C to 25Â°C) 
with excursions permitted from 15Â°C to 30Â°C in a light-resistant container. 
22.4.3. Dosing and Administration 
Participants will self-administer place bo according to the following schedule: 
ï‚· One (1) placebo tablet on Day 1;  
ï‚· One (1) placebo tablet in the morning and 1 placebo tablet in the evening on Day 2 
through Day 5; and 
ï‚· One (1) placebo tablet in the morning and 2 placebo tablets in the evening on Day 6 
through Day 14.  
CONFIDENTIAL ACTIV- 6 Protocol [v11.0] 
 
 105  
22.5. Events of Special Interest 
ï‚· Lactic acidosis will be reporte d as an ESI if the event is reported during a hospitalization 
ï‚· Occurrence of hypoglycemia will be recorded on Day 14 by asking the participant to 
report any healthcare provider documen ted occurrence of low blood sugar 
22.6. Statistical Considerations 
The most significant effect of metformin de scribed in COVID-OUT was for a combination 
outcome of mortality, hospitaliza tion and emergency department visits. Therefore, healthcare 
utilization will be the variable used for PPOS for this appendix. 
Recent data suggest that metformin may reduce th e risk of post-acute sequelae of Covid (PASC), 
or Long COVID. ACTIV-6 provides an opportunity to  validate this finding in a robust way given 
the collection of patient reporte d outcomes through 180 days. At 180 days, participants complete 
a PASC symptom questionnaire in addition to  general symptom reporting, clinical event 
reporting, and QOL. These data can be used to  assess the influence of metformin. A SAP 
specific to the PASC research question will be  developed. As noted in the sample size 
considerations below, up to 3000 participants ma y be needed to determine whether metformin 
reduces the risk of PASC. Given the increase in  sample size related, analysis of the primary 
endpoint will proceed only after all participants have been enro lled to answer the independent 
research question.  
22.6.1. Sample Size Considerations 
From 1 January 2022 to 31 December 2022, ACTIV-6 enrolled 4498 patients, of whom 3751 
patients responded to day 90 surveys (83.4% re sponse rate). Of those responding, 262 reported 
persistent symptoms at 90 days. As it currently  stands, ACTIV-6 is pow ered at about 80% to 
detect a reduction in risk from 7% to 3.5% (a 50 % relative risk reduction; required sample size 
for 80% power is 1272). Under more conservative assumptions of a 40% relative risk reduction 
from 6% to 3.6% among responders only, 2488 participants would be needed. If the rate of 
symptom persistence is lower, say 5%, slightly larger sample sizes would be required. A halving 
of risk from 5% to 2.5% would require 1812 part icipants for 80% power, and a 40% relative risk 
reduction to 3% would require 3012 participants. We  will therefore increase  accrual for the main 
analysis to ~3000.  
Given the independence of the re search questions related to tr eatment of acute COVID with 28 
day outcomes and to the prevention of PASC w ith outcomes assessed at 180 days, the SAP will 
not adjust for multiplicity due to assessing bot h questions. A futility analysis on the PASC 
endpoint will be conducted when 600 participan ts have passed day 90 under the assumption of 
accrual to n=3000. The SAP will address the influen ce of interim analyses on Type 1 error as 
appropriate. 